Conditions: Multiple Myeloma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 74
Healthy volunteers: no

Brief summary:
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.

Detailed description:

Arms:
arm 1: patients will receive treatment with elotuzumab in combination with pomalidomide and low-dose dexamethasone. Patients are eligible to receive Nivolumab at progression. arm 2: Patients will receive treatment with a combination of elotuzumab and nivolumab

Interventions: intervention 1: Elotuzumab intervention 2: Pomalidomide intervention 3: Dexamethasone intervention 4: Nivolumab
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: None

Protocol document:
Prot_000.pdf: 
Page:
1
Protocol Number:
CA204142
IND Number:
100,043
EUDRACT Number
N/A
Date:
27-Apr-2015
Revised Date
08-Mar-2018
Clinical Protocol CA204142
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and Low-
Dose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with 
Multiple Myeloma Relapsed or Refractory to Prior Treatment with Lenalidomide.
Revised Protocol Number: 03
Study Director & Medical Monitor
Rao Saleem MD, MPH
This document is the confidential and proprietary information of Bristol-Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS-sponsored 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
within your organization or to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by BMS. Any supplemental information (eg, amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document. Any person who receives 
this document without due authorization from BMS is requested to return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply 
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Revised Protocol No.: 03
Date: 08-Mar-2018
2
to partners to which BMS has transferred obligations, eg, a Contract Research Organization 
(CRO).
Replace all previous version(s) of the protocol with this revised protocol and please provide a copy of this 
revised protocol to all study personnel under your supervision, and archive the previous versions.
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Revised Protocol No.: 03
Date: 08-Mar-2018
3
DOCUMENT HISTORY
Document
Date of Issue
Summary of Change
Revised 
Protocol 03
08-Mar-2018
Major changes
•
Revisions required by the FDA based on safety concerns reported for 
patients treated in the Keynote 183 and Keynote 185 studies have 
been incorporated.
•
Incorporation of multiple myeloma program changes for biomarker 
evaluations of the elotuzumab in combination with nivolumab cohort 
(EN)
Revised 
Protocol 02
15-Feb-2017
Incorporate Amendment 02
Amendment 02
15-Feb-2017
•
Allows subjects who received elotuzumab in combination with 
pomalidomide and low-dose dexamethasone (EPd Cohort) to receive 
nivolumab upon progression 
•
Adds a cohort to receive elotuzumab in combination with nivolumab 
in a separate cohort (EN Cohort). 
Revised 
Protocol 01
16-May-2016
Incorporates Amendment 01, Administrative Letters 01 and 02.
Amendment 01
16-May-2016
Major Changes
•
Patients with multiple myeloma who may have received prior 
treatment with elotuzumab outside of a clinical trial are now eligible,
provided the patient did not discontinue treatment due to 
intolerability to elotuzumab
•
The requirement of 6 months or less for relapse to prior treatment 
with lenalidomide has been removed as a criteria for eligibility. 
•
Monthly dosing of elotuzumab will now begin at Cycle 3 rather than 
at Cycle 7.
Administrative 
Letter 02
14-Dec-2015
Personnel changes
Administrative 
Letter 01
21-Sep-2015
Alignment of the following protocol sections with revised washout 
period for study drug:
•
Sections 3.3.1 Age and Reproductive Status
•
Table 5.1-3 Pregnancy Test Note
•
Table 5.3.4-1 Pregnancy Test Note
•
Section 6.4 Pregnancy
Original 
Protocol
27-Apr-2015
Not applicable
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
OVERALL RATIONALE FOR REVISED PROTOCOL 03:
 
 
 
 
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03
Section Number & Title
Description of Change
Brief Rationale
Title Page
Change in Medical Monitor
Administrative Change
 
 
 
 
 
• Synopsis Study Design
• Section 3.1 Study 
Design and Duration
• Figure 3.1-1 Study 
Design Schematic
Removed the option to add 
nivolumab to EPd cohort, 
removed the option to add 
pomalidomide/lenalidomide 
to the EN cohort, and added 
the option for EN patients to 
crossover to EPd if they not 
respond to EN treatment.
Increased the EN cohort size 
to 30 patients.
• Synopsis Study 
Population
• Section 3.3.1 Inclusion 
Criteria
Modified the number of prior 
lines and type of therapy a EN 
patient must have received to 
be eligible for enrollment
•
Synopsis, Study Design
•
Section 3.3.4 Eligibility 
Criteria for EN Patients 
to Cross-over to EPd 
cohort
Added separate section to 
clarify eligibility criteria for 
crossover patients
Revised Protocol No.: 03
Date: 08-Mar-2018
4
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03
Section Number & Title
Description of Change
Brief Rationale
• Synopsis Statistical 
Considerations
• Section 8 Statistical 
Considerations
Statistical sections have been 
updated to reflect changes in 
study design.
 
 
Section 1.1.6.2 Non-
overlapping toxicities and 
preliminary safety
Added details about non-
overlapping toxicities and 
preliminary safety data
 
 
 
 
 
Section 3.5 
Discontinuation of 
Subjects following any 
Treatment with Study Drug
Modified 
to 
incorporate 
stopping rules and to reflect 
change in study design
 
 
 
Section 4.5 Selection and 
Timing of Dose For Each 
Subject
Tables updated to reflect 
changes in study design
 
 
Section 4.5.10 Stopping 
rules for unacceptable 
toxicity (EN cohort).
Added stopping rules for 
toxicity in the EN cohort
• Table 5.1-1 Screening; 
Screening 
Procedural 
Outline
• Table 5.1-4 CA204142 
Cycles 1 and 2 EN 
Cohort
Specifications for Bone 
Marrow Aspirates/Biopsy 
have been removed from the 
notes sections of the Time and 
Events tables along with 
specific assessment rows and 
replaced with a reference link 
to the sections and tables 
within the protocol that 
 
Revised Protocol No.: 03
Date: 08-Mar-2018
5
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03
Section Number & Title
Description of Change
Brief Rationale
• Table 5.1-5 CA204142 
Cycles 3 and 4 EN 
Cohort
• Table 5.1-6 CA204142 
Cycles 5 and beyond EN 
Cohort
• Section 
5.6.2.1 
Bone 
Marrow 
Aspirate 
Samples
specify the bone marrow 
procedures and assessments. 
• Table 5.1-1 Screening; 
Screening 
Procedural 
Outline
•
 
 
Addition of Buccal Swab 
(Germ 
Line 
Control)
for 
patients enrolled in EN cohort 
per Revised Protocol 03 and 
thereafter. 
 
 
 
 
 
 
 
 
 
Table 
5.1-4 
CA204142 
Cycles 1 and 2 EN Cohort
Deletion of specification for 
timing of thyroid function tests 
in notes 
 
Section 5.4.2 Laboratory 
Assessments for Myeloma
Adjusted to reflect changes in 
study design
 
•
Table 
5.4.2-2, 
Bone 
Marrow Samples for EN 
Cohort
•
Section 5.6.2.1 Bone 
Marrow Aspirate 
Samples
•
Section 5.6.2.2 
Peripheral Blood 
Samples
Table 5.6.2.1-1 Usage of 
bone 
marrow 
aspirate 
samples (EN cohort).
Additional specifications for 
Bone Marrow Samples for EN 
Cohorts added.
 
 
 
 
Revised Protocol No.: 03
Date: 08-Mar-2018
6
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03
Section Number & Title
Description of Change
Brief Rationale
 
 
 
Section 6.2.1 Nonserious 
Adverse Event Collection 
and Reporting
Specified 
that 
nonserious 
adverse 
events 
will 
be 
collected until 100 days from 
the last dose of study drug for 
EN and crossover subjects 
only.
NSAEs will still be 
collected for 60 days in EPd 
cohort.
Section 9.2.2 Study 
Records
Dexamethasone 
has 
been 
deleted from this section. 
 
 
 
All
Minor 
formatting 
and 
typographical corrections
 
Revised Protocol No.: 03
Date: 08-Mar-2018
7
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
SYNOPSIS
Clinical Protocol CA204142
Protocol Title: A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and Low-Dose 
Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with Multiple Myeloma Relapsed or 
Refractory to Prior Treatment with Lenalidomide.
Investigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational 
Product(s):
Elotuzumab: 10 mg/kg IV - Cycles 1 and 2: Days 1, 8, 15, 22
20 mg/kg IV - Cycle 3 and beyond: Day 1 of each cycle
Pomalidomide: 4 mg PO: Days 1 - 21 of each cycle
Dexamethasone: Days 1, 8, 15, and 22 of each cycle:
•
Subjects ≤75 years old: Weeks with elotuzumab dosing: 28 mg PO + 8 mg IV and 40 mg PO on non-elotuzumab 
dosing weeks
•
Subjects > 75 years old: Weeks with elotuzumab dosing: 8 mg PO + 8 mg IV and 20 mg PO on non-elotuzumab 
dosing weeks
Nivolumab:
•
Cycles 1 through 4: 240 mg IV Days 1, 15 of each 28-day cycle
•
Cycles 5 and beyond: 480 mg IV Day 1 of each 28-day cycle
Study Phase: Phase 2
Research Hypothesis:
Elotuzumab/Pomalidomide/Low-Dose Dexamethasone Cohort (EPd) :
Elotuzumab in combination with pomalidomide and low-dose dexamethasone will prolong progression-free survival 
(PFS) in subjects with multiple myeloma (MM) who have relapsed or are refractory or intolerant to a 
lenalidomide-based regimen.
Elotuzumab/Nivolumab Cohort (EN):
The combination of elotuzumab and nivolumab will provide clinical benefit, represented by response rate, in patients 
with relapsed or refractory multiple myeloma (MM) who have received at least 4 prior lines of therapy including a 
proteasome inhibitor (PI), immunomodulatory (IMID), and an anti-CD38 antibody.
Objectives:
Primary EPd Cohort Objective:
•
To estimate the PFS in patients with MM treated by EPd as second- or third-line regimen after relapse or being 
refractory or intolerant to a prior lenalidomide based regimen.
Primary EN Cohort Objective:
•
To estimate the Objective Response Rate (ORR).
Revised Protocol No.: 03
Date: 08-Mar-2018
8
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Secondary EPd Objectives
•
Estimate the ORR
•
Estimate the overall survival (OS) Rate
Secondary EN Cohort Objectives:
•
Estimate PFS
•
Estimate OS
 
 
Study Design:
This is a Phase 2, multi-center, open-label, multiple cohort study of elotuzumab in combination with pomalidomide 
and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the 
safety and efficacy of this combination therapy for treatment of relapsed or refractory MM patients. 
Approximately 120 subjects will be screened in this study to treat a  minimum of 60 subjects in the EPd Cohort and 
approximately 30 subjects in the EN Cohort. Screen failure rate is approximately 25%. Per Revised Protocol 03, the 
EPd cohort is closed to enrollment.
The estimated duration of enrollment is 18 to 24 months, minimum of 24 months follow-up and study duration of 
about 48 months, estimated from the date first patient, first visit.
If subjects enrolled in the EN cohort do not achieve clinical benefit represented by at least minimal response (≥MR) 
after 2 cycles of treatment or do not achieve an objective response (≥PR) after 5 cycles of treatment, they may cross 
over to the EPd cohort at Day 1 of the subsequent cycle. 
Subjects will continue treatment as long as the subject has clinical benefit from the treatment and do not meet criteria 
for discontinuation.
Revised Protocol No.: 03
Date: 08-Mar-2018
9
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Study Population:
Eligible subject must have:
a)
Documented disease progression per International Myeloma Working Group (IMWG) guidelines during or after 
their last anti-myeloma therapy
b)
As of Amendment 02, this criterion has been moved to criterion 2.g.i for clarity.
c)
As of Amendment 02, this criterion has been moved to criterion 2.g.ii for clarity.
d)
Measurable disease at screening, based on central laboratory results, defined as 1 or more of the following:
i) Serum immunoglobulin (Ig)G, IgA, IgM M-protein ≥0.5 g/dL 
ii) Urinary M Protein ≥200 mg urinary M-protein excretion in a 24 hour collection sample
iii)Involved serum free light chain (sFLC) ≥10 mg/dL provided the FLC ratio is abnormal. 
e)
Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
f)
As of Amendment 02, this criterion has been moved to criterion 2.g.iii for clarity.
g)
for the EPd Cohort:
i) Subjects must have received at least 1 but no greater than 2 prior lines of therapy (note: induction and stem 
cell transplants with or without maintenance therapy is considered 1 line of therapy)
ii) Subjects must have received prior treatment with a lenalidomide-containing regimen for at least 2 consecutive 
cycles (full therapeutic dose) and must have been deemed as relapsed, refractory, or intolerant. Refractory is 
defined as progressing on-treatment or within 60 days of the last dose.
NOTE: lenalidomide-based regimens to which the subject has relapsed or been refractory to is not required 
to be the most recent regimen received. 
Revised Protocol No.: 03
Date: 08-Mar-2018
10
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
iii)Prior elotuzumab exposure is permitted only if subjects fulfill all of the following:
(1). Did not discontinue elotuzumab due to any intolerable drug-related adverse reaction. 
(2). Did not participate in a prior elotuzumab clinical trial, regardless of treatment assignment
h)
For EN Cohort:
i)
Subjects must have received at least 4 prior lines of therapy including a proteasome inhibitor (PI), an 
immunomodulatory (IMID) agent, and an anti-CD38 antibody.
Subjects not eligible for enrollment include subjects with a) solitary bone or extramedullary plasmacytoma as the only 
evidence of plasma cells dyscrasia; b) monoclonal gammopathy of undetermined significance (MGUS), smoldering 
multiple myeloma (SMM), primary amyloidosis (no active multiple myeloma), Waldenstrom’s macroglobulinemia, 
or POEMS syndrome (plasma cell dyscrasia with poly neuropathy, organomegaly, endocrinopathy, monoclonal 
protein, and skin changes); c) active plasma cell leukemia (defined as either 20% of peripheral blood white blood cell 
count comprised of plasma/CD138+ cells or an absolute plasma cell count of 2 x 109/L); d) with Central Nervous 
System involvement with multiple myeloma.
Study Drug: includes both Investigational [Medicinal] Products (IP/IMP) and Non-investigational [Medicinal] 
Products (Non-IP/Non-IMP) as listed:
Study Drug for CA204142
Medication
Potency
IP/Non-IP
Elotuzumab Powder for Solution 
for Infusion
400 mg/vial
IP
Dexamethasone Tablets
2 mg and 4 mg and various 
strengths
Non-IP
Dexamethasone Solution
4 mg/mL, 8 mg/mL and various 
strengths
Non-IP
Nivolumab for Injection
100 mg/vial
IP
Pomalidomide Capsules
1 mg, 2 mg, 3 mg and 4 mg
IP
Study Assessments:
Assessments for safety and efficacy will be conducted as time points indicated on the time and events schedules 
included in Section 5. Safety evaluations include assessments of AEs, clinical laboratory tests (hematology, 
chemistry), vital sign measurements, and physical examination with assessment of ECOG performance score (PS).
Efficacy endpoints will be based on analysis of serum and urine electrophoresis (SPEP and UPEP), sFLC (for those 
with sFLC disease only), corrected calcium (serum calcium and serum albumin), imaging and bone marrow 
assessments, all at predefined intervals as specified in Table 5.1-1, Table 5.1-2, Table 5.1-3, Table 5.1-4, Table 5.1-5, 
and Table 5.1-6. Assessments for SPEP and UPEP will be based on central lab results, whereas assessments of bone 
marrow, bone lesions, extramedullary plasmacytomas, and corrected calcium will be based on local analysis at the 
site.
Revised Protocol No.: 03
Date: 08-Mar-2018
11
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Statistical Considerations:
Sample Size: 
EPd Cohort: 
Per Revised Protocol 03, the EPd cohort is closed to enrollment. Screening continued until a minimum of 60 patients 
were enrolled and treated. This total number is based on logistical consideration with statistical properties outlined 
below.
Under the assumptions that:
•
time to progression-free survival is exponentially distributed
•
median time of progression-free survival of 11 months among subjects treated with pomalidomide and 
dexamethasone and will increase to a median of 15 months when elotuzumab is added to the mix
•
an increase of 4 months in median corresponds to relative risk ratio of 0.73 (0.0462 monthly risk in the elotuzumab 
add on and 0.0630 monthly historical risk in the pomalidomide + dexamethasone treated subjects)
Sixty subjects enrolled over a 24-month period are sufficient to detect an increase in median from 11 to 15 months 
with about 70% power in a one-sided test with a 0.05 significance level. 
Assuming a monthly hazard rate of 0.0462, 48 of the 60 treated subjects are expected to have PFS events over a 24 
month follow up period
Power is calculated using PASS12 using the one-sample exponential module where the median is mapped to mean by 
dividing the assumed alternative median by logarithm of 2. The calculated power and event counts are consistent with 
power and event counts based on one sample log rank test where the number of events is calculated assuming relative 
risk ratio of 0.73.
EN Cohort
The planned sample size will be approximately 30 treated subjects; screening will continue until a minimum of 
30 patients are enrolled and treated. For a 30% observed ORR rate, a sample size of N=30 yields an exact confidence 
interval of [0.15, 0.49]. These design parameters ensure a lower bound higher than 15 %
Endpoints:
Primary EPd Endpoint:
PFS is defined as the time from first dosing date to the date of the first documented progression per IMWG uniform 
criteria or death due to any cause, whichever occurs first. Subjects who die without a reported prior progression will 
be considered to have progressed on the date of their death. Subjects who did not progress or die will be censored on 
the date of their last evaluable assessment. Subjects who did not have any on study efficacy assessments and did not 
die will be censored on the first dosing date.
Subjects who switched to subsequent therapy prior to documented progression will be censored on the date of the last 
evaluable assessment prior to the initiation of the new therapy. 
Primary EN Endpoints
ORR is defined as proportion of subjects with best overall response of partial response (PR) or better. Response will 
be determined per IMWG uniform criteria.
Secondary EPd Endpoints
•
Objective Response Rate (ORR) is defined as the proportion of subjects with a best overall response of partial 
response (PR) or better
•
Overall Survival (OS) is defined as the time from first dosing date to the date of death from any cause. A subject 
who has not died will be censored at last known date alive.
Revised Protocol No.: 03
Date: 08-Mar-2018
12
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Secondary EN Endpoints:
•
PFS is defined as the time from first dosing date to the date of the first documented progression per IMWG 
uniform criteria or death due to any cause, whichever occurs first. Subjects who die without a reported prior 
progression will be considered to have progressed on the date of their death.
•
OS is defined as the time from first dosing date to the date of death from any cause. A subject who has not died 
will be censored at last known date alive.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses
Demographics and Baseline Characteristics: The demographic and baseline characteristics of patients in the safety 
analysis set will be presented. 
Efficacy Analyses: The efficacy endpoints, progression free survival and objective response rate (ORR), will be 
defined using the International Myeloma Working Group criteria. Responses will be assessed at every treatment cycle 
using central laboratory test results on myeloma urine and serum, local laboratory bone marrow aspiration test, and if 
needed bone marrow and skeletal survey results and CT/MRI assessments. Objective responses will include stringent 
complete response, complete response, very good partial response and partial responses. The objective response rate 
and its 95% confidence interval (CI) using the Clopper-Pearson estimation procedure will be reported. Progression 
free survival and overall survival will be plotted using Kaplan-Meier estimates, and if estimable, median and its 95% 
CI will be reported.
 
Revised Protocol No.: 03
Date: 08-Mar-2018
13
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
 
For EPd cohort, the primary analysis of PFS will be conducted when 48 progression events have been observed.
For EN cohort, the primary analyses for ORR will be conducted when enrollment in the EN cohort is complete and 
all enrolled patients treated with the combination have received at least 3 cycles of treatment.
 
 
 
 
 
Safety Analyses
Safety assessments will be performed prior, during and between dosing, and up to 100 days after last treatment in the 
EN cohort, 60 days after the last dose in the EPd cohort and for subjects in the EN cohort who cross-over to the EPd 
cohort but discontinue treatment within 2 cycles of EPd treatment safety assessments will be performed up to 100 days 
after the last dose of nivolumab. The frequency, severity, relationship to combination of drug treatment, seriousness, 
and outcomes of adverse events (AEs) will be reported for the full safety analysis set. AE severity will be graded 
according to the NCI Common Terminology Criteria for Adverse Events 3.0. Results of targeted physical 
examinations prior to each dosing cycle will be presented. Summary statistics on vital signs at screening,  pre-infusion, 
30 minutes after the start of infusion, at end of infusion and 30 minutes after the completion of infusion will be reported 
for Cycle 1 and pre-infusion for Cycle 2 and beyond. Concomitant medications, SAEs, and performance status prior 
to dosing will be presented. The safety analysis set will be used for reporting safety /adverse events.
Biomarker Analyses
No biomarker analysis is planned for the EPd Cohort. In the EN Cohort, the potential association between PD-L1 
expression and clinical efficacy measures, such as overall response, will be assessed using methods such as Fisher’s 
exact test if sample size is large enough to allow meaningful analysis or other methodology as appropriate.
Revised Protocol No.: 03
Date: 08-Mar-2018
14
4.0
Approved
930091242
4.0
v


TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................................................................. 
OVERALL RATIONALE FOR REVISED PROTOCOL 03: ..................................... 
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 03 ......................... 
SYNOPSIS .................................................................................................................... 
TABLE OF CONTENTS .............................................................................................. 
1. INTRODUCTION AND STUDY RATIONALE .................................................... 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 Research Hypotheses ........................................................................................ 
1.2.1 EPd Cohort .............................................................................................. 
1.2.2 EN Cohort ................................................................................................ 
1.3 Objectives(s) ..................................................................................................... 
1.3.1 Primary Objectives .................................................................................. 
1.3.1.1 EPd Cohort: .................................................................................... 
1.3.1.2 EN Cohort: ...................................................................................... 
1.3.2 Secondary Objectives ............................................................................... 
1.3.2.1 EPd Cohort: .................................................................................... 
1.3.2.2 EN Cohort: ...................................................................................... 
 
 
 
 
 
 
 
 
 
1.5 Overall Risk/Benefit Assessment ..................................................................... 
2. ETHICAL CONSIDERATIONS .............................................................................. 
1
3
4
4
8
15
20
33
33
33
33
33
33
33
34
34
34
41
43
Clinical Protocol
BMS-901608
CA204142
elotuzumab
Revised Protocol No.: 03
Date: 08-Mar-2018
15
4.0
Approved
930091242
4.0
v


2.1 Good Clinical Practice ...................................................................................... 
2.2 Institutional Review Board/Independent Ethics Committee ............................. 
2.3 Informed Consent.............................................................................................. 
3. INVESTIGATIONAL PLAN ................................................................................... 
3.1 Study Design and Duration ............................................................................... 
3.2 Post Study Access to Therapy ........................................................................... 
3.3 Study Population ............................................................................................... 
3.3.1 Inclusion Criteria ..................................................................................... 
3.3.2 Exclusion Criteria .................................................................................... 
3.3.3 Women of Childbearing Potential ........................................................... 
3.3.4 Eligibility Criteria for EN Patients to Cross-over to EPd cohort. .......... 
 
 
 
 
 
 
3.5 Discontinuation of Subjects following any Treatment with Study Drug .......... 
3.6 Post Study Drug Study Follow up .................................................................... 
3.6.1 Withdrawal of Consent ............................................................................ 
3.6.2 Lost to Follow-Up .................................................................................... 
4. STUDY DRUG ......................................................................................................... 
4.1 Investigational Product ..................................................................................... 
4.2 Non-investigational Product ............................................................................. 
4.3 Storage and Dispensing..................................................................................... 
4.3.1 Elotuzumab .............................................................................................. 
4.3.2 Nivolumab ................................................................................................ 
4.3.3 Pomalidomide .......................................................................................... 
4.3.4 Dexamethasone ........................................................................................ 
4.4 Method of Assigning Subject Identification ..................................................... 
4.5 Selection and Timing of Dose for Each Subject ............................................... 
4.5.1 Pomalidomide .......................................................................................... 
4.5.2 Dexamethasone ........................................................................................ 
4.5.3 Elotuzumab .............................................................................................. 
4.5.3.1 Premedication Before Elotuzumab in Subjects Without a Prior 
Infusion Reaction .................................................................................. 
4.5.3.2 Elotuzumab Premedication Regimen in Subjects With a Prior 
Infusion Reaction .................................................................................. 
4.5.3.3 Elotuzumab Infusion Rate ............................................................... 
4.5.4 Nivolumab ................................................................................................ 
4.5.5 Guidelines for Elotuzumab Infusion in Subjects with Infusion Reactions
.....................................................................................................................
4.5.5.1 Grade 1 Infusion Reaction .............................................................. 
4.5.5.2 Grade 2 or 3 Infusion Reaction ...................................................... 
4.5.5.3 Grade 4 Infusion Reaction .............................................................. 
4.5.6 Treatment of Nivolumab-Related Infusion Reactions .............................. 
43
43
43
45
45
46
46
46
49
51
52
54
55
55
55
56
58
58
58
59
59
59
60
60
61
62
62
63
63
64
65
66
67
67
67
67
67
Clinical Protocol
BMS-901608
CA204142
elotuzumab
Revised Protocol No.: 03
Date: 08-Mar-2018
16
4.0
Approved
930091242
4.0
v


4.5.7 Management Algorithms for Immune Related Adverse Events ................ 
4.5.8 Dose Delay, Interruption, or Discontinuation for All Subjects ............... 
4.5.8.1 Dose Delay for Elotuzumab ............................................................ 
4.5.8.2 Dose Delay for Dexamethasone ...................................................... 
4.5.8.3 Dose Delay for Pomalidomide ........................................................ 
4.5.8.4 Dose Delay for Nivolumab .............................................................. 
4.5.8.5 Criteria to Resume Treatment with Nivolumab .............................. 
4.5.8.6 Nivolumab Dose Discontinuation ................................................... 
4.5.9 Recommended Dose Reduction ................................................................ 
4.5.9.1 Elotuzumab and Nivolumab ............................................................ 
4.5.9.2 Dexamethasone ............................................................................... 
4.5.9.3 Pomalidomide ................................................................................. 
4.5.10 EN Cohort: Stopping Rules for Unacceptable Toxicity ......................... 
4.6 Blinding/Unblinding ......................................................................................... 
4.7 Treatment Compliance ...................................................................................... 
4.8 Destruction of Study Drug ................................................................................ 
4.9 Return of Study Drug ........................................................................................ 
5. STUDY ASSESSMENTS AND PROCEDURES .................................................... 
5.1 Flow Chart/Time and Events Schedule ............................................................. 
5.1.1 Retesting During Screening Period ......................................................... 
5.2 Study Materials ................................................................................................. 
5.3 Safety Assessments ........................................................................................... 
5.3.1 Imaging Assessment for the Study............................................................ 
5.3.2 Vital Signs, Physical Measurements, and Physical Examination ............ 
5.3.3 Performance Status .................................................................................. 
5.3.4 Laboratory Assessments for Safety .......................................................... 
5.4 Efficacy Assessments ........................................................................................ 
5.4.1 Primary Efficacy Assessment ................................................................... 
5.4.2 Laboratory Assessments for Myeloma ..................................................... 
5.4.3 Imaging Assessments for Myeloma .......................................................... 
5.4.3.1 Skeletal Imaging.............................................................................. 
5.4.3.2 Assessment of Extramedullary Plasmacytoma................................ 
5.4.4 Definitions of Response and Progression Criteria .................................. 
 
 
 
 
 
 
 
5.7 Outcomes Research Assessments ..................................................................... 
5.8 Other Assessments ............................................................................................ 
5.8.1 Pharmacogenomic/Pharmacogenetic Assessments ................................. 
6. ADVERSE EVENTS ................................................................................................ 
6.1 Serious Adverse Events .................................................................................... 
6.1.1 Serious Adverse Event Collection and Reporting .................................... 
69
69
70
70
70
70
71
71
72
73
73
74
75
75
75
75
76
77
77
93
93
93
94
94
94
94
96
96
97
99
99
99
100
105
105
105
105
105
106
Clinical Protocol
BMS-901608
CA204142
elotuzumab
Revised Protocol No.: 03
Date: 08-Mar-2018
17
4.0
Approved
930091242
4.0
v


6.2 Nonserious Adverse Events .............................................................................. 
6.2.1 Nonserious Adverse Event Collection and Reporting .............................. 
6.3 Laboratory Test Result Abnormalities .............................................................. 
6.4 Pregnancy .......................................................................................................... 
6.5 Overdose ........................................................................................................... 
6.6 Potential Drug Induced Liver Injury (DILI) ..................................................... 
6.7 Other Safety Considerations ............................................................................. 
7. DATA MONITORING COMMITTEE AND OTHER EXTERNAL 
COMMITTEES.......................................................................................................
8. STATISTICAL CONSIDERATIONS...................................................................... 
8.1 Sample Size Determination ............................................................................... 
8.1.1 EPd Cohort .............................................................................................. 
8.1.2 EN Cohort ................................................................................................ 
8.2 Populations for Analyses .................................................................................. 
8.3 Endpoints .......................................................................................................... 
8.3.1 Primary Endpoint(s) ................................................................................ 
8.3.1.1 EPd Cohort ..................................................................................... 
8.3.1.2 EN Cohort ....................................................................................... 
8.3.2 Secondary Endpoint(s) ............................................................................. 
8.3.2.1 EPd Cohort ..................................................................................... 
8.3.2.2 EN Cohort ....................................................................................... 
 
 
 
8.4 Analyses ............................................................................................................ 
8.4.1 Demographics and Baseline Characteristics........................................... 
8.4.2 Efficacy Analyses ..................................................................................... 
8.4.3 Safety Analyses......................................................................................... 
 
 
8.4.6 Outcomes Research Analyses (both cohorts) ........................................... 
8.5 Interim Analyses ............................................................................................... 
9. STUDY MANAGEMENT ....................................................................................... 
9.1 Compliance ....................................................................................................... 
9.1.1 Compliance with the Protocol and Protocol Revisions ........................... 
9.1.2 Monitoring ............................................................................................... 
9.1.2.1 Source Documentation .................................................................... 
9.1.3 Investigational Site Training.................................................................... 
9.2 Records ............................................................................................................. 
9.2.1 Records Retention .................................................................................... 
9.2.2 Study Drug Records ................................................................................. 
9.2.3 Case Report Forms .................................................................................. 
9.3 Clinical Study Report and Publications ............................................................ 
10. GLOSSARY OF TERMS ....................................................................................... 
11. LIST OF ABBREVIATIONS ................................................................................. 
 
107
107
108
108
109
109
109
109
110
110
110
110
111
111
111
111
111
111
111
111
112
112
112
113
114
114
114
114
114
115
115
116
116
116
116
116
117
118
119
Clinical Protocol
BMS-901608
CA204142
elotuzumab
Revised Protocol No.: 03
Date: 08-Mar-2018
18
4.0
Approved
930091242
4.0
v


APPENDIX 1 DEFINITION OF LINES OF THERAPY ............................................ 
 
APPENDIX 2 PERFORMANCE STATUS SCALES ................................................. 
 
APPENDIX 3 PREPARATION AND ADMINISTRATION OF ELOTUZUMAB ... 
 
APPENDIX 4 DEFINITIONS OF RESPONSE AND PROGRESSION CRITERIA 
(MODIFIED FROM IMWG) ................................................................................. 
APPENDIX 5 THE INTERNATIONAL STAGING SYSTEM (ISS) FOR MULTIPLE 
MYELOMA ............................................................................................................ 
APPENDIX 6 POMALIDOMIDE PREGNANCY RISK PREVENTION PLAN ...... 
 
 
 
125
126
127
131
133
134
Clinical Protocol
BMS-901608
CA204142
elotuzumab
Revised Protocol No.: 03
Date: 08-Mar-2018
19
4.0
Approved
930091242
4.0
v




























Clinical Protocol
CA204142
BMS-901608
elotuzumab
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2
Research Hypotheses
1.2.1
EPd Cohort
Elotuzumab in combination with pomalidomide and low-dose dexamethasone will prolong PFS in 
subjects with MM who have relapsed or are refractory or intolerant to a lenalidomide-based 
regimen.
1.2.2
EN Cohort
The combination of elotuzumab and nivolumab will provide clinical benefit, represented by 
response rate, in patients with relapsed or refractory multiple myeloma (MM) who have received 
at least 4 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory 
(IMID) agent and an anti-CD38 antibody.
1.3
Objectives(s)
1.3.1
Primary Objectives
1.3.1.1
EPd Cohort:
•
To estimate the PFS in patients with MM treated by EPd as second- or third-line regimen after 
relapse or being refractory or intolerant to a prior lenalidomide-based regimen.
1.3.1.2
EN Cohort:
•
To estimate the ORR.
Revised Protocol No.: 03
Date: 08-Mar-2018
33
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
1.3.2
Secondary Objectives
1.3.2.1
EPd Cohort:
•
Estimate the ORR
•
Estimate OS Rate
1.3.2.2
EN Cohort:
•
Estimate PFS
•
Estimate OS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 03
Date: 08-Mar-2018
34
4.0
Approved
930091242
4.0
v














Clinical Protocol
CA204142
BMS-901608
elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5
Overall Risk/Benefit Assessment
The American Cancer Society has estimated 30,330 new MM cases in the US in 2016, with an 
estimated 12,650 deaths.1 While recent advances in the use of high-dose chemotherapy, targeted 
therapeutics, and stem cell transplantation have improved overall and event-free survival, the 
majority of patients with myeloma will relapse and disease progression is expected for all but a 
small percentage.5 The subjects enrolled in the EPd trial will receive an anti-myeloma regimen of 
pomalidomide + dexamethasone which demonstrated improvements in PFS, OS, and overall 
response in patients with refractory or relapsed and refractory multiple myeloma, including 
patients with disease refractory to both bortezomib and lenalidomide.29 Pomalidomide has gained 
U.S. FDA accelerated approval and EMA approval in this population of MM patients at a dose of 
4 mg, which is the dose being used in this trial.
Since pomalidomide may enhance the activity of NK cells, which are central to the main biological 
activity of elotuzumab, combining both drugs is likely to enhance elotuzumab mediated ADCC 
towards primary myeloma cells in a similar way to that observed with lenalidomide. The 
expectation is that subjects in this trial will derive clinical benefit.
Revised Protocol No.: 03
Date: 08-Mar-2018
41
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Pomalidomide is an analogue of thalidomide, which is known to cause severe life-threatening 
human birth defects. Because of this potential toxicity and to avoid fetal exposure, pomalidomide 
is only available under a special restricted distribution program Pomalyst® REMS (Section 4.3.3). 
Subjects may also follow Pomalidomide Pregnancy Risk Prevention Plan (Appendix 6) where 
applicable. All investigators and subjects must fully comply with and participate in the distribution
program in order to participate in this trial.
Elotuzumab as monotherapy or in combination with immunomodulatory agents such as 
thalidomide or lenalidomide is well tolerated. Safety data from an interim analysis of the ongoing 
randomized phase 3 study of lenalidomide and dexamethasone with or without elotuzumab in 
patients with relapsed or refractory multiple myeloma (Eloquent 2) has shown that elotuzumab 
was well tolerated in combination with lenalidomide/dexamethasone, with minimal incremental 
toxicity and no new safety signals. The safety profile of elotuzumab was consistent across IMiD 
combination studies (thalidomide and lenalidomide). As pomalidomide is an analogue of 
thalidomide, a similar safety profile is expected when pomalidomide + dexamethasone is 
combined with elotuzumab. Key elotuzumab adverse events have been infusion related events.14
These have all been managed by medications and resolved in less than 24 hours. The frequency 
and intensity of infusion related adverse events has been mitigated with premedications, including 
corticosteroids, histamine-1 and -2 antagonists, and acetaminophen. Guidelines for the 
management of infusion reactions are also provided in this protocol (See Section 4.5.5).
Nivolumab is approved in multiple solid tumor indications and hematologic malignancies 
(eg, classical Hodgkin lymphoma) based on its favorable benefit/risk assessment. In hematological 
malignancies including multiple myeloma, nivolumab monotherapy was generally well tolerated 
and toxicity profile was similar to that observed in solid tumors. Nivolumab has the potential for 
clinically relevant unique AEs potentially caused by an inflammatory mechanism. These include 
pulmonary toxicity, hepatotoxicity, diarrhea/colitis, endocrinopathies, and nephrotoxicity. To date, 
these unique AEs have been manageable with frequent monitoring, prompt diagnosis, and 
initiation of corticosteroids, dose interruption, and adequate supportive care. The management 
algorithms of the immune-related AEs are included in Appendix 7. 
Because nivolumab and elotuzumab have non-overlapping toxicity profiles, the combination of 
both drugs is not expected to increase toxicities. 
Elotuzumab combination with nivolumab is an experimental therapy and it is possible that 
unforeseen or unanticipated adverse events may occur although both agents have been evaluated 
separately in combination with other agents in multiple myeloma and have known toxicity profiles.
In order to minimize the overall risks to participating subjects, the protocol has inclusion-exclusion 
criteria appropriate to the population, and specific follow-up safety assessments. Adverse events 
and serious adverse events will be reviewed on an ongoing basis by the Medical Monitor and the 
Sponsor’s pharmacovigilance group to look for trends and safety concerns. Stopping rules for 
unexpected toxicity have been incorporated into the protocol. Treatment options in this later line 
relapsed/refractory myeloma setting are limited and it is possible that this combination may 
provide clinical benefit to patients.
Revised Protocol No.: 03
Date: 08-Mar-2018
42
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
The overall assessment of risk/benefit supports the evaluation of elotuzumab in combination with 
pomalidomide and dexamethasone in multiple myeloma and also the combination of elotuzumab
with nivolumab in the later line relapsed/refractory multiple myeloma setting.
2.
ETHICAL CONSIDERATIONS
2.1
Good Clinical Practice
This study will be conducted in accordance with Good Clinical Practice (GCP), as defined by the 
International Conference on Harmonisation (ICH) and in accordance with the ethical principles 
underlying European Union Directive 2001/20/EC and the United States Code of Federal 
Regulations, Title 21, Part 50 (21CFR50).
The study will be conducted in compliance with the protocol. The protocol and any amendments 
and the subject informed consent will receive Institutional Review Board/Independent Ethics 
Committee (IRB/IEC) approval/favorable opinion prior to initiation of the study.
All potential serious breaches must be reported to BMS immediately. A serious breach is a breach 
of the conditions and principles of GCP in connection with the study or the protocol, which is 
likely to affect, to a significant degree, the safety or physical or mental integrity of the subjects of 
the study or the scientific value of the study.
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where sanctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment).
2.2
Institutional Review Board/Independent Ethics Committee
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, subject recruitment materials (eg,
advertisements), and any other written information to be provided to subjects. The investigator or 
BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product labeling 
information to be provided to subjects and any updates.
The investigator or BMS should provide the IRB/IEC with reports, updates and other information 
(eg, expedited safety reports, amendments, and administrative letters) according to regulatory 
requirements or institution procedures.
2.3
Informed Consent
Investigators must ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate.
In situations where consent cannot be given to subjects, their legally acceptable representatives 
(as per country guidelines) are clearly and fully informed about the purpose, potential risks, and 
other critical issues regarding clinical studies in which the subject volunteers to participate.
BMS will provide the investigator with an appropriate (ie, Global or Local) sample informed 
consent form which will include all elements required by ICH, GCP and applicable regulatory 
Revised Protocol No.: 03
Date: 08-Mar-2018
43
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
requirements. The sample informed consent form will adhere to the ethical principles that have 
their origin in the Declaration of Helsinki.
Investigators must:
1) Provide a copy of the consent form and written information about the study in the language in 
which the subject is most proficient prior to clinical study participation. The language must be 
non-technical and easily understood.
2) Allow time necessary for subject or subject's legally acceptable representative to inquire about 
the details of the study.
3) Obtain an informed consent signed and personally dated by the subject or the subject's legally 
acceptable representative and by the person who conducted the informed consent discussion.
4) Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent form 
and any other information to be provided to the subjects, prior to the beginning of the study, 
and after any revisions are completed for new information.
5) If informed consent is initially given by a subject’s legally acceptable representative or legal 
guardian, and the subject subsequently becomes capable of making and communicating his or 
her informed consent during the study, consent must additionally be obtained from the subject.
6) Revise the informed consent whenever important new information becomes available that is 
relevant to the subject's consent. The investigator, or a person designated by the investigator, 
should fully inform the subject or the subject's legally acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
subject's willingness to continue participation in the study. This communication should be 
documented.
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules applicable to regulatory requirements, the subjects' signed ICF and, in the 
US, the subjects’ signed HIPAA Authorization.
The consent form must also include a statement that BMS and regulatory authorities have direct 
access to subject records.
Subjects unable to give their written consent (eg, stroke or subjects with or severe dementia) may 
only be enrolled in the study with the consent of a legally acceptable representative. The subject 
must also be informed about the nature of the study to the extent compatible with his or her 
understanding, and should this subject become capable, he or she should personally sign and date 
the consent form as soon as possible. The explicit wish of a subject who is unable to give his or 
her written consent, but who is capable of forming an opinion and assessing information to refuse 
participation in, or to be withdrawn from, the clinical study at any time should be considered by 
the investigator.
The rights, safety, and well-being of the study subjects are the most important considerations and 
should prevail over interests of science and society.
Revised Protocol No.: 03
Date: 08-Mar-2018
44
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
3.
INVESTIGATIONAL PLAN
3.1
Study Design and Duration
This is a Phase 2, multi-center, open-label, multiple cohort study of elotuzumab in combination 
with pomalidomide and low-dose dexamethasone (EPd Cohort) and elotuzumab in combination
with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for 
treatment of relapsed or refractory MM patients.
In the EPd Cohort, subjects will receive treatment with elotuzumab in combination with 
pomalidomide and low-dose dexamethasone in a 28 day cycle. Subjects will receive 10 mg/kg IV 
elotuzumab on Days 1, 8, 15, and 22 of Cycles 1 and 2. Starting with Cycle 3, subjects will receive 
20 mg/kg on Day 1. 
As of Amendment 02, subjects will also be enrolled in the EN cohort to receive a combination of 
elotuzumab and nivolumab in a 28-day cycle. EN subjects will receive nivolumab 240 mg IV on 
Days 1 and 15 for Cycles 1-4. At Cycle 5 and beyond, subjects will receive 480 mg IV on Day 1. 
Subjects will also receive elotuzumab 10 mg/kg on Days 1, 8, 15, and 22 of Cycles 1 and 2. At 
Cycle 3 and beyond, subjects will receive 20 mg/kg of elotuzumab IV on Day 1. If subjects do not 
achieve clinical benefit represented by at least minimal response (≥MR) after 2 cycles of treatment
or do not achieve an objective response (≥PR) after 5 cycles of treatment, they may cross over to 
the EPd cohort at Day 1 of the subsequent cycles if they also meet the eligibility criteria for cross-
over specified in Section 3.3.4. 
Subjects will continue treatment as long as the subject has clinical benefit from the treatment and 
do not meet criteria for discontinuation.
All subjects will be assessed for safety and response as presented in the Time and Event Tables in 
Section 5. Subjects who are discontinued from further study treatment for reasons other than 
progression will be followed for disease progression. Following disease progression, subjects will 
be followed at least annually for survival.
Approximately 120 subjects will be screened in this study. A minimum of 60 subjects will be 
treated in the EPd Cohort. Approximately 30 subjects will be treated in the EN Cohort. The 
estimated duration of enrollment is 18 to 24 months, and the duration of the study is estimated at 
48 months from the date of first patient, first visit. Per Revised Protocol 03, the EPd cohort is 
closed for enrollment.
The study design schematic is presented in Figure 3.1-1.
Revised Protocol No.: 03
Date: 08-Mar-2018
45
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Figure 3.1-1:
Study Design Schematic
3.2
Post Study Access to Therapy
At the conclusion of the study, subjects who continue to demonstrate clinical benefit are eligible 
to receive BMS supplied study drug. Study drug will be provided via an extension of the study, a 
rollover study requiring approval by responsible health authority and ethics committee or through 
another mechanism at the discretion of BMS. BMS reserves the right to terminate access to BMS 
supplied study drug if any of the following occur: a) the marketing application is rejected by 
responsible health authority; b) the study is terminated due to safety concerns; c) the subject can 
obtain medication from a government sponsored or private health program; or d) therapeutic 
alternatives become available in the local market.
3.3
Study Population
For entry into the study, the following criteria MUST be met.
3.3.1
Inclusion Criteria
1. Signed Written Informed Consent
a) Subject is, in the investigator’s opinion, willing and able to comply with the protocol 
requirements.
b)
Subject has given voluntary written informed consent before performance of any 
study-related procedure not part of normal medical care, with the understanding that 
consent may be withdrawn by the subject at any time without prejudice to their future 
medical care.
2. Target Population
a) All subjects must have documented disease progression per IMWG (Appendix 4) criteria 
during or after their last anti-myeloma therapy.
Revised Protocol No.: 03
Date: 08-Mar-2018
46
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
b) As of Amendment 02, this criterion has been moved to criterion 2.i.i for clarity.
c) As of Amendment 02, this criterion has been moved to criterion 2.i.ii for clarity. 
d) Per Amendment 1, this criterion is no longer applicable. Specifications previously listed in 
criterion d) have been included in the revised criterion c) above. 
e) Measurable disease at screening, based on central laboratory results, defined as one or more 
of the following:
i)
Serum IgG, IgA, IgM M-protein ≥0.5 g/dL
ii) Urinary M-Protein ≥200 mg urinary M-protein excretion in a 24 hour collection sample 
iii) Involved serum free light chain (sFLC) ≥10 mg/dL provided the FLC ratio is abnormal.
f)
ECOG Performance Status ≤2 (Appendix 2).
g) Subject Re-enrollment: This study permits the re-enrollment of a subject that has 
discontinued the study as a pre-treatment failure (ie, has not been treated). If re-enrolled, 
the subject must be re-consented.
h) As of Amendment 02, this criterion has been moved to criterion 2.i.iii for clarity.
i)
for the EPd Cohort:
i)
Subjects must have received at least 1 but no greater than 2 prior lines of therapy (note: 
induction and stem cell transplants with or without maintenance therapy is considered 
1 line of therapy)
ii) Subjects must have received prior treatment with a lenalidomide-containing regimen 
for at least 2 consecutive cycles (full therapeutic dose) and must have been deemed as 
relapsed, refractory, or intolerant. Refractory is defined as progressing on-treatment or 
within 60 days of the last dose.30
NOTE: lenalidomide-based regimens to which the subject has relapsed or been 
refractory to is not required to be the most recent regimen received. 
iii) Prior elotuzumab exposure is permitted only if subjects fulfill all of the following:
(1).Did not discontinue elotuzumab due to any intolerable drug-related adverse 
reaction. 
(2).Did not participate in a prior elotuzumab clinical trial, regardless of treatment 
assignment
j)
For EN Cohort:
i)
Subjects must have received at least 4 prior lines of therapy including a proteasome 
inhibitor (PI), an immunomodulatory (IMID) agent, and an anti-CD38 antibody. 
3. Age and Reproductive Status
a) Males and Females, at least 18 years or legal age of consent per local regulations
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy tests (minimum sensitivity 25 IU/L or equivalent units of HCG), at 10-14 days 
prior to start of study drug; another within 24 hours prior to the start of study drug.
c) Women must not be breastfeeding
d) WOCBP must agree to follow instructions for method(s) of contraception for 1 month 
(4 weeks) before the start of treatment with study drugs, for the duration of treatment with 
study drugs, and for a total of 5 months post-treatment completion. 
Revised Protocol No.: 03
Date: 08-Mar-2018
47
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
e) Males who are sexually active with WOCBP must always use a latex or synthetic condom 
during any sexual contact with females of reproductive potential while taking 
pomalidomide and for up to 28 days after discontinuing pomalidomide, even if they have 
undergone a successful vasectomy. Male patients must not donate sperm. 
f)
Azoospermic males and WOCBP who are continuously not heterosexually active are 
exempt from contraceptive requirements. However, they must still undergo pregnancy 
testing as described in this section.
g) All subjects must be willing and able to comply with the local pomalidomide risk 
management program or the Pomalidomide Pregnancy Risk Prevention Plan
h) All subjects must agree not to share study medication. 
i)
Male subjects receiving elotuzumab or nivolumab must also agree to follow instructions 
for method(s) of contraception for 1 month (4 weeks) before the start of treatment with 
study drugs, for the duration of treatment with study drugs, and for a total of 7 months post-
treatment completion.
j)
Subjects must be willing to refrain from blood donations during study drug therapy and for 
90 days after therapy.
Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on 
the importance of pregnancy prevention and the implications of an unexpected pregnancy 
Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the 
use of highly effective methods of contraception. Highly effective methods of contraception have 
a failure rate of < 1% when used consistently and correctly.
At a minimum, subjects must agree to the use of two methods of contraception, with one method 
being highly effective and the other method being either highly effective or less effective as listed 
below:
HIGHLY EFFECTIVE METHODS OF CONTRACEPTION
•
Male condoms with spermicide
•
Hormonal methods of contraception including combined oral contraceptive pills, vaginal ring, 
injectables, implants and intrauterine devices (IUDs) such as Mirena® by WOCBP subject or 
male subject’s WOCBP partner. Female partners of male subjects participating in the study 
may use hormone based contraceptives as one of the acceptable methods of contraception since 
they will not be receiving study drug
•
IUDs, such as ParaGard®
•
Tubal ligation
•
Vasectomy
•
Complete Abstinence*
*Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an 
acceptable form of contraception for all study drugs. Female subjects must continue to have 
pregnancy tests. Acceptable alternate methods of highly effective contraception must be discussed 
in the event that the subject chooses to forego complete abstinence.
Revised Protocol No.: 03
Date: 08-Mar-2018
48
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
LESS EFFECTIVE METHODS OF CONTRACEPTION
•
Diaphragm with spermicide
•
Cervical cap with spermicide
•
Vaginal sponge
•
Male Condom without spermicide
•
Progestin only pills by WOCBP subject or male subject’s WOCBP partner
•
Female Condom*
•
* A male and female condom must not be used together
3.3.2
Exclusion Criteria
1. Target Disease Exceptions: EN and EPd Cohorts
a) Subjects with solitary bone or extramedullary plasmacytoma as the only evidence of 
plasma cells dyscrasia.
b) Subjects with monoclonal gammopathy of undetermined significance (MGUS), 
smoldering multiple myeloma (SMM), primary amyloidosis (no active multiple myeloma), 
Waldenstrom’s macroglobulinemia, or POEMS syndrome (plasma cell dyscrasia with poly 
neuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
c) Subjects with active plasma cell leukemia (defined as either 20% of peripheral blood white 
blood cell count comprised of plasma/CD138+ cells or an absolute plasma cell count of 
2 x 109/L)
d) Subjects with Central Nervous System involvement with multiple myeloma
2. Medical History and Concurrent Diseases - for both cohorts unless otherwise noted.
a) Any serious medical condition, laboratory abnormality, or psychiatric illness that would 
prevent the patient from signing the informed consent form
b) Any serious concurrent medical conditions that may make the patient non-evaluable or put
the patient’s safety at risk
c) Active infection that requires parenteral anti-infective treatment >14 days
d) Unable to tolerate thromboembolic prophylaxis while on the study
e) Severe hypersensitivity reaction to prior IMiD (thalidomide or lenalidomide)
f)
Grade > 2 peripheral neuropathy (per National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI CTCAE) v3.0)
g) Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic 
infection. 
h) Known HIV infection or known acquired immunodeficiency syndrome (AIDS). NOTE: 
Testing for HIV must be performed at sites where mandated locally
i)
Prior or concurrent malignancy, except for the following:
i)
Adequately treated basal cell or squamous cell skin cancer or in-situ carcinoma.
ii) Any other cancer from which the subject has been disease free for > 3 years prior to 
study entry.
Revised Protocol No.: 03
Date: 08-Mar-2018
49
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
j)
Additionally for EN Cohort:
i)
Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes 
mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, 
psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in 
the absence of an external trigger are permitted to enroll
ii) Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg 
daily prednisone equivalent) or other immunosuppressive medications within 14 days of 
initiation of study drug. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 
mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
3. Prior therapy or surgery
a) For EPd Cohort
i)
Prior treatment with pomalidomide
ii) Prior participation in an elotuzumab clinical trial regardless of treatment assignment.
iii) Prior discontinuation of treatment with elotuzumab due to intolerable drug-related 
adverse reactions
iv) Use of any anti-myeloma drug therapy within 14 days of the initiation of study drug 
treatment or use of any experimental drug therapy within 28 days of the initiation of 
study drug treatment
v) Treatment with melphalan within 4 weeks of the first dose of study drug
vi) Treatment with corticosteroids (other than the dexamethasone of anti-myeloma 
regimens) within 3 weeks of the first dose of study drug, except for the equivalent of 
≤10 mg prednisone per day or corticosteroids with minimal to no systemic absorption 
(ie, topical or inhaled steroids)
vii)Prior autologous stem cell transplant within 12 weeks of the first dose of study drug
viii)
Prior allogeneic stem cell transplant except subjects who have completed the stem 
cell transplant > 12 months prior to first dose of study drug, have no history of graft 
versus host disease, and are not on systemic immunosuppressive therapy
ix) Major cardiac surgery within 8 weeks prior to the first dose of study drug; all other 
major surgery within 4 weeks prior to the first dose of study drug.
b) For EN Cohort
i)
Prior treatment with elotuzumab or nivolumab (or any PD-1 or PD-L1 inhibitor).
ii) Use of any anti-myeloma drug therapy, within 14 days of the initiation of study drug 
treatment. Bisphosphonate use permitted if initiated prior to first dose of study 
medication
iii) All prior drug-related AEs should have resolved or returned to baseline for the subject 
to be eligible
iv) Prior autologous stem cell transplant within 12 weeks of the first dose of study drug
v) Prior allogeneic stem cell transplant or graft versus host disease (GVHD) within 
12 months of the first dose of study drug, or subjects on topical or systemic 
immunosuppressive therapy for GVHD
vi) Treatment with corticosteroids within 2 weeks of the first dose of study drug, except 
for the equivalent of ≤10 mg prednisone per day or corticosteroids with minimal to no 
systemic absorption (ie, topical or inhaled steroids) or for short course (≤4 days) of 
Revised Protocol No.: 03
Date: 08-Mar-2018
50
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
40 mg dexamethasone or equivalent for emergency use (baseline M proteins must be 
drawn after this short course and prior to randomization). Adrenal replacement steroid 
doses > 10 mg daily prednisone equivalent, are permitted in the absence of active 
autoimmune disease
vii)Major cardiac surgery within 8 weeks prior to the first dose of study drug; all other 
major surgery within 4 weeks prior to the first dose of study drug. (Kyphoplasty is not 
considered major surgery); subjects should have been fully recovered from any surgical 
related toxicities
4. Physical and Laboratory Test Findings - For both cohorts:
•
Absolute neutrophil count < 1 x 109/L (without growth factor support within 1 week)
•
Platelets < 75 x 109/L (< 30 x 109/L if ≥50% of bone marrow nucleated cells were 
plasma cells) (without transfusion support within 3 days)
•
Creatinine clearance < 30 ml/min according to the Cockroft-Gault formula:
−Female CrCl = (140 - age in years) x weight in kg x 0.85
72 x serum creatinine in mg/dl
−Male CrCl = (140 - age in years) x weight in kg x 1.00
72 x serum creatinine in mg/dl
•
Total bilirubin ≥2 x ULN (≥3 x ULN if Gilbert’s syndrome)
•
AST or ALT ≥3x ULN
5. Allergies and Adverse Drug Reaction (For both Cohorts)
a) Known severe hypersensitivity or allergy to dexamethasone, any excipients in elotuzumab, 
formulation or recombinant protein, or any monoclonal antibody
6. Other Exclusion Criteria (For both Cohorts)
a) Prisoners or subjects who are involuntarily incarcerated
b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness
3.3.3
Women of Childbearing Potential
A Women of childbearing potential (WOCBP) is defined as any female who has experienced 
menarche and who has not undergone surgical sterilization (hysterectomy or bilateral 
oophorectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in 
a woman over age 45 years in the absence of other biological or physiological causes. In addition, 
females under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level 
> 40mIU/mL to confirm menopause.
*Females treated with hormone replacement therapy, (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the investigators should use their judgment 
in checking serum FSH levels. If the serum FSH level is > 40 mIU/ml at any time during the 
washout period, the woman can be considered postmenopausal:
•
1 week minimum for vaginal hormonal products (rings, creams, gels)
Revised Protocol No.: 03
Date: 08-Mar-2018
51
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
•
4 week minimum for transdermal products
•
8 week minimum for oral products
Other parenteral products may require washout periods as long as 6 months.
3.3.4
Eligibility Criteria for EN Patients to Cross-over to EPd cohort. 
Crossover to EPd is permitted if:
•
No clinical benefit (≥minimal response) after 2 cycles. 
•
No objective response (≥PR) after 5 cycles of treatment. 
EN patients who cross-over will no longer be treated with nivolumab after the cross-over to the 
EPd cohort. Re-consent is not required for EN patients who cross-over to treatment with EPd. 
EN patients who do not cross-over can continue treatment with EN until discontinuation criteria 
are met, as specified in Section 3.5. 
Eligibility criteria for this study have been carefully considered to ensure the safety of the study 
subjects and that the results of the study can be used. It is imperative that subjects fully meet all 
eligibility criteria.
 
 
 
 
 
 
 
Revised Protocol No.: 03
Date: 08-Mar-2018
52
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 03
Date: 08-Mar-2018
53
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
 
 
 
 
3.5
Discontinuation of Subjects following any Treatment with Study Drug
Subjects MUST discontinue investigational product (and non-investigational product at the 
discretion of the investigator) for any of the following reasons:
•
Subject’s request to stop study treatment
•
Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the 
opinion of the investigator, indicates that continued participation in the study is not in the best 
interest of the subject
•
Termination of the study by Bristol-Myers Squibb (BMS) or meeting the criteria for stopping 
rules for cohort(Section 4.5.10). 
•
Loss of ability to freely provide consent through imprisonment or involuntary incarceration for 
treatment of either a psychiatric or physical (eg, infectious disease) illness
•
Pregnancy (Subjects must discontinue the study drugs.
•
Progressive Disease (Appendix 4)
•
Subjects who receive any non-protocol specified systemic anti-myeloma therapy before 
documented progression will be discontinued from all study treatment (including 
pomalidomide/dexamethasone); however, tumor assessments will continue at 4 week intervals 
until documented progression.
•
Subjects experiencing a Grade 4 infusion reaction related to elotuzumab must discontinue 
elotuzumab (refer to the Grade 4 Infusion Reaction subsection presented in Section 4.5.5)
Subjects may continue pomalidomide and dexamethasone treatment.
•
Subjects experiencing a Grade 3 or 4 infusion reaction related to nivolumab must discontinue 
nivolumab (only).
•
Subjects experiencing angioedema, Grade 4 rash, exfoliative or bullous rash, Stevens-Johnson 
syndrome, or toxic epidermal necrolysis related to pomalidomide must discontinue 
pomalidomide. Subjects may continue elotuzumab and dexamethasone.
•
Subjects experiencing a 56 day delay in all study drugs (elotuzumab, nivolumab, 
pomalidomide, and dexamethasone) due to an adverse event(s) related to study treatment must 
be discontinued from study drug. Subjects experiencing delays unrelated to study therapy, for 
example due to radiation therapy may delay study treatment up to 84 days. Further delays may 
be allowed after discussion with the medical monitor.
In the case of pregnancy, the investigator must immediately notify the BMS Medical 
Monitor/designee of this event, and treatment with the IMPs would immediately be stopped. In 
most cases, the study drug will be permanently discontinued in an appropriate manner. Please call 
the BMS Medical Monitor within 24 hours of awareness of the pregnancy. If the investigator 
Revised Protocol No.: 03
Date: 08-Mar-2018
54
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
determines a possible favorable benefit/risk ratio that warrants continuation of study drug 
(ie, allowing restart of study drug if the patient choses to terminate the pregnancy), a discussion 
between the investigator and the BMS Medical Monitor/designee must occur so that permission 
can be granted.
All subjects who discontinue study drug should comply with protocol-specified follow-up 
procedures outlined in Section 5. The only exception to this requirement is when a subject 
withdraws consent for all study procedures including post-treatment study follow-up or loses the 
ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either 
a psychiatric or physical illness).
If study drug is discontinued prior to the subject’s completion of the study, the reason for the 
discontinuation must be documented in the subject’s medical records and entered on the 
appropriate case report form (CRF/eCRF) page.
3.6
Post Study Drug Study Follow up
In this study, PFS is a key endpoint of the study. Post study follow-up is of critical importance and 
is essential to preserving subject safety and the integrity of the study. Subjects who discontinue 
study drug must continue to be followed for collection of PFS. Subjects who discontinue study 
therapy must also continue to be followed for overall survival data in line with Section 5 until 
death or the conclusion of the study.
3.6.1
Withdrawal of Consent
Subjects who request to discontinue study drug will remain in the study and must continue to be 
followed for protocol specified follow-up procedures. The only exception to this is when a subject 
specifically withdraws consent for any further contact with him/her or persons previously 
authorized by subject to provide this information. Subjects should notify the investigator of the 
decision to withdraw consent from future follow-up in writing, whenever possible. The 
withdrawal of consent should be explained in detail in the medical records by the investigator, as 
to whether the withdrawal is from further treatment with study drug only or also from study 
procedures and/or post treatment study follow-up, and entered on the appropriate CRF/eCRF page. 
In the event that vital status (whether the subject is alive or dead) is being measured, publicly 
available information should be used to determine vital status only as appropriately directed in 
accordance with local law.
3.6.2
Lost to Follow-Up
All reasonable efforts must be made to locate subjects to determine and report their ongoing status. 
This includes follow-up with persons authorized by the subject as noted above. Lost to follow-up 
is defined by the inability to reach the subject after a minimum of three documented phone calls, 
faxes, or emails as well as lack of response by subject to one registered mail letter. All attempts 
should be documented in the subject’s medical records. If it is determined that the subject has died, 
the site will use permissible local methods to obtain the date and cause of death.
If investigator’s use of third-party representative to assist in the follow-up portion of the study has 
been included in the subject’s informed consent, then the investigator may use a Sponsor-retained 
Revised Protocol No.: 03
Date: 08-Mar-2018
55
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
third-party representative to assist site staff with obtaining subject’s contact information or other 
public vital status data necessary to complete the follow-up portion of the study. The site staff and 
representative will consult publicly available sources, such as public health registries and 
databases, in order to obtain updated contact information. If after all attempts, the subject remains 
lost to follow-up, then the last known alive date as determined by the investigator should be 
reported and documented in the subject’s medical records.
4.
STUDY DRUG
Study drug includes both Investigational [Medicinal] Product (IP/IMP) and Non-investigational 
[Medicinal] Product (Non-IP/Non-IMP) and are listed in Table 4.-1.
Revised Protocol No.: 03
Date: 08-Mar-2018
56
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 4.-1:
Study Drugs for CA204142
Product Description / 
Class and Dosage Form
Potency
IMP/Non-IMP
Blinded or 
Open Label
Packaging / 
Appearance
Storage Conditions
(per label)
Elotuzumab Powder for 
Solution for Infusion
300 mg/vial or 400 
mg/vial
IMP
Open Label
Vial 
Refer to the label on the 
container and/or the pharmacy 
manual.
Nivolumab Solution for 
Injection
100 mg (10 mg/mL)
IMP
Open label
Vial
Refer to the label on the 
container and/or the pharmacy 
manual.
Dexamethasone Tablets
2 mg and 4 mg and 
various strengths
Non-IMP
Open-label
Various packing 
configurations
Refer to label on container or 
package insert / summary of 
product characteristics
Dexamethasone Solution
4 mg/mL, 8 mg/mL and 
various strengths
Non-IMP
Open-label
Various packing 
configurations
Refer to label on container or 
package insert / summary of 
product characteristics
Pomalidomide Capsules
1 mg, 2 mg, 3 mg and 4 
mg
IMP
Open label
Various packing 
configurations
Refer to label on container or 
package insert 
Pomalidomide (Pomalyst®), Dexamethasone tablets and solution for IV infusion will be obtained by the investigating site’s standard prescribing procedures.
Revised Protocol No.: 03
Date: 08-Mar-2018
57
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
4.1
Investigational Product
An investigational product, also known as investigational medicinal product in some regions, is 
defined a pharmaceutical form of an active substance or placebo being tested or used as a reference 
in a clinical study, including products already with a marketing authorization but used or 
assembled (formulated or packaged) differently than the authorized form, or used for an 
unauthorized indication, or when used to gain further information about the authorized form.
The investigational product should be stored in a secure area according to local regulations. It is 
the responsibility of the investigator to ensure that investigational product is only dispensed to 
study subjects. The investigational product must be dispensed only from official study sites by 
authorized personnel according to local regulations.
4.2
Non-investigational Product
Other medications used as support or escape medication for preventative, diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diagnosis, may be considered as non-
investigational products.
In this protocol, non-investigational product(s) are: dexamethasone tablets and concentrate for 
solution for IV infusion, or products used for Elotuzumab premedication Section 4.5.3.1 or 
thromboprophylaxis (Section 3.4.1).
4.3
Storage and Dispensing
The product storage manager should ensure that the study drug is stored in accordance with the
environmental conditions (temperature, light, and humidity) as determined by BMS. If concerns 
regarding the quality or appearance of the study drug arise, the study drug should not be dispensed 
and contact BMS immediately.
Study drug not supplied by BMS will be stored in accordance with the package insert.
Investigational product documentation (whether supplied by BMS or not) must be maintained that 
includes all processes required to ensure drug is accurately administered. This includes 
documentation of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).
Procedures for proper handling and disposal of anticancer drugs should be considered.
The investigator or designee accepts responsibility for documenting traceability and study drug 
integrity in accordance with requirements applicable under law and the standard operating 
procedures (SOPs)/standards of the sourcing pharmacy. These records should include:
•
label identification number or batch number
•
the amount dispensed to and returned by each subject, including unique subject identifiers 
dates and initials of person responsible for Investigational Product dispensing/accountability, 
as per the Delegation of Authority Form.
Revised Protocol No.: 03
Date: 08-Mar-2018
58
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
4.3.1
Elotuzumab
The lyophilized elotuzumab drug product should be stored at 2° to 8°C. Before administration the 
drug product must be reconstituted with Sterile Water for Injection, USP, and then further diluted 
in 0.9% sodium chloride normal saline, United States Pharmacopoeia (USP), as per the instructions 
in Appendix 3. The dose of elotuzumab to be administered to a subject will be calculated by 
multiplying the subject’s weight (kg) by 10 or 20 mg/kg. The subject’s predose weight on Day 1 
of each cycle will be used to calculate the dose for each cycle. The screening weight can be used 
for the Cycle 1 dose calculation. Each dose should be infused as per instructions in Appendix 3. 
The infusion start and stop time will be recorded in the CRF/eCRF. If the infusion is stopped 
mid-session for any reason, the stop/start time must be recorded together with an explanation. 
Please refer to the pharmacy manual for detailed guidance on storage, preparation and 
administration.
4.3.2
Nivolumab
Nivolumab will be administered at a dose of 240 mg as an intravenous infusion over 30 minutes 
every 2 weeks (Days 1 and 15 of each 28 day cycle) during Cycles 1 through 4. Starting Cycle 5 
and beyond, nivolumab will be administered at a dose of 480 mg as an intravenous infusion over 
30 minutes every 4 weeks (Day 1 of each 28 day cycle). 
Please refer to the nivolumab investigator brochure and/or pharmacy reference sheet for guidelines 
on drug preparation and administration. Flush the intravenous line at the end of infusion.
Nivolumab vials must be stored at a temperature of 2°to 8°C and should be protected from light 
and freezing. Recommended safety measures for preparation and handling of nivolumab include 
laboratory coats and gloves.
4.3.3
Pomalidomide
Pomalidomide is an analogue of thalidomide. Thalidomide is a known human teratogen that causes 
severe life-threatening human birth defects. If pomalidomide is taken during pregnancy, it may 
cause birth defects or death to an unborn baby.
Because of this potential toxicity and to avoid fetal exposure to pomalidomide, pomalidomide is 
only available under a special restricted distribution program. This program is called Pomalyst®
REMS. Pomalidomide must only be dispensed to subjects who meet all the conditions of 
Pomalyst® REMS. Subjects who have the potential of pregnancy in Pomalyst® REMS must be 
instructed about contraception and undergo the scheduled pregnancy tests.
Please see the US package insert for additional information for prescribing to female subjects and 
male subjects about this restricted distribution program.
Subjects should not break, chew or open the capsules. Pomalidomide should be taken without food 
(at least 2 hours before or 2 hours after a meal). Only enough pomalidomide for one cycle of 
therapy will be supplied to the patient each cycle in accordance with Pomalyst® REMS.
Revised Protocol No.: 03
Date: 08-Mar-2018
59
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
4.3.4
Dexamethasone
Dexamethasone tablets and solution for IV infusion is considered NIMP for this study and will not 
be provided by the sponsor. It will be obtained by the investigating sites standard prescribing 
procedures. Marketed product will be utilized for this study and should be stored in accordance 
with the package insert.
4.4
Method of Assigning Subject Identification
After the subject’s eligibility is established and informed consent has been obtained, the subject 
must be enrolled into the study by calling an interactive voice response system (IVRS) to obtain 
the subject number. The following information is required for subject enrollment:
•
Date of Birth
•
Gender
•
Site number
•
Date that informed consent was obtained
Instructions on the use of IVRS will be provided in a separate document.
Revised Protocol No.: 03
Date: 08-Mar-2018
60
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
4.5
Selection and Timing of Dose for Each Subject
Table 4.5-1:
Treatment Schedule for EPd Cohort and Cross over Patients from EN Cohort
Cycle
Cycle 1
Cycle 2
Cycle 3 and beyondb
Day
1
8
15
22
1
8
15
22
1
8
15
22
Elotuzumab
10 
mg/kg
10 
mg/kg
10 
mg/kg
10 
mg/kg
10 
mg/kg
10 
mg/kg
10 
mg/kg
10 
mg/kg
20 
mg/kg
Dexamethasonea
Pomalidomide
Days 1-21
Days 1-21
Days 1-21
a See Table 4.5.2-1 for the dose of dexamethasone.
b Patients who cross over from the EN cohort will follow the treatment schedule for Cycle 3 and beyond
Table 4.5-2:
Treatment Schedule for the EN Cohort
Cycle
Cycles 1 and 2
Cycles 3 and 4
Cycle 5 and beyond
Day
1
8
15
22
1
8
15
22
1
8
15
22
Elotuzumab
10 
mg/kg
10 
mg/kg
10 
mg/kg
10 
mg/kg
20 
mg/kg
20 
mg/kg
Nivolumab
240 
mg
240 
mg
240 
mg
240 
mg
480 
mg
See Table 4.5.2-2 for dexamethasone IV dose administered as pre-medication for elotuzumab
Revised Protocol No.: 03
Date: 08-Mar-2018
61
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
4.5.1
Pomalidomide
Pomalidomide 4 mg will be administered orally once daily for the first 3 weeks of a 4-week cycle. 
Pomalidomide should be taken without food (at least 2 hours before or 2 hours after a meal). 
Subjects should not break, chew or open the capsules.
On the days of elotuzumab administration, the dose of pomalidomide is to be administered at 
least 2 hours after completion of elotuzumab dosing. 
Pomalidomide delay should be performed as clinically indicated at the discretion of the 
investigator.
Subjects should be instructed that if a dose of pomalidomide has been missed and it has been less 
than 12 hours since the subject’s regular dosing time, to take pomalidomide as soon as the subject 
remembers. If it has been more than 12 hours, the dose must be skipped. Subjects should not take 
2 doses at the same time
Females of reproductive potential must have negative pregnancy testing and use contraception 
methods before initiating pomalidomide.
4.5.2
Dexamethasone
Dexamethasone for subjects in the EPd cohort will be administered as indicated in Table 4.5.2-1. 
Table 4.5.2-1:
Dexamethasone Dosing, EPd Cohort
Age
Day
1
8
15
22
Cycles 1 and 2
≤ 75 years old
Dexamethasone
(mg)
28 mg PO +
8 mg IVa,b
28 mg PO +
8 mg IVa,b
28 mg PO +
8 mg IVa,b
28 mg PO +
8 mg IVa,b
> 75 years old
Dexamethasone
(mg)
8 mg PO +
8 mg IVa,b
8 mg PO +
8 mg IVa,b
8 mg PO +
8 mg IVa,b
8 mg PO +
8 mg IVa,b
Cycles 3 and beyond
≤ 75 years old
Dexamethasone
(mg)
28 mg PO +
8 mg IVa,b
40 mg PO per 
weekc
40 mg PO per 
weekc
40 mg PO per 
weekc
> 75 years old
Dexamethasone
(mg)
8 mg PO +
8 mg IVa,b
20 mg PO per 
weekc
20 mg PO per 
weekc
20 mg PO per 
weekc
a On days of elotuzumab, infusion dexamethasone will be administered as a split dose of:
28 mg PO, for subjects ≤75 years old or 8 mg PO for subjects > 75 years old (between 3 - 24 hours before the start 
of elotuzumab infusion)
AND
8 mg IV (on the day of elotuzumab infusion at least 45 minutes before the start of infusion)
b If elotuzumab dosing is skipped or discontinued, dexamethasone will be administered orally as in days without 
elotuzumab.
c Note the dexamethasone dose, as elotuzumab is not given on Days 8, 15 and 22 of cycle 3 and beyond.
Revised Protocol No.: 03
Date: 08-Mar-2018
62
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
At the investigator’s discretion, the oral dexamethasone may be given as a split dose over 
2 consecutive days. Dexamethasone delay should be performed as clinically indicated at the 
discretion of the investigator.
Dexamethasone for subjects in the EN cohort will be administered as indicated in Table 4.5.2-2.
Table 4.5.2-2:
Dexamethasone Dosing: EN Cohort
Age
Day
1
8
15
22
Cycles 1 and 2
All subjects 
Dexamethasone
(mg)
8 mg IVa,b
8 mg IVa,b
8 mg IVa,b
8 mg IVa,b
Cycles 3 and beyond
All subjects
Dexamethasone
(mg)
8 mg IVa,b
--
--
--
a On days of elotuzumab, dexamethasone will be administered as a premedication at dose of 8 mg IV at least 45 
minutes before the start of infusion)
b If elotuzumab dosing is skipped or discontinued, dexamethasone will be not be administered.
4.5.3
Elotuzumab
Elotuzumab will be administered intravenously at a dose of 10 mg/kg weekly (Days 1, 8, 15, and 
22 of a 4-week cycle) of the first 2 cycles and starting Cycle 3, elotuzumab will be administered 
intravenously at a dose of 20 mg/kg of Day 1 of each cycle. A window of -1 to + 3 days is permitted 
in Cycles 1 and 2.
In Cycle 1 and 2, an elotuzumab dose that falls outside of the pre-specified window must be 
skipped.
In Cycles 3 and beyond, elotuzumab dosing may be delayed for up to 1 week as clinically 
indicated. If unable to administer within 1 week, then the dose should be skipped and resumption 
of the elotuzumab continues per the protocol defined schedule.
4.5.3.1
Premedication Before Elotuzumab in Subjects Without a Prior Infusion 
Reaction
On weeks of elotuzumab infusion, the dexamethasone dose for the EPd cohort will be split into a 
PO and IV administration (described in Section 4.5.2), which will also serve as premedication for 
elotuzumab.
Intravenous and PO dexamethasone doses are calculated to provide a total dose that is 
bioequivalent to an oral dose of 40 mg (subjects who are ≤75 years old) or 20 mg (in subjects who 
are > 75 years old). (Dexamethasone 8 mg IV is approximately bioequivalent to 11 mg PO).
Revised Protocol No.: 03
Date: 08-Mar-2018
63
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
For the EN cohort, dexamethasone will still be administered as a premedication for elotuzumab at 
a dose of 8 mg IV 45-90 minutes prior to initiating the elotuzumab infusion.
In addition, the following must also be administered 45 to 90 minutes before initiating the 
elotuzumab:
•
H1 blocker: diphenhydramine (25 - 50 mg PO or IV) or equivalent
•
H2 blocker: ranitidine (50 mg IV) or equivalent (eg, 150 mg PO)
•
Acetaminophen (650 - 1000 mg PO)
4.5.3.2
Elotuzumab Premedication Regimen in Subjects With a Prior Infusion 
Reaction
To be re-treated with elotuzumab, subjects with a prior infusion reaction must receive H1, H2 
blockers and acetaminophen at maximum doses specified (ie, 50 mg diphenhydramine, 50 mg 
ranitidine [or equivalent], and 650-1000 mg acetaminophen) 45 to 90 minutes before initiating the 
elotuzumab.
Recommended dexamethasone dosing is summarized in Table 4.5.3.2-1.
Decisions to use more aggressive premedication schemes in subjects with prior Grade 1 infusion 
reactions or only one prior Grade 2 infusion reaction must be approved by the Medical Monitor.
Revised Protocol No.: 03
Date: 08-Mar-2018
64
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 4.5.3.2-1:
Corticosteroid Premedication
For Subjects ≤75 years old
For Subjects > 75 years old
Prior Infusion 
Reaction
Corticosteroid Premedicationa Before Elotuzumab
None or
Only Grade 1 
infusion reactionb
28 mg po dexamethasone (3 - 24 hrs 
before elotuzumab)
AND
8 mg IV dexamethasone at least 45 min 
before elotuzumab 
8 mg po dexamethasone (3 - 24 hrs before 
elotuzumab) 
AND
8 mg IV dexamethasone at least 45 min before 
elotuzumab 
Prior Grade 2 
infusion reactionc
28 mg po dexamethasone (3 - 24 hrs 
before elotuzumab) 
AND
10 mg IV dexamethasone at least 45 min 
before elotuzumab 
8 mg po dexamethasone (3 - 24 hrs before 
elotuzumab) 
AND
10 mg IV dexamethasone at least 45 min 
before elotuzumab 
Prior Grade 3 or 
recurrent Grade 2 
infusion reaction
8 mg oral dexamethasone (12 - 24 hrs 
before elotuzumab) 
AND
8 mg oral dexamethasone (at least 3 hrs 
before elotuzumab, on the same day as 
the infusion) 
AND
18 mg IV dexamethasone at least 45 min 
before elotuzumab
2 mg oral dexamethasone (12 - 24 hrs before 
elotuzumab) 
AND
2 mg oral dexamethasone (at least 3 hrs before 
elotuzumab, on the same day as the infusion) 
AND
12 mg IV dexamethasone at least 45 min 
before elotuzumab
For prior infusion reactions, use maximum doses H1, H2 blockers and acetaminophen as described in Section 4.5.3.1.
a At the discretion of the investigator, the oral dexamethasone component may be given as a split dose 12-24 and 
3 hours before elotuzumab.
b Subjects with prior Grade 1 infusion reaction may be pre-medicated as per Grade 2 infusion reactions.
c Subjects with prior Grade 2 infusion reaction may be pre-medicated as per Grade 3 infusion reactions.
If a subject with a prior Grade 2 to 3 infusion reaction also requires dose reduction of 
dexamethasone, the dexamethasone dose on the days of elotuzumab infusion should be no less 
than 8 mg IV (on the day of elotuzumab infusion at least 45 minutes before elotuzumab).
Subjects with Grade 4 infusion reaction are not eligible to receive additional elotuzumab. These 
subjects may continue to receive pomalidomide and dexamethasone.
4.5.3.3
Elotuzumab Infusion Rate
During the first cycle, the elotuzumab infusion rate will be increased gradually to a maximum of 
5 mL/min as presented in the table below. An infusion rate increase to the next higher level is 
permitted only if no infusion reactions are encountered.
Revised Protocol No.: 03
Date: 08-Mar-2018
65
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 4.5.3.3-1:
Elotuzumab Infusion Rate
Infusion Rate
Duration of infusion
Volume delivered
Volume remaining
Cycle 1 Dose 1
Approximate Total Duration: 2hrs 50min
262 mL*
0.5 mL/min
30 min
15 mL
247 mL
1 mL/min
30 min
30 mL
217 mL
2 mL/min
110 min
217 mL
0 mL
Cycle 1 Dose 2
Approximate Total Duration: 1hr 13min
262 mL
3 mL/min
30 min
90 mL
172 mL
4 mL/min
43 min
172 mL
0 mL
Cycle 1 Dose 3 and 4
Approximate Total Duration: 53min
262 mL
5 mL/min
53 min
262 mL
0 mL
Cycle 2 +
Approximate Total Duration: 53min
262 mL
5 mL/min
53 min
262 mL
0 mL
* Volume for 80 kg subject. Total volume varies according to the subject weight.
Please note that infusion rate increase to the next higher level only if no infusion reactions 
encountered.
4.5.4
Nivolumab
Nivolumab will be administered at a dose of 240 mg as an intravenous infusion over 30 minutes 
every 2 weeks (Days 1 and 15 of each 28 day cycle) during Cycles 1 through 4. Starting Cycle 5 
and beyond, nivolumab will be administered at a dose of 480 mg as an intravenous infusion over 
30 minutes every 4 weeks (Day 1 of each 28 day cycle).
Nivolumab should be administered before elotuzumab. 
When administering Q2W, subjects may be dosed no less than 12 days from the previous dose. 
There are no premedications recommended for nivolumab on the first cycle.
Nivolumab can be delayed within a 3 day window of Day 1 and Day 15, during cycles 1 through 4, 
as long as the 12 day interval between 2 nivolumab doses is respected. 
When administering Q4W, subjects may be dosed no less than 21 days from the previous dose. 
During cycles 5 and beyond, nivolumab can be delayed within a week.
Doses that fall outside the allowed window, regardless of the schedule, should be skipped.
Subjects should be carefully monitored for infusion reactions during nivolumab administration. If 
an acute infusion reaction is noted, subjects should be managed according to Section 4.5.6.
There will be no dose escalations or reductions of nivolumab allowed. Doses of nivolumab may 
be interrupted, delayed, or discontinued in accordance with Section 4.5.8 depending on how well 
the subject tolerates the treatment.
Revised Protocol No.: 03
Date: 08-Mar-2018
66
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
4.5.5
Guidelines for Elotuzumab Infusion in Subjects with Infusion Reactions
4.5.5.1
Grade 1 Infusion Reaction
Grade 1 elotuzumab infusion-related reactions by definition do not require intervention; however, 
increased monitoring is recommended.
4.5.5.2
Grade 2 or 3 Infusion Reaction
Infusion reactions during the elotuzumab infusion: For a Grade 2 or 3 elotuzumab 
infusion-related reaction, the infusion must be interrupted. The subject should be treated as 
clinically indicated with one or more of the following medications or interventions: antiemetics, 
antihistamines, analgesics, corticosteroids, leukotriene inhibitors, oxygen inhalation, epinephrine, 
bronchodilators, or other supportive measures as indicated.
Once the elotuzumab infusion-related reaction has resolved to Grade ≤1, the infusion can be 
restarted at 0.5 mL/minute. If symptoms do not recur after 30 minutes, the infusion rate may be 
increased in a stepwise fashion (0.5 mL/minute every 30 minutes) to the rate at which the infusion 
reaction occurred. If no recurrence of the infusion reaction, the escalation regimen can be resumed. 
Subjects who experience an infusion reaction require vital signs to be monitored every 30 minutes 
for 1 or 2 hours after the end of the elotuzumab infusion (as clinically indicated). If the elotuzumab 
infusion reaction recurs, the infusion must be stopped and not restarted on that day. Appropriate 
therapy should be administered to address the subject’s signs and symptoms. The infusion can be 
reattempted at the next protocol defined infusion time point at the investigator’s discretion with 
additional premedication as described throughout Section 4.5.3.1
Infusion reactions after the completion of elotuzumab infusion: Should a Grade 2 or 3 infusion 
reaction occur following completion of an elotuzumab infusion, the subject should be treated as 
clinically indicated with 1 or more of the following medications or interventions: 
diphenhydramine, acetaminophen, hydrocortisone, H2 inhibitor, leukotriene inhibitor, oxygen 
inhalation, epinephrine, bronchodilators, or other supportive measures as indicated.
Elotuzumab infusions on subsequent weeks after a prior Grade 2 or 3 infusion reaction: 
Subjects with prior Grade 2 or 3 infusion reactions should have the next infusion started at 
0.5 mL/min and then escalated in a stepwise fashion (0.5 mL/minute every 30 minutes) to the rate 
at which the infusion reaction occurred. If no Grade ≥2 infusion reaction occurs, the escalation 
regimen may be resumed and the next infusion may be initiated as planned per the regimen.
4.5.5.3
Grade 4 Infusion Reaction
Subjects with a Grade 4 elotuzumab infusion reaction must have elotuzumab permanently 
discontinued.
4.5.6
Treatment of Nivolumab-Related Infusion Reactions
Since nivolumab contains only human immunoglobulin protein sequences, it is unlikely to be 
immunogenic and induce infusion or hypersensitivity reactions. However, if such a reaction were 
to occur, it might manifest with fever, chills, rigors, headache, rash, pruritus, arthralgia, 
hypotension, hypertension, bronchospasm, or other allergic-like reactions. All Grade 3 or 
Revised Protocol No.: 03
Date: 08-Mar-2018
67
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
4 infusion reactions should be reported within 24 hours to the study medical monitor and reported 
as an SAE if it meets the criteria. Infusion reactions should be graded according to NCI CTCAE 
(Version 3.0) guidelines.
Treatment recommendations are provided below and may be modified based on local treatment 
standards and guidelines, as appropriate:
For Grade 1 symptoms: (mild reaction; infusion interruption not indicated; intervention not 
indicated):
•
Remain at bedside and monitor subject until recovery from symptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg 
(or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg at least 30 minutes before 
additional nivolumab administrations.
For Grade 2 symptoms: (moderate reaction required therapy or infusion interruption but responds 
promptly to symptomatic treatment (eg, antihistamines, non-steroidal anti-inflammatory drugs, 
narcotics, corticosteroids, bronchodilators, IV fluids); prophylactic medications indicated for 
≤24 hours):
•
Stop the nivolumab infusion, begin an IV infusion of normal saline, and treat the subject with 
diphenhydramine 50 mg IV (or equivalent) and/or acetaminophen/paracetamol 325 to 
1000 mg; remain at bedside and monitor subject until resolution of symptoms. Corticosteroid 
and/or bronchodilator therapy may also be administered as appropriate. If the infusion is 
interrupted, then restart the infusion at 50% of the original infusion rate when symptoms 
resolve; if no further complications ensue after 30 minutes, the rate may be increased to 100% 
of the original infusion rate. Monitor subject closely. If symptoms recur, then no further 
nivolumab will be administered at that visit.
•
For future infusions, the following prophylactic premedications are recommended: 
diphenhydramine 50 mg (or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg 
should be administered at least 30 minutes before nivolumab infusions. If necessary, 
corticosteroids (up to 25 mg of SoluCortef or equivalent) may be used.
For Grade 3 or 4 symptoms: (severe reaction, Grade 3: prolonged [ie, not rapidly responsive to 
symptomatic medication and/or brief interruption of infusion]; recurrence of symptoms following 
initial improvement; hospitalization indicated for other clinical sequelae (eg, renal impairment, 
pulmonary infiltrates). Grade 4: Life-threatening; pressor or ventilator support indicated):
•
Immediately discontinue infusion of nivolumab. Begin an IV infusion of normal saline and 
treat the subject as follows: Recommend bronchodilators, epinephrine 0.2 to 1 mg of a 1:1000 
solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution injected 
slowly for IV administration, and/or diphenhydramine 50 mg IV with methylprednisolone 
100 mg IV (or equivalent), as needed. Subject should be monitored until the Investigator is 
comfortable that the symptoms will not recur. Nivolumab will be permanently discontinued. 
Investigators should follow their institutional guidelines for the treatment of anaphylaxis. 
Remain at bedside and monitor subject until recovery of the symptoms.
Revised Protocol No.: 03
Date: 08-Mar-2018
68
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
In case of late-occurring hypersensitivity symptoms (eg, appearance of a localized or generalized 
pruritus within 1 week after treatment), symptomatic treatment may be given (eg, oral 
antihistamine or corticosteroids).
4.5.7
Management Algorithms for Immune Related Adverse Events
Immuno-oncology (I-O) agents are associated with AEs that can differ in severity and duration 
than AEs caused by other therapeutic classes. Nivolumab is considered an immuno-oncology agent 
in this protocol. Early recognition and management of AEs associated with immuno-oncology 
agents may mitigate severe toxicity. Management Algorithms have been developed to assist 
investigators in assessing and managing the following groups of AEs:
•
Gastrointestinal
•
Renal
•
Pulmonary
•
Hepatic
•
Endocrinopathy
•
Skin
•
Neurological
The above algorithms are found in Appendix 7 and in the nivolumab Investigator Brochure.
4.5.8
Dose Delay, Interruption, or Discontinuation for All Subjects
Please refer to Sections 4.5.8.1, 4.5.8.2, 4.5.8.3, and 4.5.8.4 for drug-specific delay guidance.
For each cohort, if the dose of one drug in the regimen (ie, pomalidomide, dexamethasone, 
nivolumab, or elotuzumab) is delayed, interrupted, or discontinued, the treatment with the other 
drugs may continue as scheduled. However, in the EPd cohort, if dexamethasone is delayed or 
discontinued discuss ongoing elotuzumab administration with the Medical Monitor. Subjects 
experiencing a 56 day delay in all study drugs due to an adverse event(s) related to study treatment 
must be discontinued from study drug. Subjects experiencing delays unrelated to study therapy, 
for example due to radiation therapy, may delay study treatment after discussion with the medical 
monitor.
Each cycle is 28 days. While dose delays or interruptions are permitted, the start of each cycle 
cannot be delayed and is fixed (ie, anchored) relative to Cycle 1 Day 1. Adjustments to the Cycle 1 
Day 1 anchored schedule should not be performed. Missed doses should be skipped, not delayed, 
if not given within the allowed window.
Subjects may continue on study therapy even if components of the study therapy must be 
discontinued. For example, a subject may continue on study therapy if elotuzumab must be 
discontinued for an adverse event or other reason. Patients are considered still on study therapy 
even if they continue solely on pomalidomide, dexamethasone, or nivolumab.
Revised Protocol No.: 03
Date: 08-Mar-2018
69
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
4.5.8.1
Dose Delay for Elotuzumab
In Cycles 1 to 2, elotuzumab doses that fall outside of the pre-specified window of -1 to +3 days 
must be skipped.
Beginning with Cycle 3 and beyond, elotuzumab dosing may be delayed for up to 1 week. If unable 
to administer within 1 week, then the dose should be skipped and resumption of the elotuzumab 
continues per the protocol defined schedule.
Subjects experiencing a Grade 4 infusion reaction related to elotuzumab must permanently 
discontinue elotuzumab.
4.5.8.2
Dose Delay for Dexamethasone
Dexamethasone interruption should be performed as clinically indicated at the discretion of the 
investigator.
The weekly dexamethasone that coincides with or is temporally closest to the next elotuzumab 
dosing must be administered as part of the premedication for elotuzumab per the guidance in 
Section 4.5.3.1.
4.5.8.3
Dose Delay for Pomalidomide
Pomalidomide interruption should be performed as clinically indicated at the discretion of the 
investigator.
Subjects should be instructed that if a dose of pomalidomide has been missed and it has been less 
than 12 hours since the subject’s regular dosing time, to take pomalidomide as soon as the subject 
remembers. If it has been more than 12 hours, the dose must be skipped. Subjects should not take 
2 doses at the same time
4.5.8.4
Dose Delay for Nivolumab
Nivolumab administration should be delayed for the following:
•
Any Grade ≥2 non-skin, drug-related adverse event, with the following exceptions:
−
Grade 2 drug-related fatigue or laboratory abnormalities do not require a treatment 
delay/ interruption.
•
Any Grade 3 skin, drug-related adverse event
•
Any Grade 3 drug-related laboratory abnormality, with the following exceptions for 
lymphopenia, AST, ALT, or total bilirubin or asymptomatic amylase or lipase:
−
Grade 3 lymphopenia does not require dose delay/interruption
−
If a subject has a baseline AST, ALT, or total bilirubin that is within normal limits, 
delay/interrupt dosing for drug-related Grade ≥2 toxicity.
−
If a subject has baseline AST, ALT, or total bilirubin within the Grade 1 toxicity range, 
delay/interrupt dosing for drug-related Grade ≥3 toxicity.
−
Any Grade ≥3 drug-related amylase or lipase abnormality that is not associated with 
symptoms or clinical manifestations of pancreatitis does not require dose 
delay/interruption.
•
Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying the dose of study medication.
Revised Protocol No.: 03
Date: 08-Mar-2018
70
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Subjects who require delay/interruption of nivolumab should be re-evaluated as clinically 
indicated and resume nivolumab dosing, as per the protocol dosing schedule when re-treatment 
criteria are met.
4.5.8.5
Criteria to Resume Treatment with Nivolumab
Subjects may resume treatment with nivolumab when the drug-related AE(s) resolve(s) to 
Grade ≤1 or baseline, with the following exceptions:
•
Subjects may resume treatment in the presence of Grade 2 fatigue
•
Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in 
the presence of Grade 2 skin toxicity
−
Subjects with baseline Grade 1 AST/ALT or total bilirubin who require dose 
delays/interruptions for reasons other than a 2-grade shift in AST/ALT or total bilirubin 
may resume treatment in the presence of Grade 2 AST/ALT OR total bilirubin
−
Subjects with combined Grade 2 AST/ALT AND total bilirubin values meeting 
discontinuation parameters (Section 4.5.8.6) should have treatment permanently 
discontinued
•
Drug-related pulmonary toxicity, diarrhea, colitis, uveitis or neurologic toxicity must have 
resolved to baseline before treatment is resumed. Subjects with persistent Grade 1 pneumonitis 
after completion of a steroid taper over at least 1 month may be eligible for retreatment if 
discussed with and approved by the BMS Medical Monitor.
•
Drug-related endocrinopathies adequately controlled with only physiologic hormone 
replacement may resume treatment after consultation with the BMS Medical Monitor
Dose delay/interruption of nivolumab which results in treatment interruption of > 8 weeks require 
treatment discontinuation, with exceptions as noted in Section 4.5.8.6. There will be no dose 
reductions for nivolumab.
4.5.8.6
Nivolumab Dose Discontinuation
Nivolumab treatment should be permanently discontinued for the following:
•
Any Grade 2 drug-related uveitis, eye pain or blurred vision that does not respond to topical 
therapy and does not improve to Grade 1 severity within the re-treatment period OR requires 
systemic treatment
•
Any Grade 3 non-skin, drug-related adverse event lasting > 7 days, with the following 
exceptions for laboratory abnormalities, drug-related uveitis, pneumonitis, bronchospasm, 
hypersensitivity reactions, infusion reactions, and endocrinopathies:
−
Grade 3 drug-related uveitis, pneumonitis, bronchospasm, hypersensitivity reaction, or 
infusion reaction of any duration requires discontinuation
−
Grade 3 drug-related endocrinopathies adequately controlled with only physiologic 
hormone replacement do not require discontinuation
−
Grade 3 drug-related laboratory abnormalities do not require treatment discontinuation 
except:
♦Grade 3 drug-related thrombocytopenia > 7 days or associated with bleeding requires 
Revised Protocol No.: 03
Date: 08-Mar-2018
71
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
discontinuation
♦Any drug-related liver function test (LFT) abnormality that meets the following criteria 
require discontinuation:
•
AST or ALT > 5-10 x ULN for 2 weeks
•
AST or ALT > 10 x ULN
•
Total bilirubin > 5 x ULN
•
Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN
•
Any Grade 4 drug-related adverse event or laboratory abnormality, except for the 
following events which do not require discontinuation:
−
Grade 4 neutropenia ≤7 days
−
Grade 4 lymphopenia or leukopenia
−
Isolated Grade 4 amylase or lipase abnormalities that are not associated with symptoms or 
clinical manifestations of pancreatitis. The BMS Medical Monitor should be consulted for 
Grade 4 amylase or lipase abnormalities.
−
Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 hours 
of their onset
−
Grade 4 drug-related endocrinopathy adverse events, such as adrenal insufficiency, ACTH 
deficiency, hyper- or hypothyroidism, or glucose intolerance, which resolve or are 
adequately controlled with physiologic hormone replacement (corticosteroids, thyroid 
hormones) or glucose-controlling agents, respectively, may not require discontinuation 
after discussion with and approval from the BMS Medical Monitor.
•
Any event that leads to delay in dosing lasting > 8 weeks from the previous dose requires 
discontinuation, with the following exceptions:
−
Dosing delays to allow for prolonged steroid tapers to manage drug-related adverse events 
are allowed. Prior to re-initiating treatment in a subject with a dosing delay lasting 
> 8 weeks from the previous dose, the BMS medical monitor must be consulted. Tumor 
assessments should continue as per protocol even if dosing is delayed/interrupted. Periodic 
study visits to assess safety and laboratory studies should also continue as clinically 
indicated during such dosing delays/interruption.
−
Dosing delays lasting > 8 weeks from the previous dose that occur for non-drug-related 
reasons may be allowed if approved by the BMS medical monitor. Prior to re-initiating 
treatment in a subject with a dosing delay lasting > 8 weeks, the BMS medical monitor 
must be consulted. Tumor assessments should continue as per protocol even if dosing is 
delayed/interrupted. Periodic study visits to assess safety and laboratory studies should 
also continue as clinically indicated during such dosing delays/interruption.
•
Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the subject with continued nivolumab 
dosing.
4.5.9
Recommended Dose Reduction
The criteria presented in this section for dose modification of dexamethasone and pomalidomide 
are meant as general guidelines. They are based on current US standards of clinical practice. Dose 
Revised Protocol No.: 03
Date: 08-Mar-2018
72
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
modification may occur in the setting of lower grade toxicity if the investigator, in consultation 
with the Medical Monitor/Sponsor, believes that it is in the interest of subject safety.
4.5.9.1
Elotuzumab and Nivolumab
No dose reduction is allowed for elotuzumab or nivolumab.
4.5.9.2
Dexamethasone
Dexamethasone dose reductions for toxicity related to study drug, must be performed as clinically 
indicated. Recommended management is described in Table 4.5.9.2-1 and Table 4.5.9.2-2. 
Deviations to the recommended dose reductions are allowed based on the clinical judgment of the 
investigator.
Table 4.5.9.2-1:
Dexamethasone Dose Reductions
CTCAE 
Category
Adverse Event
Treatment Adjustment
Gastrointestinal
Dyspepsia, gastric or duodenal 
ulcer, gastritis
Grade 1 - 2 
(requiring medical management)
Treat with a proton pump inhibitor.
If symptoms persist despite above measures, decrease by 
1 dose level.
≥Grade 3 
(requiring hospitalization or 
surgery)
Hold dexamethasone until symptoms are adequately 
controlled. Reduce by 1 dose level and resume along with 
concurrent therapy with a proton pump inhibitor.
If symptoms persist despite above measures, reduce to dose 
level -3 (dose withheld).
Acute pancreatitis
Reduce to dose level -3 (dose withheld).
Cardiovascular
Edema
≥Grade 3 (limiting function and 
unresponsive to therapy or 
anasarca)
Use diuretics as needed, and decrease dexamethasone by 
1 dose level. If edema persists despite above measures, 
decrease by another dose level.
Neurology
Confusion or Mood alteration 
≥Grade 2 (interfering with 
function ± interfering with 
activities of daily living)
Hold dexamethasone until symptoms resolve.
Decrease by 1 dose level and resume.
If symptoms persist despite above measures, decrease by 
another dose level.
Musculoskeletal
Muscle weakness 
≥Grade 2 (symptomatic and 
interfering with function ±
interfering with activities of 
daily living)
Hold dose until muscle weakness is ≤Grade 1.
Decrease dexamethasone by 1 dose level and resume.
If weakness persists despite above measures, decrease by 
another dose level.
Metabolic
Hyperglycemia
≥Grade 3 or higher
Treat with insulin or oral hypoglycemics as needed. If 
uncontrolled despite above measures, decrease by 1 dose 
level until glucose levels are satisfactory.
Constitutional
Insomnia ≥Grade 2
Decrease by 1 dose level and resume.
Dose reduction for persistent Grade 2 or Grade ≥3 AEs believed to be related to dexamethasone 
and not listed above are permitted.
Revised Protocol No.: 03
Date: 08-Mar-2018
73
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Contact the medical monitor to discuss dexamethasone premedication for subjects who reach dose 
level -3 or must discontinue dexamethasone due to toxicity.
Table 4.5.9.2-2:
Dexamethasone Dose Levels
Dose Level
Reducing Dexamethasone on
Weeks with Elotuzumab
Reducing Dexamethasone on
Weeks Without Elotuzumab
PO
IV
PO
IV
0
≤75 years old - 28 mg
8 mg
≤75 years old - 40 mg
N/A
> 75 years old - 8 mg
> 75 years old - 20 mg
-1
≤75 years old - 12 mg
8 mg
≤75 years old - 20 mg
N/A
> 75 years old - 8 mg
> 75 years old - 12 mg
-2
≤75 years old - 0 mg
8 mg
≤75 years old - 12 mg
N/A
> 75 years old - 0 mg
> 75 years old - 8 mg
-3
≤75 years old - 0 mg 
Contact 
Medical 
Monitor
≤75 years old - 0 mg 
N/A
> 75 years old - 0 mg 
> 75 years old - 0 mg 
4.5.9.3
Pomalidomide
Below are the recommended dose adjustments for the management of NCI CTCAE Grade 3 and 
4 toxicities for thrombocytopenia and neutropenia judged by the investigator to be related to 
pomalidomide. Information in Table 4.5.9.3-1 and Table 4.5.9.3-2 is based on pomalidomide 
prescribing information, which contains additional guidance on pomalidomide dosing.29,31
Table 4.5.9.3-1:
Treating Thrombocytopenia Related to Pomalidomide
When Platelet Count:
Recommended Course:
Fall to < 25,000 per mm3
Interrupt pomalidomide treatment, follow Complete 
Blood Count weekly.
Return to > 50,000 per mm3
Resume pomalidomide at 3 mg daily
For each subsequent drop < 25,000 mm3
Interrupt pomalidomide treatment
Return to ≥50,000 mm3
Resume pomalidomide at 1 mg less than previous dose
Table 4.5.9.3-2:
Treating Neutropenia Related to Pomalidomide
When Neutrophil Count:
Recommended Course:
Fall to < 500 per mm3 or febrile neutropenia (fever 
≥38.5oC and ANC < 1,000 mm3)
Interrupt pomalidomide treatment, follow Complete 
Blood Count weekly.
ANC returns to ≥500 per mm3
Resume pomalidomide at 3 mg daily
Revised Protocol No.: 03
Date: 08-Mar-2018
74
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 4.5.9.3-2:
Treating Neutropenia Related to Pomalidomide
When Neutrophil Count:
Recommended Course:
For each subsequent drop < 500 mm3
Interrupt pomalidomide treatment
Return to ≥500 mm3
Resume pomalidomide at 1 mg less than previous dose
ANC, absolute neutrophil count.
If necessary to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of 
CYP3A4 and P-glycoprotein, consider reducing pomalidomide dose by 50%.29,31
4.5.10
EN Cohort: Stopping Rules for Unacceptable Toxicity
The rate of AE occurrence will be assessed on an ongoing basis during treatment and within 100 
days of last dose of therapy with nivolumab.
Enrollment in the EN cohort and continued treatment of patients already enrolled in the EN cohort 
will be stopped if either of the safety signals below are observed:
•
Grade 5 adverse events, excluding those due to disease progression: cumulative rate ≥20% 
occurrence in the first 50% of treated patients
•
Grade ≥3 nivolumab immune-related adverse events: ≥10% occurrence in the first 50% of 
treated patients.
4.6
Blinding/Unblinding
Not applicable.
4.7
Treatment Compliance
Starting at Cycle 1, Day 1, all treated subjects will be assessed for drug compliance of all 
treatments administered during the course of the study. Treatment compliance will be monitored 
by drug accountability and recorded in the subject’s medical record. For those medications taken 
at home (PO dexamethasone and pomalidomide), subjects will be provided with a medication diary 
in which to record study drug doses and will be instructed to bring this diary and study drug 
containers to clinic visits.
4.8
Destruction of Study Drug
For this study, study drugs (those supplied by BMS or sourced by the investigator) such as partially 
used study drug containers, vials and syringes may be destroyed on site.
Any unused study drugs can only be destroyed after being inspected and reconciled by the 
responsible Study Monitor unless study drug containers must be immediately destroyed as required 
for safety, or to meet local regulations (eg, cytotoxics or biologics).
On-site destruction is allowed provided the following minimal standards are met:
•
On-site disposal practices must not expose humans to risks from the drug.
Revised Protocol No.: 03
Date: 08-Mar-2018
75
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
•
On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
•
Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a copy provided to BMS upon request.
•
Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
•
Accountability and disposal records are complete, up-to-date, and available for the Monitor to 
review throughout the clinical trial period.
If conditions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study drug.
It is the investigator’s responsibility to arrange for disposal of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept.
4.9
Return of Study Drug
If study drug will not be destroyed upon completion or termination of the study, all unused and/or 
partially used study drug that was supplied by BMS must be returned to BMS. The return of study 
drug will be arranged by the responsible Study Monitor.
Revised Protocol No.: 03
Date: 08-Mar-2018
76
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
5.
STUDY ASSESSMENTS AND PROCEDURES
5.1
Flow Chart/Time and Events Schedule 
Table 5.1-1:
Screening Procedural Outline (CA204142)
Procedure
Screening
Visit 
Notes
Eligibility Assessments
Informed Consent
X
Prior to any screening procedures
Inclusion/Exclusion Criteria
X
Within 14 days prior to first dose of study drug
Medical History/Treatment History
X
Safety Assessments
Physical Examination
X
Includes height and weight within 14 days prior to first dose of study drug
Vital Signs
X
Temperature, BP, HR, within 14 days prior to first dose of study drug
Performance Status (ECOG)
X
Within 14 days prior to first dose of study drug
Serious Adverse Events Assessment
X
Collected from the time of informed consent
Concomitant Medications
X
Within 14 days prior to first dose of study drug
ECG
X
Within 28 days of randomization
Laboratory Assessments 
CBC, differential, platelets
X
Within 14 days prior to first dose of study drug
Chemistry
X
Within 14 days prior to first dose of study drug (See Section 5.3.4)
Serum β2-microglobulin
X
Within 28 days prior to first dose of study drug (Central Lab Analysis) 
Albumin
X
Within 28 days prior to first dose of study drug
Pregnancy Test
X
For WOCBP only, 2 pregnancy tests, one 10 - 14 days prior to start of study drug and one within 24 
hours prior to start of study drug. Urine tests must have a sensitivity of at least 25 IU/L.
Thyroid Function Tests (TFTs)
(reflex to free T3/total T3, free T4 for 
abnormal TSH result).
X
Within 28 days prior to first dose of study drug. Required only after Amendment 02.
Revised Protocol No.: 03
Date: 08-Mar-2018
77
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-1:
Screening Procedural Outline (CA204142)
Procedure
Screening
Visit 
Notes
Hepatitis B surface antigen (HBsAg), 
and hepatitis C antibody (HCV Ab) or 
HCV ribonucleic acid (RNA).
X
Within 28 days prior to first dose of study drug. Required only after Amendment 02.
Revised Protocol No.: 03
Date: 08-Mar-2018
78
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-2:
CA204142 Cycles 1 and 2 - EPd Cohort Only
Procedure
Day 
1
Day 
8
Day 
15
Day 
22
Rest Days 
23 – 28
Notes
Safety Assessments
Targeted Physical Examination
X
Perform prior to dosing, include weight
Vital Signs
X
X
X
X
Cycle 1: Measure vital signs pre-elotuzumab infusion, 30 minutes after the 
start of elotuzumab infusion, at the end of infusion, and 30 minutes after 
the completion of infusion
Cycle 2 and beyond: evaluate prior to dosing
Performance Status (ECOG)
X
Evaluate prior to dosing
Serious Adverse Event Assessment
X
X
X
X
Evaluate prior to dosing
Adverse Events Assessment
X
X
X
X
Evaluate prior to dosing
Concomitant Medications
X
X
X
X
Evaluate prior to dosing
Laboratory Tests
CBC, differential, platelets
X
X
X
X
Can be drawn up to 3 days prior to study visit (See Section 5.3.4). Screening 
results are sufficient for Cycle 1
Chemistry
X
Can be drawn up to 3 days prior to study visit 
Pregnancy Test
X
For WOCBP only. Urine tests must have a sensitivity of at least 25 IU/L.
Test within 24 hours of Dose 1 study medication.
Efficacy Assessments
Myeloma Urine and Serum Lab tests
(Central Lab Analysis)
Every 4 weeks from date of
first dose of study drug until disease 
progression
Day 1 of each cycle (except Cycle 1 - refer to Screening visit for defined 
window as listed on Table 5.1-1) (See also: Section 5.4.2)
24-hour urine sample can be collected within ± 7 days of visit, and must be 
obtained in all subjects who have measurable UPEP M protein 
(≥200 mg/24 hours) at baseline with each cycle.
See Section 5.4.2 for subjects without measurable urine M protein at 
baseline and no FLC detected by the serum test.
Revised Protocol No.: 03
Date: 08-Mar-2018
79
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-2:
CA204142 Cycles 1 and 2 - EPd Cohort Only
Procedure
Day 
1
Day 
8
Day 
15
Day 
22
Rest Days 
23 – 28
Notes
Bone Marrow Aspiration/Biopsy
For confirmation of CR if applicable or, 
if clinically indicated at time of suspected 
disease progression
Bone marrow aspirate is mandatory. Bone marrow biopsy is optional.
Bone marrow will be analyzed in local laboratory, with performance of 
IHC and/or flow cytometry to assess for sCR.
Skeletal Imaging
If clinically indicated
CT/MRI assessment 
As clinically indicated
Response per IMWG uniform 
criteria
Every 4 weeks from date of first dose of 
study drug on Cycle 1 Day 1 until 
progression. (Cycles cannot be delayed. 
In the event that the first dose within a 
cycle is delayed or omitted, the tumor 
assessment should still be done on Day 1 
of the cycle and should not be delayed 
until dosing.).
Subjects who discontinue from study treatment for reasons other than 
progression will continue to have tumor assessment every 4 weeks from 
C1D1 until progression.
Revised Protocol No.: 03
Date: 08-Mar-2018
80
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-3:
CA204142 Cycles 3 and Beyond - EPd Cohort and Cross-over Patients from EN Cohort
Procedure
Day 
1
Day 
8
Day 
15
Day 
22
Rest Days 
23 - 28
End of 
Treatment
Days 30 & 
60 
post end of 
treatment*
Notes
Safety Assessments
Targeted Physical Examination
X
Perform prior to dosing, includes weight 
Vital Signs
X
X
Evaluate prior to dosing.
Performance Status (ECOG)
X
X
Evaluate prior to dosing
Serious Adverse Event 
Assessment
X
X
X
Evaluate prior to dosing
SAEs will be collected for EPd subjects up to 100 days 
of last dose (per Section 6.1.1).
Adverse Events Assessment
X
X
X
Evaluate prior to dosing
Concomitant Medications
X
X
X
Evaluate prior to dosing
Laboratory Tests
CBC, differential, platelets
X
X
Can be drawn up to 3 days prior to visit. Additional 
samples as clinically indicated.
Chemistry
X
X
Can be drawn up to 3 days prior to visit (See 
Section 5.3.4)
Pregnancy Test
X
X
X
For WOCBP only. Tests must occur within 24 hours 
prior to dosing. The pregnancy test should occur on 
Days 1 of each cycle. Urine tests must have a sensitivity 
of at least 25 IU/L. Pregnancy test must also be 
performed at end of treatment and at 30, 60 and 90 days 
off treatment. The test at 90 days off treatment may be 
performed locally if the patient is not scheduled to return 
to the center for other reasons.
Revised Protocol No.: 03
Date: 08-Mar-2018
81
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-3:
CA204142 Cycles 3 and Beyond - EPd Cohort and Cross-over Patients from EN Cohort
Procedure
Day 
1
Day 
8
Day 
15
Day 
22
Rest Days 
23 - 28
End of 
Treatment
Days 30 & 
60 
post end of 
treatment*
Notes
Efficacy Assessments
Myeloma Urine and Serum 
Lab tests
(Central Lab Analysis)
Every 4 weeks from date of
first dose of study drug until disease progression
Day 1 of each cycle (except Cycle 1 - refer to Screening 
visit for defined window).
24-hour urine sample can be collected within ± 7 days of 
visit and must be obtained in all subjects who have 
measurable UPEP M protein (≥200 mg/24 hours) at 
baseline with each cycle.
See Section 5.4.2 for subjects without measurable urine 
M protein at baseline and no FLC detected by the serum 
test.
Bone Marrow 
Aspiration/Biopsy
For confirmation of CR if applicable or, if clinically indicated at time 
of suspected disease progression
Bone marrow aspirate is mandatory. Bone marrow 
biopsy is optional.
Bone marrow will be analyzed in local laboratory, with 
performance of IHC and/or flow cytometry to assess for 
sCR.
Corrected calcium
Every 4 weeks from the date of the first dose of study drug until 
disease progression, regardless of whether the subject is on study 
therapy or subsequent therapy.
Serum calcium and albumin from peripheral blood at D1 
of each cycle until disease progression, even if subject is 
on subsequent therapy; if used as criterion for disease 
progression, must be confirmed by second value.
Skeletal Imaging
If clinically indicated
CT/MRI assessment 
As clinically indicated
Revised Protocol No.: 03
Date: 08-Mar-2018
82
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-3:
CA204142 Cycles 3 and Beyond - EPd Cohort and Cross-over Patients from EN Cohort
Procedure
Day 
1
Day 
8
Day 
15
Day 
22
Rest Days 
23 - 28
End of 
Treatment
Days 30 & 
60 
post end of 
treatment*
Notes
Response per IMWG uniform 
criteria
Every 4 weeks from date of first dose of study drug on Cycle 1 Day 1 
until progression. (Cycles cannot be delayed. In the event that the first 
dose within a cycle is delayed or omitted, the tumor assessment 
should still be done on Day 1 of the cycle and should not be delayed 
until dosing.).
Subjects who discontinue from study treatment for 
reasons other than progression will continue to have 
tumor assessment every 4 weeks from C1D1 until 
progression.
Following disease progression, subjects will be followed 
at least annually for survival.
* Subjects in the EN cohort who cross-over to the EPd cohort but discontinue treatment within 2 cycles of EPd treatment will still need to undergo 100 day follow-
up visit from last dose of nivolumab to evaluate safety events related to study treatment.
Revised Protocol No.: 03
Date: 08-Mar-2018
83
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-4:
CA204142 Cycles 1 and 2 - EN Cohort
Procedure
Day
1
Day 
8
Day
15
Day
22
Rest Days 
23 – 28
Notes
Safety Assessments
Targeted Physical 
Examination
X
Perform prior to dosing, include weight
Vital Signs
X
X
X
X
Cycle 1: Measure vital signs pre-elotuzumab infusion, 30 minutes after the start of 
elotuzumab infusion, at the end of infusion, and 30 minutes after the completion of 
infusion
Cycle 2 and beyond: Evaluate prior to dosing. 
Vital signs must be collected if infusion related AE occurs.
Performance Status 
(ECOG)
X
Evaluate prior to dosing
Serious Adverse 
Event Assessment
X
X
X
X
Evaluate prior to dosing
Adverse Events 
Assessment
X
X
X
X
Evaluate prior to dosing
Concomitant 
Medications
X
X
X
X
Evaluate prior to dosing
Second Primary 
Malignancy
X
Laboratory Tests
CBC, differential, 
platelets
X
X
X
X
Can be drawn up to 3 days prior to study visit (See Section 5.3.4). Screening results 
are sufficient for Cycle 1
Chemistry
X
Can be drawn up to 3 days prior to study visit 
Pregnancy Test
X
For WOCBP only. Urine tests must have a sensitivity of at least 25 IU/L.
Test within 24 hours of Dose 1 study medication. 
Revised Protocol No.: 03
Date: 08-Mar-2018
84
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-4:
CA204142 Cycles 1 and 2 - EN Cohort
Procedure
Day
1
Day 
8
Day
15
Day
22
Rest Days 
23 – 28
Notes
Thyroid stimulating 
hormone (TSH) 
(reflex to free 
T3/total T3, free T4 
for abnormal TSH 
result).
X*
To be performed every *2 cycles (± 7 days) from first dose regardless of dosing 
schedule 
Efficacy Assessments
Myeloma Urine and 
Serum Lab tests
(SPEP/EPEP/sFLC/
Igs)
(Central Lab Analysis)
Every 4 weeks from date of
first dose of study drug until disease progression 
of study drug until disease progression regardless 
of whether subject is on study therapy or 
subsequent therapy 
Day 1 of each cycle (Optional at C1D1 if conducted at screening.)
(See also: Section 5.4.2)
24-hour urine sample can be collected within ± 7 days of visit, and must be 
obtained in all subjects 
Bone Marrow 
Aspiration/Biopsy
For confirmation of CR, if applicable or, if 
clinically indicated at time of suspected disease 
progression (Local Lab analysis)
Bone Marrow plasma cell percentage.
Performance of IHC or flow cytometry to assess for sCR (for subjects with CR).
Corrected Calcium
Every 4 weeks from the date of the first dose of 
study drug until disease progression, regardless 
of whether the subject is on study therapy or 
subsequent therapy.
Serum calcium and albumin from peripheral blood at D1 of each cycle until disease 
progression, even if subject is on subsequent therapy; if used as criterion for 
disease progression, must be confirmed by second value.
Skeletal Imaging
If clinically indicated
CT/MRI assessment 
As clinically indicated and at the time of CR/sCR 
assessments
Response per 
IMWG uniform 
criteria
Every 4 weeks from date of first dose of study 
drug on Cycle 1 Day 1 until progression. (Cycles 
cannot be delayed. In the event that the first dose 
within a cycle is delayed or omitted, the tumor 
assessment should still be done on Day 1 of the 
cycle and should not be delayed until dosing.).
Subjects who discontinue from study treatment for reasons other than progression 
will continue to have tumor assessment every 4 weeks from C1D1 until 
progression.
Response assessments and PD require confirmation (2 consecutive assessments 
made at any time) before the institution of any new therapy.
Revised Protocol No.: 03
Date: 08-Mar-2018
85
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-4:
CA204142 Cycles 1 and 2 - EN Cohort
Procedure
Day
1
Day 
8
Day
15
Day
22
Rest Days 
23 – 28
Notes
Revised Protocol No.: 03
Date: 08-Mar-2018
86
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-5:
CA204142 Cycles 3 and 4 - EN Cohort
Procedure
Day 1
Day 8
Day 15
Day 22
Rest Days 
23 – 28
Notes
Safety Assessments
Targeted 
Physical 
Examination
X
Perform prior to dosing, include weight
Vital Signs
X
X
Evaluate prior to dosing. 
Performance 
Status (ECOG)
X
Evaluate prior to dosing
Serious Adverse 
Event 
Assessment
X
X
Evaluate prior to dosing
Adverse Events 
Assessment
X
X
Evaluate prior to dosing
Concomitant 
Medications
X
X
Evaluate prior to dosing
Second Primary 
Malignancy
X
Laboratory Tests
CBC, 
differential, 
platelets
X
Can be drawn up to 3 days prior to study visit (See Section 5.3.4). 
Chemistry
X
Can be drawn up to 3 days prior to study visit 
Pregnancy Test
X
For WOCBP only. Urine tests must have a sensitivity of at least 25 IU/L.
Test within 24 hours. 
Revised Protocol No.: 03
Date: 08-Mar-2018
87
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-5:
CA204142 Cycles 3 and 4 - EN Cohort
Procedure
Day 1
Day 8
Day 15
Day 22
Rest Days 
23 – 28
Notes
Thyroid 
stimulating 
hormone (TSH) 
(reflex to free 
T3/total T3, free 
T4 for abnormal 
TSH result).
X*
To be performed every *2 cycles (± 7 days) from first dose regardless of 
dosing schedule.
Efficacy Assessments
Myeloma Urine 
and Serum Lab 
tests
(SPEP/UPEP/sF
LC/Igs)
(Central Lab Analysis)
Every 4 weeks from date of first dose of study drug until 
disease progression regardless of whether subject is on 
study therapy or subsequent therapy 
Day 1 of each cycle (See also: Section 5.4.2)
24-hour urine sample can be collected within ± 7 days of visit, and must be 
obtained in all subjects 
Bone marrow 
aspiration/biopsy
For confirmation of CR, if applicable, or if clinically at the 
time of suspected disease progression (local lab analysis)
Bone marrow plasma cell percentage
Performance of IHC or flow cytometry to assess for sCR (for subjects with 
CR).
Corrected 
Calcium
Every 4 weeks from the date of the first dose of study drug 
until disease progression, regardless of whether the subject 
is on study therapy or subsequent therapy.
Serum calcium and albumin from peripheral blood at D1 of each cycle until 
disease progression, even if subject is on subsequent therapy; if used as 
criterion for disease progression, must be confirmed by second value.
Skeletal Imaging
If clinically indicated
CT/MRI 
assessment 
As clinically indicated and at the time of CR/sCR 
assessments
Response per 
IMWG uniform 
criteria
Every 4 weeks from date of first dose of study drug on 
Cycle 1 Day 1 until progression. (Cycles cannot be 
delayed. In the event that the first dose within a cycle is 
delayed or omitted, the tumor assessment should still be 
done on Day 1 of the cycle and should not be delayed until 
dosing.).
Subjects who discontinue from study treatment for reasons other than 
progression will continue to have tumor assessment every 4 weeks from 
C1D1 until progression.
Response assessments and PD require confirmation (2 consecutive 
assessments made at any time) before the institution of any new therapy.
Revised Protocol No.: 03
Date: 08-Mar-2018
88
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-5:
CA204142 Cycles 3 and 4 - EN Cohort
Procedure
Day 1
Day 8
Day 15
Day 22
Rest Days 
23 – 28
Notes
Revised Protocol No.: 03
Date: 08-Mar-2018
89
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-6:
CA204142 Cycles 5 and Beyond - EN Cohort
Procedure
Day 
1
Day 
8
Day 
15
Day 
22
Rest Days 
23 - 28
End of 
Treatment
Days 30 & 100
(+/- 7 days)
post end of 
treatment
Notes
Safety Assessments
Targeted Physical 
Examination
X
Perform prior to dosing, includes weight 
Vital Signs
X
X
Evaluate prior to dosing. 
Performance Status (ECOG)
X
X
Evaluate prior to dosing
Serious Adverse Event 
Assessment
X
X
X
Evaluate prior to dosing
Adverse Events Assessment
X
X
X
Evaluate prior to dosing
Concomitant Medications
X
X
X
Evaluate prior to dosing
Second Primary Malignancy
X
X
X
Laboratory Tests
CBC, differential, platelets
X
X
Can be drawn up to 3 days prior to visit. Additional 
samples as clinically indicated.
Chemistry
X
X
Can be drawn up to 3 days prior to visit (See 
Section 5.3.4)
Revised Protocol No.: 03
Date: 08-Mar-2018
90
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-6:
CA204142 Cycles 5 and Beyond - EN Cohort
Procedure
Day 
1
Day 
8
Day 
15
Day 
22
Rest Days 
23 - 28
End of 
Treatment
Days 30 & 100
(+/- 7 days)
post end of 
treatment
Notes
Pregnancy Test
X
X
X
For WOCBP only. Tests must occur within 24 hours prior 
to dosing. The pregnancy test should occur on Days 1 of 
each cycle. Urine tests must have a sensitivity of at least 
25 IU/L. Pregnancy test must also be performed at end 
of treatment and at 30, 60 and 90 days off treatment.
The test at 90 days off treatment may be performed 
locally if the patient is not scheduled to return to the 
center for other reasons.
Thyroid stimulating hormone 
(TSH) (reflex to free T3/total 
T3, free T4 for abnormal TSH 
result).
X
X
To be performed every 2 cycles (± 7 days) from first dose 
regardless of dosing schedule.
Efficacy Assessments
Myeloma Urine and Serum 
Lab tests
(SPEP/UPEP/sFLC/Igs)
(Central Lab Analysis)
Every 4 weeks from date of first dose of study drug until disease 
progression regardless of whether subject is on study therapy or 
subsequent therapy 
Day 1 of each cycle (including Cycle 1 See also 
Section 5.4.2) 
24-hour urine sample can be collected within ± 7 days of 
visit, and must be obtained in all subjects 
Bone marrow 
aspiration/biopsy
For confirmation of CR, if applicable or if clinically indicated at the 
time of suspected disease progression (local lab analysis). 
Bone marrow plasma cell percentage
Performance of IHC or flow cytometry to assess for a 
sCR (for subjects with CR).
Skeletal Imaging
If clinically indicated
CT/MRI assessment 
As clinically indicated
Revised Protocol No.: 03
Date: 08-Mar-2018
91
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.1-6:
CA204142 Cycles 5 and Beyond - EN Cohort
Procedure
Day 
1
Day 
8
Day 
15
Day 
22
Rest Days 
23 - 28
End of 
Treatment
Days 30 & 100
(+/- 7 days)
post end of 
treatment
Notes
Response per IMWG uniform 
criteria
Every 4 weeks from date of first dose of study drug on Cycle 1 Day 
1 until progression. (Cycles cannot be delayed. In the event that the 
first dose within a cycle is delayed or omitted, the tumor assessment 
should still be done on Day 1 of the cycle and should not be delayed 
until dosing.). 
Response assessments (≥PR) and PD require confirmation 
(2 consecutive assessments made at any time before the institution of 
new therapy).
Subjects who discontinue from study treatment for 
reasons other than progression will continue to have 
tumor assessment every 4 weeks from C1D1 until 
progression. 
Following disease progression, subjects will be followed 
at least annually for survival.
Revised Protocol No.: 03
Date: 08-Mar-2018
92
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
5.1.1
Retesting During Screening Period
Retesting of laboratory parameters and/or other assessments within any single Screening period 
will be permitted (in addition to any parameters that require a confirmatory value).
Any new result will override the previous result (ie, the most current result prior to Treatment) and 
is the value by which study inclusion will be assessed, as it represents the subject’s most current, 
clinical state.
Laboratory parameters and/or assessments that are included in Screening Procedural Outline may 
be repeated in an effort to find all possible well-qualified subjects. Consultation with the Medical 
Monitor may be needed to identify whether repeat testing of any particular parameter is clinically 
relevant.
5.2
Study Materials
The following will be distributed to sites for use in this study:
•
Instructions and kits for collections, processing, and shipment of blood and tissue samples
•
NCI CTCAE booklets version 3.0
•
Elotuzumab Investigator Brochure
•
Nivolumab Investigator Brochure
•
Pomalidomide (Pomalyst®) Package Insert
•
Site Manual for operation of IVRS
•
Subject Dosing Diary 
•
Serious Adverse Event (SAE) Case Report Form (CRF/eCRF) pages
•
Pregnancy Surveillance Forms
5.3
Safety Assessments
Only data for the procedures and assessments specified in this protocol should be submitted to 
BMS. Additional procedures and assessments may be performed as part of standard of care; 
however, the data for these assessments should remain in the subject’s medical record and should 
not be provided to BMS, unless specifically requested from the Sponsor. Safety assessments must 
be done prior to dosing. The local safety labs (complete blood count, chemistry panel) and 
procedures may be collected or performed up to 3 days prior to the visit. For subjects who skip a 
dose, local safety labs results must be submitted to BMS at least once per cycle. In addition, all 
safety lab results that lead to dose delay or discontinuation must be submitted to BMS.
All subjects will be assessed for safety. Safety evaluations include assessments of AEs, clinical 
laboratory tests (hematology, chemistry), vital sign measurements, and physical examination with 
assessment of ECOG PS. Investigators are responsible for monitoring the safety of subjects who 
have entered this study and for alerting the Sponsor to any event that seems unusual, even if this 
event may be considered an unanticipated benefit to the subject. The investigator is responsible 
for appropriate medical care of subjects during the study.
Revised Protocol No.: 03
Date: 08-Mar-2018
93
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
5.3.1
Imaging Assessment for the Study
Any incidental findings of potential clinical relevance that are not directly associated with the 
objectives of the protocol should be evaluated and handled by the Study Investigator as per 
standard medical/clinical judgment.
5.3.2
Vital Signs, Physical Measurements, and Physical Examination
Vital signs (body temperature, blood pressure and heart rate) will be recorded as outlined in Table 
5.1-1, Table 5.1-2, Table 5.1-3, Table 5.1-4 , Table 5.1-5, and Table 5.1-6. Blood pressure and 
heart rate should be measured after the subject has been seated quietly for at least 5 minutes prior 
to dosing. On Cycle 1 only, the days of elotuzumab dosing, vital signs monitoring should be 
performed as follows:
•
Prior to the start of the elotuzumab infusion
•
Thirty minutes after the start of infusion
•
At the end of the infusion
•
Thirty minutes post completion of the elotuzumab infusion.
•
Subjects who experience a Grade ≥2 infusion reaction require vital signs to be monitored every 
30 minutes for 1- 2 hours (as clinically indicated) after the end of the elotuzumab infusion.
Height will be recorded at screening. Weight will be measured at study visits as indicated in Table 
5.1-1, Table 5.1-2, Table 5.1-3, Table 5.1-4, Table 5.1-5, and Table 5.1-6. 
A full physical examination will be performed at the screening visit, whereas a targeted exam will 
occur at Day 1 and during on-treatment up to 3 days prior to dosing and post-treatment visits. A 
targeted physical examination may be performed by a qualified professional guided by the 
examiner’s observations and/or subject complaints on new or changed conditions, symptoms, or 
concerns. Targeted physical exam includes assessment of heart, lung, and abdomen.
5.3.3
Performance Status
Performance assessment will be performed as indicated in Table 5.1-1, Table 5.1-2, Table 5.1-3, 
Table 5.1-4, Table 5.1-5, and Table 5.1-6 using ECOG performance scale and criteria as described 
in Appendix 2.
5.3.4
Laboratory Assessments for Safety
Laboratory assessments for safety will be performed at local laboratories. Safety laboratory 
assessments are listed in Table 5.3.4-1.
Revised Protocol No.: 03
Date: 08-Mar-2018
94
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.3.4-1:
Safety Laboratory Assessments
Safety Laboratory Assessments
Screening as outlined in 
Table 5.1-1. Within 14 days 
of first dose of study drug
Study Visits as outlined in
Table 5.1-2,Table 5.1-3, Table 5.1-4, 
Table 5.1-5, and Table 5.1-6. 
Hematology
CBC
X
X
Differential
X
X
Platelets
X
X
Chemistry
Sodium
X
X
Potassium
X
X
Chloride
X
X
Albumin
X
(within 28 days of first dose 
of study drug) 
X
Alkaline Phosphatase
X
X
ALT (SGPT)
X
X
AST (SGOT)
X
X
Total Bilirubin
X
X
Lactate Dehydrogenase
X
X
BUN (or Urea)
X
X
Creatinine
X
X
Glucose
X
X
Calcium
X
X
Pregnancy Test
Urine or Serum Pregnancy
X (2 tests: one 10 - 14 days 
prior to the start of study 
drug and one within 24 hours 
prior to the start of study 
drug)
X Pregnancy test must also be 
performed at end of treatment, and at
30, 60 and 90 days off treatment. The 
test at 90 days off treatment may be 
performed locally if the patient is not 
scheduled to return to the center for 
other reasons. Urine tests must have a 
sensitivity of at least 25 IU/L.
Hepatitis B surface antigen (HBV sAg, 
Australia antigen) and hepatitis C 
antibody (HCV Ab) or HCV 
ribonucleic acid (RNA)
Xa
Revised Protocol No.: 03
Date: 08-Mar-2018
95
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Table 5.3.4-1:
Safety Laboratory Assessments
Safety Laboratory Assessments
Screening as outlined in 
Table 5.1-1. Within 14 days 
of first dose of study drug
Study Visits as outlined in
Table 5.1-2,Table 5.1-3, Table 5.1-4, 
Table 5.1-5, and Table 5.1-6. 
Thyroid stimulating hormone (TSH) 
(reflex to free T3, free T4 or abnormal 
result)
Xa
Xb
a Within 28 days of first dose of study drug
b TSH (reflex to free/total T3, free T4 for abnormal result) to be performed every 2 cycles (± 7 days) from first dose 
regardless of schedule.
5.4
Efficacy Assessments
Efficacy endpoints will be based on analysis of serum and urine electrophoresis (SPEP and UPEP), 
sFLC (for those with sFLC disease only), corrected calcium (serum calcium and serum albumin), 
imaging and bone marrow assessments, all at predefined intervals as specified in Table 5.1-1, 
Table 5.1-2, Table 5.1-3, Table 5.1-4, Table 5.1-5, and Table 5.1-6. Assessments done at local labs 
versus central labs are indicated in Table 5.1-1, Table 5.1-2, Table 5.1-3, Table 5.1-4, Table 5.1-
5, and Table 5.1-6. Assessments for SPEP and UPEP and molecular MRD will be based on central 
lab results, whereas assessments of bone marrow, bone lesions, extramedullary plasmacytomas, 
and corrected calcium will be based on local analysis at the site.
5.4.1
Primary Efficacy Assessment
Response criteria according to guidelines of the modified IMWG33,34 (Appendix 4) will be used 
for the primary analysis. For the purposes of this study, all subjects’ tumor assessments by 
myeloma laboratory tests should be re-evaluated per the protocol-stated frequency relative to the 
date of first dose of study drug until disease progression based on the modified IMWG criteria, 
irrespective of dose delays or treatment cycle. If subject does not have documented disease 
progression at time of study drug discontinuation, then tumor assessments should still be 
performed according to the same schedule described above until disease progression. 
Subjects will be followed for survival at least once a year by phone after disease progression.
All efficacy laboratory assessments should be done through the central laboratory, except corrected 
calcium (serum calcium and serum albumin), and bone marrow assessments for plasma cell 
percentage and light chain restriction (clonality by IHC or flow cytometry). Only if a subject is 
unable to come to the site for a visit to have specimens collected for a central lab (especially after 
study drug discontinuation), a SPEP, UPEP, or sFLC assessment can be performed locally, in lieu 
of a central lab assessment. M protein quantification or Serum Free Light Chain (sFLC) must be 
performed. Any laboratory samples analyzed locally, including for efficacy, must be entered on 
the appropriate CRF/eCRF.
Revised Protocol No.: 03
Date: 08-Mar-2018
96
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
5.4.2
Laboratory Assessments for Myeloma
Subjects who have urine M protein of zero mg/24 hours at baseline, but have measurable serum 
M-protein, do not have to continue UPEP assessments until SPEP M protein values are 
undetectable. Assessment of UPEP M protein and urine immunofixation at the time of possible 
CR/sCR is mandatory, that is negative urine immunofixation is required to fulfill CR/sCR criteria, 
even in subjects with non-measurable values at baseline. Therefore, when serum immunofixation 
electrophoresis (SIFE) becomes negative, UPEP and urine immunofixation electrophoresis (UIFE)
collection should begin for these subjects. In addition, a UPEP should be collected if clinically 
warranted (for example, signs of disease progression (eg, anemia) even when SPEP M-protein is 
stable).
1) Serum: Serum protein electrophoresis (SPEP) for M protein quantification, immunofixation, 
and quantitative immunoglobulin assay.
a) Immunofixation of serum is required at baseline and to confirm CR regardless of whether 
measurable M-protein was present at baseline.
b) All other serum tests will be followed at each tumor assessment. Confirmation of ≥PR is 
required on 2 consecutive assessments.
2) Urine: 24-hour urine collection electrophoresis for M protein quantification and 
immunofixation.
a) Immunofixation of urine is required at baseline and to confirm CR regardless of whether 
measurable M-protein was present at baseline.
b) All other urine tests will be followed at each tumor assessment Confirmation of ≥PR is 
required on 2 consecutive assessments.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 03
Date: 08-Mar-2018
97
4.0
Approved
930091242
4.0
v




Clinical Protocol
CA204142
BMS-901608
elotuzumab
 
 
 
 
 
 
 
5.4.3
Imaging Assessments for Myeloma
5.4.3.1
Skeletal Imaging
Skeletal imaging, by conventional radiography or other methods, for bone lesions will be 
performed within 60 days prior to first dose of study drug in all EPd cohort subjects and within 
28 days in the EN Cohort subjects. Skeletal imaging will be performed on study if clinically 
indicated. Use of conventional or low dose CT scan (ie, of the spine) or MRI bone survey is 
acceptable. If imaging is performed on treatment for assessment of progression, the site must use 
the same modality of imaging as used in screening.
5.4.3.2
Assessment of Extramedullary Plasmacytoma
Computed tomography or MRI should be performed at screening, if clinically indicated, to assess 
for extramedullary plasmacytoma. To minimize unnecessary radiation in myeloma subjects where 
progression is primarily based on serum and urine M-protein, on study assessments should only 
be performed if clinically indicated (ie, pain, concern for disease progression), whether or not 
present at baseline, and at the time of CR/sCR assessment.
A sum of the products of the longest diameters and longest perpendicular diameter for all 
measurable lesions will be calculated at screening. This sum will be used as the reference for on 
study assessments by which to characterize the objective tumor response.
All tumor measurements must be made in millimeters. All documented measurable lesions are to 
be followed throughout the trial. All assessments to be used for tumor response evaluation, 
Revised Protocol No.: 03
Date: 08-Mar-2018
99
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
including the baseline assessment, must be performed using the same method for repeat 
assessment. CT and MRI scanning are the preferable methods of assessment. Conventional CT 
and MRI should be performed with contiguous cuts of 10 mm or less or with cuts of 5 (or 10) mm 
if spiral CT scanning is used. Imaging-based evaluation is preferred to evaluation by clinical 
examination. Evaluation by chest x-ray is less preferable than CT or MRI, and should only be used 
for well-defined lesions surrounded by aerated lung. Clinical examination is only acceptable when 
lesions are superficial, such as a skin nodule or palpable lymph node. Skin lesions must be 
documented by a photograph with a ruler. Ultrasound is not acceptable for documentation of 
measurable disease.
Duplicate copies of all imaging studies used for tumor response evaluation will be made 
available for review by the Sponsor upon request.
Measurable disease are lesions that can be accurately measured in 2 dimensions and both diameters 
must be ≥20 mm when evaluated by standard CT scanning or ≥10 mm when evaluated by spiral 
CT scanning or MRI. The minimum diameter size should be at least twice the slice thickness.
Non-measurable disease are all other lesions (or sites of disease), including those that are too small 
(ie, do not meet above criteria), occur within a previously irradiated area (unless they are 
documented as new lesions since the completion of radiation therapy), bone lesions, 
leptomeningeal disease, ascites, pleural or pericardial effusion (exception for effusions 
documented by cytology as not malignant or present at baseline without progression), lymphangitis 
cutis/pulmonis, abdominal masses that are not pathologically/cytologically confirmed and 
followed by imaging techniques, and cystic lesions.
5.4.4
Definitions of Response and Progression Criteria
See Appendix 4 for definitions of response and progression. All criteria are derived from 
IMWG,33,34 except for minor (minimal) response, which is derived from the European Society for 
Blood and Marrow Transplantation (EBMT). All response categories require 2 consecutive 
assessments made before initiation of any new therapy.
 
 
Revised Protocol No.: 03
Date: 08-Mar-2018
100
4.0
Approved
930091242
4.0
v










Clinical Protocol
CA204142
BMS-901608
elotuzumab
5.7
Outcomes Research Assessments
Not applicable
5.8
Other Assessments
5.8.1
Pharmacogenomic/Pharmacogenetic Assessments
Genetic assessment (FISH) of myeloma cells is optional and will be performed by a central 
laboratory on the fresh bone marrow, during the screening period. If a fresh aspirate is not 
available, but local genetic assessment has been performed, these results must be entered into the 
CRF/eCRF. This assessment is considered to be standard of care for myeloma. Aspirates obtained 
will be used to identify prognostic cytogenetic markers that may include: t(4;14), t(14;16), 
t(11;14), t(6;14), t(14;20), 1q gains/amp, del(17p), del(1p), and del(13).
6.
ADVERSE EVENTS
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation subject administered study drug and that 
does not necessarily have a causal relationship with this treatment. An AE can therefore be any 
unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of study drug, whether or not considered related to the study 
drug.
The causal relationship to study drug is determined by a physician and should be used to assess all 
adverse events (AE). The causal relationship can be one of the following:
Related: There is a reasonable causal relationship between study drug administration and the AE.
Not related: There is not a reasonable causal relationship between study drug administration and 
the AE.
The term "reasonable causal relationship" means there is evidence to suggest a causal relationship.
Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs.)
6.1
Serious Adverse Events
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:
•
results in death
•
is life-threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)
•
requires inpatient hospitalization or causes prolongation of existing hospitalization (see NOTE
below)
•
results in persistent or significant disability/incapacity
•
is a congenital anomaly/birth defect
Revised Protocol No.: 03
Date: 08-Mar-2018
105
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
•
is an important medical event (defined as a medical event(s) that may not be immediately life-
threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above.) Examples 
of such events include, but are not limited to, intensive treatment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization.) Potential drug induced liver injury (DILI) is also considered an important 
medical event. (See Section 6.6 for the definition of potential DILI.)
Suspected transmission of an infectious agent (eg, pathogenic or nonpathogenic) via the study drug 
is an SAE.
Although pregnancy, overdose, cancer, and potential drug induced liver injury (DILI) are not 
always serious by regulatory definition, these events must be handled as SAEs. (See Section 6.1.1
for reporting pregnancies).
Any component of a study endpoint that is considered related to study therapy (eg, death is an 
endpoint, if death occurred due to anaphylaxis, anaphylaxis must be reported) should be reported 
as SAE (see Section 6.1.1 for reporting details).
NOTE:
The following hospitalizations are not considered SAEs in BMS clinical studies:
•
a visit to the emergency room or other hospital department < 24 hours, that does not result in 
admission (unless considered an important medical or life-threatening event)
•
elective surgery, planned prior to signing consent
•
admissions as per protocol for a planned medical/surgical procedure
•
routine health assessment requiring admission for baseline/trending of health status (eg, routine 
colonoscopy)
•
medical/surgical admission other than to remedy ill health and planned prior to entry into the 
study. Appropriate documentation is required in these cases
•
admission encountered for another life circumstance that carries no bearing on health status 
and requires no medical/surgical intervention (eg, lack of housing, economic inadequacy, 
caregiver respite, family circumstances, administrative reason).
•
admission for administration of anticancer therapy in the absence of any other SAEs (applies 
to oncology protocols)
6.1.1
Serious Adverse Event Collection and Reporting
Sections 5.6.1 and 5.6.2 in the Investigator Brochure (IB) represent the Reference Safety 
Information to determine expectedness of serious adverse events for expedited reporting. 
Following the subject’s written consent to participate in the study, all SAEs, whether related or not 
related to study drug, must be collected, including those thought to be associated with protocol-
specified procedures. All SAEs must be collected that occur during the screening period and within 
Revised Protocol No.: 03
Date: 08-Mar-2018
106
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
100 days of discontinuation of dosing. If applicable, SAEs must be collected that relate to any later 
protocol-specified procedure (eg, a follow-up skin biopsy).
The Investigator must report any SAE that occurs after these time periods and that is believed to 
be related to study drug or protocol-specified procedure.
An SAE report must be completed for any event where doubt exists regarding its seriousness.
If the investigator believes that an SAE is not related to study drug, but is potentially related to the 
conditions of the study (such as withdrawal of previous therapy or a complication of a study 
procedure), the relationship must be specified in the narrative section of the SAE Report Form.
SAEs, whether related or not related to study drug, and pregnancies must be reported to BMS (or 
designee) within 24 hours of awareness of the event. SAEs must be recorded on the SAE Report 
Form; pregnancies on a Pregnancy Surveillance Form (electronic or paper forms). The preferred 
method for SAE data reporting collection is through the eCRF. The paper SAE/pregnancy 
surveillance forms are only intended as a back-up option when the eCRF system is not functioning.
In this case, the paper forms are to be transmitted via email or confirmed facsimile (fax) 
transmission to:
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number:  Refer to Contact Information list.
For studies capturing SAEs through electronic data capture (EDC), electronic submission is the 
required method for reporting. In the event the electronic system is unavailable for transmission, 
paper forms must be used and submitted immediately. When paper forms are used, the original 
paper forms are to remain on site.
SAE Telephone Contact (required for SAE and pregnancy reporting): Refer to Contact 
Information list.
If only limited information is initially available, follow-up reports are required. (Note: Follow-up 
SAE reports must include the same investigator term(s) initially reported.)
If an ongoing SAE changes in its intensity or relationship to study drug or if new information 
becomes available, the SAE report must be updated and submitted within 24 hours to BMS (or 
designee) using the same procedure used for transmitting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
6.2
Nonserious Adverse Events
A nonserious adverse event is an AE not classified as serious.
6.2.1
Nonserious Adverse Event Collection and Reporting
The collection of nonserious AE information should begin at initiation of study drug until 60 days 
from the last dose of study drug for patients in the EPd cohort and until 100 days from the last dose 
of study drug for the EN cohort. Subjects in the EN cohort who cross-over to the EPd cohort but 
discontinue treatment within 2 cycles of EPd treatment will still need to undergo 100 day follow-
Revised Protocol No.: 03
Date: 08-Mar-2018
107
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
up visit from last dose of the nivolumab to evaluate safety events related to study treatment.
Nonserious AE information should also be collected from the start of a placebo lead-in period or 
other observational period intended to establish a baseline status for the subjects.
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see Section 6.1.1). Follow-up is also required for nonserious AEs that cause 
interruption or discontinuation of study drug and for those present at the end of study treatment as 
appropriate. All identified nonserious AEs must be recorded and described on the nonserious AE 
page of the CRF/eCRF (paper or electronic).
Completion of supplemental CRF/eCRFs may be requested for AEs and/or laboratory 
abnormalities that are reported/identified during the course of the study.
6.3
Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the nonserious AE 
CRF/eCRF page or SAE Report Form (paper or electronic) as appropriate:
•
Any laboratory test result that is clinically significant or meets the definition of an SAE
•
Any laboratory test result abnormality that required the subject to have study drug discontinued 
or interrupted
•
Any laboratory test result abnormality that required the subject to receive specific corrective 
therapy.
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting investigator (eg, anemia versus low hemoglobin value).
6.4
Pregnancy
If, following initiation of the study drug, it is subsequently discovered that a female study subject 
or female partner of male study subject is pregnant or may have been pregnant at the time of 
investigational product exposure, including during the time to washout (90 days) plus one 
ovulatory cycle (30 days) for a total of 5 months after product administration (female study 
subjects); or plus one spermatogenesis cycle (90 days) for a total of 7 months after product 
administration (female partners of male study subjects), the investigator must immediately notify 
the BMS Medical Monitor/designee of this event and complete and forward a Pregnancy 
Surveillance Form to BMS Designee within 24 hours and in accordance with SAE reporting 
procedures described in Section 6.1.1.
In most cases, the study drug will be permanently discontinued in an appropriate manner (eg, dose 
tapering if necessary for subject safety).
In the rare event that the benefit of continuing study drug is thought to outweigh the risk, after 
consultation with BMS, the pregnant subject may continue study drug after a thorough discussion 
of benefits and risk with the subject.
The investigator must immediately notify the BMS (or designee) Medical Monitor of this event 
and complete and forward a Pregnancy Surveillance Form to BMS (or designee) within 24 hours 
Revised Protocol No.: 03
Date: 08-Mar-2018
108
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
of awareness of the event and in accordance with SAE reporting procedures described in 
Section 6.1.1.
Follow-up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and, where applicable, offspring information must be reported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study participant should be reported to 
BMS. Information on this pregnancy will be collected on the Pregnancy Surveillance Form.
6.5
Overdose
An overdose is defined as the accidental or intentional administration of any dose of a product that 
is considered both excessive and medically important. All occurrences of overdose must be 
reported as an SAE (see Section 6.1.1 for reporting details.).
6.6
Potential Drug Induced Liver Injury (DILI)
Specific criteria for identifying potential DILI have not been identified for this protocol. Standard 
medical practice in identifying and monitoring hepatic issues should be followed.
Potential drug induced liver injury is defined as:
1) AT (ALT or AST) elevation > 3 times upper limit of normal (ULN)
AND
2) Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase)
AND
3) No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Section 6.1.1 for reporting details).
6.7
Other Safety Considerations
Any significant worsening noted during interim or final physical examinations, electrocardiogram, 
x-ray filming, any other potential safety assessment required or not required by protocol should 
also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.
7.
DATA MONITORING COMMITTEE AND OTHER EXTERNAL 
COMMITTEES
Not applicable
Revised Protocol No.: 03
Date: 08-Mar-2018
109
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
8.
STATISTICAL CONSIDERATIONS
Descriptive statistics (n, mean, median, and standard deviation; minimum, maximum or 
interquartile range) will be provided for the safety analysis and by subgroups based on types of 
prior therapy and line of therapy (2L/3L) groups. Because the sample size for the study is small, 
summary statistics with their associated 95% confidence intervals and tests of hypotheses will be 
based, to the extent possible, using small-sample statistics like the Clopper-Pearson for binomial 
data. Median time-to-event and its 95% confidence interval will be based on the Kaplan-Meier 
(KM) estimation procedure. The KM curves will be presented for time-to-event endpoints.
8.1
Sample Size Determination
8.1.1
EPd Cohort 
Seventy-two subjects will be screened with approximately 17% projected to fail screening. This 
total number is based on logistical consideration with statistical properties outlined below. 
Screening will continue until a minimum of 60 subjects are enrolled and treated.
Under the assumptions that:
•
time to PFS is exponentially distributed
•
median time of PFS is 11 months for subjects treated with pomalidomide + dexamethasone 
and will increase to median of 15 months with the addition of elotuzumab to the treatment mix
•
an increase of 4 months in median corresponds to relative risk ratio of 0.73 (0.0462 monthly 
risk in the elotuzumab add-on and 0.0630 monthly historical risk in the pomalidomide + 
dexamethasone treated-subjects)
Sixty subjects enrolled over a 24-month period are sufficient to detect an increase in median from 
11 to 15 months with about 70% power in a one-sided test with a 0.05 significance level. 
Assuming a monthly hazard rate of 0.0462, 48 of the 60 treated subjects are expected to have PFS 
events over a 24-month follow up period.
Power is calculated using PASS12 using the one-sample exponential module where the median is 
mapped to mean by dividing the assumed alternative median by logarithm of 2. The calculated 
power and event counts are consistent with power and event counts based on one sample log rank 
test where the number of events is calculated assuming relative risk ratio of 0.73.
8.1.2
EN Cohort
The planned sample size will be approximately 30 treated subjects; screening will continue until a 
minimum of 30 patients are enrolled and treated. 
For a 30% observed ORR rate and a sample size of N=30 yields an exact confidence interval of
[0.15, 0.49]. These design parameters ensure a lower bound higher than 15%.
Revised Protocol No.: 03
Date: 08-Mar-2018
110
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
8.2
Populations for Analyses
•
The safety analysis set consists of subjects who receive at least one dose of study drug. The 
safety analysis set is also the all treated analysis set.
•
The efficacy analysis set is the same as the all treated analysis set.
8.3
Endpoints
8.3.1
Primary Endpoint(s)
8.3.1.1
EPd Cohort
PFS is defined as the time from first dosing date to the date of the first documented progression 
per IMWG uniform criteria or death due to any cause, whichever occurs first. Subjects who die 
without a reported prior progression will be considered to have progressed on the date of their 
death. Subjects who did not progress or die will be censored on the date of their last evaluable 
assessment. Subjects who did not have any on study efficacy assessments and did not die will be 
censored on the first dosing date. 
Subjects who switched to subsequent therapy prior to documented progression will be censored 
on the date of the last evaluable assessment prior to the initiation of the new therapy.
8.3.1.2
EN Cohort
ORR is defined as proportion of subjects with best overall response of partial response (PR) or 
better. Response will be determined per IMWG uniform criteria.
8.3.2
Secondary Endpoint(s)
8.3.2.1
EPd Cohort
•
ORR is defined as proportion of subjects with a best overall response of partial response (PR)
or better. 
•
OS is defined as the time from first dosing date to the date of death from any cause. A subject 
who has not died will be censored at last known date alive.
8.3.2.2
EN Cohort
•
PFS definition: See Section 8.3.1.1
•
OS is defined as the time from first dosing date to the date of death from any cause. A subject 
who has not died will be censored at last known date alive.
 
 
 
Revised Protocol No.: 03
Date: 08-Mar-2018
111
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.4
Analyses
8.4.1
Demographics and Baseline Characteristics
The demographic and baseline characteristics of patients in the safety analysis set will be 
presented. Among the baseline clinical characteristics are patients’ ECOG Performance Status, 
baseline laboratory assessment for safety and efficacy endpoints, number of prior lines of therapy 
and types of previous therapy (Appendix 1), and disease status/stage (Appendix 5) at entry. 
8.4.2
Efficacy Analyses
The efficacy endpoints, PFS and ORR, will be defined using the IMWG criteria. Responses will 
be assessed at every treatment cycle using central laboratory test results on myeloma urine and 
serum, local laboratory bone marrow aspiration test, and if needed bone marrow and skeletal 
survey results and CT/MRI assessments. Objective responses will include stringent complete 
Revised Protocol No.: 03
Date: 08-Mar-2018
112
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
response, complete response, very good partial response and partial responses. The ORR and its 
95% confidence interval (CI) using the Clopper-Pearson estimation procedure will be reported. 
PFS and OS will be plotted using Kaplan-Meier estimates, and if estimable, median and its 95% 
CI will be reported. Time to response will be analyzed for responders only with summary statistics 
provided. Duration of response will be reported using K-M estimates. The time to event responses 
will be recorded from the first day of the first cycle to the day that an event occurs. If no event 
occurs by the time the study is completed, the patient is censored for that event at the last day of 
subject contact.
For EPd cohort, the primary analysis of PFS will be conducted when 48 progression events have 
been observed.
For EN cohort, the primary analyses for ORR will be conducted when enrollment in the EN cohort 
is complete and all enrolled patients treated with the combination have received at least 3 cycles 
of treatment.
MRD negativity status for subjects in the EN Cohort will be evaluated by time points. The 
frequency of the MRD negativity status and the best MRD negativity status will be summarized 
for the EN cohort. The cross tabulation of the MRD negativity status and BOR will be presented. 
Summary statistics of the MRD levels and their corresponding percent changes from baseline will 
be tabulated by planned study day for the EN cohort. Potential association between the first/best 
MRD negativity status with PFS and OS will be evaluated in all treated patients. Additional details 
will be presented in the Statistical Analysis Plan.
8.4.3
Safety Analyses
Safety assessments will be performed prior, during and between dosing, and up to 100 days after 
the last treatment for the EN cohort and 60 days after the last dose in the EPd cohort and for 
subjects in the EN cohort who cross-over to the EPd cohort but discontinue treatment within 2 
cycles of EPd treatment safety assessments will be performed up to 100 days after the last dose of 
nivolumab. The frequency, severity, relationship to combination of drug treatment, seriousness, 
and outcomes of adverse events (AEs) will be reported for the full safety analysis set. AE severity 
will be graded according to the NCI Common Terminology Criteria for Adverse Events 3.0. 
Results of targeted physical examinations prior to each dosing cycle will be presented.
Summary statistics on vital signs at screening, pre-infusion, 30 minutes after the start of infusion, 
at end of infusion and 30 minutes after the completion of infusion will be reported for each dosing 
cycle. Concomitant medications, SAEs, laboratory parameters, and performance status prior to 
dosing will be presented. The safety analysis set will be used for reporting safety /adverse events.
 
 
 
Revised Protocol No.: 03
Date: 08-Mar-2018
113
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
8.4.6
Outcomes Research Analyses (both cohorts)
Not applicable.
8.5
Interim Analyses
Administrative interim analyses may be performed at several times prior to completion of the study 
in order to facilitate program decisions and to support presentations or publications.
9.
STUDY MANAGEMENT
9.1
Compliance
9.1.1
Compliance with the Protocol and Protocol Revisions
The study shall be conducted as described in this approved protocol. All revisions to the protocol 
must be discussed with, and be prepared by, BMS. The investigator should not implement any 
deviation or change to the protocol without prior review and documented approval/favorable 
opinion from the IRB/IEC of an amendment, except where necessary to eliminate an immediate 
hazard(s) to study subjects.
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining IRB/IEC approval/favorable opinion, as soon as possible the deviation or change will be 
submitted to:
•
IRB/IEC for review and approval/favorable opinion
•
BMS
•
Regulatory Authority(ies), if required by local regulations
Revised Protocol No.: 03
Date: 08-Mar-2018
114
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Documentation of approval signed by the chairperson or designee of the IRB(s)/IEC(s) must be 
sent to BMS.
If an amendment substantially alters the study design or increases the potential risk to the subject: 
(1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and 
approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study if they are affected by the amendment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
9.1.2
Monitoring
BMS representatives will review data centrally to identify potential issues to determine a schedule 
of on-site visits for targeted review of study records.
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with the investigator, and verify that the 
facilities remain acceptable. Certain CRF/eCRF pages and/or electronic files may serve as the 
source documents.
In addition, the study may be evaluated by BMS internal auditors and government inspectors who 
must be allowed access to CRF/eCRFs, source documents, other study files, and study facilities. 
BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities, 
and promptly forward copies of inspection reports to BMS.
9.1.2.1
Source Documentation
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand-written on paper or entered 
electronically. If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments, and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A certified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes and information as the original.
Revised Protocol No.: 03
Date: 08-Mar-2018
115
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
9.1.3
Investigational Site Training
Bristol-Myers Squibb will provide quality investigational staff training prior to study initiation. 
Training topics will include but are not limited to: GCP, AE reporting, study details and procedure, 
electronic CRF/eCRFs, study documentation, informed consent, and enrollment of WOCBP.
9.2
Records
9.2.1
Records Retention
The investigator must retain all study records and source documents for the maximum period 
required by applicable regulations and guidelines, or institution procedures, or for the period 
specified by BMS, whichever is longer. The investigator must contact BMS prior to destroying 
any records associated with the study.
BMS will notify the investigator when the study records are no longer needed.
If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, IRB). Notice of such 
transfer will be given in writing to BMS.
9.2.2
Study Drug Records
It is the responsibility of the investigator to ensure that a current disposition record of study drug 
(inventoried and dispensed) is maintained at the study site for all investigational products. Records 
or logs must comply with applicable regulations and guidelines and should include:
•
amount received and placed in storage area
•
amount currently in storage area
•
label identification number or batch number
•
amount dispensed to and returned by each subject, including unique subject identifiers
•
amount transferred to another area/site for dispensing or storage
•
nonstudy disposition (eg, lost, wasted)
•
amount destroyed at study site, if applicable
•
amount returned to BMS
•
retain samples for bioavailability/bioequivalence, if applicable
•
dates and initials of person responsible for Investigational Product dispensing/accountability, 
as per the Delegation of Authority Form.
BMS will provide forms to facilitate inventory control if the investigational site does not have an 
established system that meets these requirements.
9.2.3
Case Report Forms
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF/eCRF must be consistent with the source documents or the discrepancies 
must be explained. Additional clinical information may be collected and analyzed in an effort to 
Revised Protocol No.: 03
Date: 08-Mar-2018
116
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
enhance understanding of product safety. CRF/eCRFs may be requested for AEs and/or laboratory 
abnormalities that are reported or identified during the course of the study.
For sites using the BMS electronic data capture tool, electronic CRF/eCRFs will be prepared for 
all data collection fields except for fields specific to SAEs and pregnancy, which will be reported 
on the paper or electronic SAE form and Pregnancy Surveillance form, respectively. Spaces may 
be left blank only in those circumstances permitted by study-specific CRF/eCRF completion 
guidelines provided by BMS.
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules in accordance with the applicable regulatory requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRF/eCRFs.
The completed CRF/ECRF, including any paper or electronic SAE/pregnancy CRF/eCRFs, must 
be promptly reviewed, signed, and dated by the investigator or qualified physician who is a 
subinvestigator and who is delegated this task on the Delegation of Authority Form. For electronic 
CRF/ECRFs, review and approval/signature is completed electronically through the BMS 
electronic data capture tool. The investigator must retain a copy of the CRF/eCRFs including 
records of the changes and corrections.
Each individual electronically signing electronic CRF/eCRFs must meet BMS training 
requirements and must only access the BMS electronic data capture tool using the unique user 
account provided by BMS. User accounts are not to be shared or reassigned to other individuals.
9.3
Clinical Study Report and Publications
A Signatory Investigator must be selected to sign the clinical study report.
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria:
•
Subject recruitment (eg, among the top quartile of enrollers)
•
Involvement in trial design
•
Regional representation (eg, among top quartile of enrollers from a specified region or country)
•
Other criteria (as determined by the study team)
The data collected during this study are confidential and proprietary to BMS. Any publications or 
abstracts arising from this study must adhere to the publication requirements set forth in the clinical 
trial agreement (CTA) governing [Study site or Investigator] participation in the study. These 
requirements include, but are not limited to, submitting proposed publications to BMS at the 
earliest practicable time prior to submission or presentation and otherwise within the time period 
set forth in the CTA.
Revised Protocol No.: 03
Date: 08-Mar-2018
117
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
10.
GLOSSARY OF TERMS
Term
Definition
Complete Abstinence
If one form of contraception is required, Complete Abstinence is defined as 
complete avoidance of heterosexual intercourse and is an acceptable form of 
contraception for all study drugs. Female subjects must continue to have pregnancy 
tests. Acceptable alternate methods of highly effective contraception must be 
discussed in the event that the subject chooses to forego complete abstinence.
If two forms of contraception is required, Complete abstinence is defined as 
complete avoidance of heterosexual intercourse and is an acceptable form of 
contraception for all study drugs. Subjects who choose complete abstinence are not 
required to use a second method of contraception, but female subjects must 
continue to have pregnancy tests. Acceptable alternate methods of highly effective 
contraception must be discussed in the event that the subject chooses to forego 
complete abstinence.
Expanded definition Complete abstinence as defined as complete avoidance of 
heterosexual intercourse is an acceptable form of contraception for all study drugs.
This also means that abstinence is the preferred and usual lifestyle of the patient. 
This does not mean periodic abstinence (eg, calendar, ovulation, symptothermal, 
profession of abstinence for entry into a clinical trial, post-ovulation methods) and 
withdrawal, which are not acceptable methods of contraception. Subjects who 
choose complete abstinence are not required to use a second method of 
contraception, but female subjects must continue to have pregnancy tests. 
Acceptable alternate methods of highly effective contraception must be discussed in 
the event that the subject chooses to forego complete abstinence
Revised Protocol No.: 03
Date: 08-Mar-2018
118
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
11.
LIST OF ABBREVIATIONS
Term
Definition
ACTH
adrenocorticotropic Hormone
ADCC
antibody-dependent cell-mediated cytotoxicity
AE
adverse event
AIDS
acquired immunodeficiency syndrome
ALT
alanine aminotransferase
ANC
absolute neutrophil count
AST
aspartate aminotransferase
HCG
human chorionic gonadotrophin
BMS
Bristol-Myers Squibb
BMSC
bone marrow stromal cells
BOR
best overall response
BP
blood pressure
BUN
blood urea nitrogen
CBC
complete blood count
CFR
code of Federal Regulations 
CI
confidence interval
Cm
centimeter
CR
complete response
CrCLr
creatinine clearance
Cm
centimeter
CRF
case report Form
CSR
clinical study report
dL
deciliter
DOR
duration of response
ECG
electrocardiogram
eCRF
electronic Case Report Form
ECOG
eastern Cooperative Oncology Group
EDC
electronic Data Capture
Eg
exempli gratia (for example)
EMR/EHR
electronic medical/health records
EN
elotuzumab and nivolumab combination cohort
EPd
elotuzumab in combination with pomalidomide and low dose dexamethasone 
FDA
Food and Drug Administration
FISH
fluorescence in situ hybridization
FSH
follicle stimulating hormone
G
gram
GCP
Good Clinical Practice
H
hour
HBsAg
hepatitis B surface antigen
HBV
hepatitis B virus
HCV
hepatitis C virus
Revised Protocol No.: 03
Date: 08-Mar-2018
119
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Term
Definition
HIV
human immunodeficiency virus
HR
heart rate
HRT
hormone replacement therapy
ICH
International Conference on Harmonisation 
Ie
id est (that is)
IEC
Independent Ethics Committee
IHC
immunohistochemistry
IMWG
International Myeloma Working Group
IMP/IP
investigational medicinal products
IND
Investigational New Drug Exemption
I-O
immuno-oncology
IRB
Institutional Review Board
IU
International Unit
IV
intravenous
Kg
kilogram
L
liter
MedDRA
Medical Dictionary for Regulatory Activities
Mg
milligram
Min
minute
mL
milliliter
MR
minimal response
MRD
minimum residual disease
MTD
maximum tolerated dose
μg
microgram
N
number of subjects or observations
N/A
not applicable
NCI CTCAE
National Cancer Institute Common Terminology Criteria for Adverse Events 
Ng
nanogram
NIMP
non-investigational medicinal products 
ORR
objective response rate
OS
overall survival
PC
plasma cell
PD
pharmacodynamics
PDL-1
programmed death ligand-1
PFS
progression free survival
PK
pharmacokinetics
PR
partial response
PS
performance score
PO
per os (by mouth route of administration)
sCR
stringent complete response
SAE
serious adverse event
SIFE
serum immunofixation electrophoresis
Revised Protocol No.: 03
Date: 08-Mar-2018
120
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Term
Definition
sFLC
serum free light chain
SIFE
serum immunofixation electrophoresis
SOP
Standard Operating Procedures
SPEP
serum protein electrophoresis
Subj
subject
T
temperature
T
time
TCR
T Cell Receptor 
TFTs
thyroid function tests
TSH
thyroid stimulating hormone
TTR
time to response
UIFE
urine immunofixation electrophoresis
UPEP
urine protein electrophoresis
USP
United States Pharmacopoeia
VGPR
very good partial response
WOCBP
women of childbearing potential
Revised Protocol No.: 03
Date: 08-Mar-2018
121
4.0
Approved
930091242
4.0
v








Clinical Protocol
CA204142
BMS-901608
elotuzumab
APPENDIX 1
DEFINITION OF LINES OF THERAPY
A line of therapy is defined by the 
 as 
one or more cycles of a planned treatment program. This may consist of one or more planned 
cycles of single-agent therapy or combination therapy, as well as a sequence of treatments 
administered in a planned manner. For example, a planned treatment approach of induction 
therapy followed by antilogous stem cell transplantation, followed by maintenance is considered 
one line of therapy. A new line of therapy starts when a planned course of therapy is modified to 
include other treatment agents (alone or in combination) as a result of disease progression, 
relapse, or toxicity. A new line of therapy also starts when a planned period of observation off 
therapy is interrupted by a need for additional treatment for the disease.
Revised Protocol No.: 03
Date: 08-Mar-2018
125
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
APPENDIX 2
PERFORMANCE STATUS SCALES
STATUS
STATUS
STATUS
ZUBROD-ECOG-WHO
Normal, no complaints
0
Normal activity
Able to carry on normal activities
Minor signs or symptoms of disease
1
Symptoms, but fully 
ambulatory
Cares for self. Unable to carry on normal 
activity or to do active work
2
Symptomatic, but in bed 
< 50% of the day.
Requires considerable assistance and 
frequent medical care
3
Needs to be in bed > 50% of 
the day, but not bedridden
Severely disabled. Hospitalization indicated 
though death non imminent
4
Unable to get out of bed
Dead
5
Dead
 
Revised Protocol No.: 03
Date: 08-Mar-2018
126
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
APPENDIX 3
PREPARATION AND ADMINISTRATION OF ELOTUZUMAB
Note: Subjects must be premedicated as described in Section 4.5.4 prior to elotuzumab infusion.
Dose Preparation Instructions
After dilution in normal saline, elotuzumab infusion must be completed within 8 hours if kept at 
room temperature (25 °C). In the United States and Puerto Rico, where a shortage of normal 
saline has been reported, dextrose 5% water (D5W) may be used. Normal saline is the preferred 
diluent and D5W should only be used if normal saline is not available. If a delay is anticipated 
after the dose has been diluted in normal saline, the prepared dose (properly identified) may be 
refrigerated at 2 °C to 8 °C for up to 24 hours. If stored under refrigerated conditions, the study 
drug solution should be equilibrated to room temperature (takes about 2 to 2.5 hours), and the 
container must be gently inverted to thoroughly mix the contents before administration. If the 
storage time limit is exceeded, the prepared dose solution must be discarded and the reason 
documented by the pharmacist in the study drug accountability records.
Elotuzumab will be administered to each subject as an IV infusion, using an automated infusion 
pump set at the appropriate rate according to the dose administration section (see Administration 
Instruction section below). The dose of elotuzumab will be calculated using the subject’s predose 
weight on Day 1 of each cycle (the screening weight can be used for Cycle 1 dose calculation), 
and then added to 0.9% saline for infusion.
Reconstitute elotuzumab lyophilized study drug, as described in steps 1 to 5.
Step 1:  For a 440 mg vial of lyophilized elotuzumab, draw 17 mL of Sterile Water for Injection 
(SWFI), USP into a syringe equipped with an 18-gauge or smaller needle.
Step 2:  Remove the flip-top from the elotuzumab vial.
Step 3:  Place the vial upright on a flat surface and, using standard aseptic techniques, insert the 
syringe needle into the vial through the center of the rubber stopper and deliver 17 mL (into the 
20-mL vial containing 440 mg elotuzumab) SWFI, USP, into the vial. Slowly remove the syringe 
needle out of the vial. The final volume of the reconstituted solution is approximately 17.6 mL, 
which includes the volume displaced by the solid cake. The concentration of elotuzumab in the 
reconstituted solution is approximately 25 mg/mL.
Step 4:  DO NOT SHAKE. Hold the vial upright and gently swirl the solution by rotating the vial 
to dissolve the lyophilized cake. Then gently invert the vial a few times in order to dissolve any 
powder that may be present on top of the vial or the stopper. Finally, hold the vial upright again 
and gently swirl the solution a few more times to dissolve any remaining particles. Avoid 
prolonged or vigorous agitation. DO NOT SHAKE.  
Step 5:  After the remaining solids are completely dissolved, allow the reconstituted solution to 
stand for 5 to 10 minutes.
It is acceptable to have small bubbles and/or foam around the edge of the vial. The reconstituted 
preparation results in a colorless to slightly yellow, clear to slightly opalescent solution 
containing approximately 25 mg/mL of elotuzumab.
Revised Protocol No.: 03
Date: 08-Mar-2018
127
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Step 6:  Once the reconstitution is completed, withdraw the calculated drug volume and further 
dilute with 100-500 ml of normal saline into an infusion bag (see Pharmacy Manual for 
additional details). The volume of saline or D5W can be adjusted so as not to exceed 5 mL/kg of 
patient weight at any given dose of elotuzumab. The resulting elotuzumab concentration must be 
from 1.0 mg/mL to 6.0 mg/mL. Elotuzumab solutions are compatible with polyvinyl chloride 
and polyolefin bags. Examples of such bags include Viaflo, MacoPharma Easyflex N, Macoflex 
N, B Braun Excel, and Braun Ecobag.
Drug volume will be calculated based on subject weight: For example, a subject receiving 
10 mg/kg elotuzumab who weighs 80 kg on Day 1 [predose] will require 800 mg of study drug 
for infusion. Withdraw 32 mL of elotuzumab (25 mg/mL) from 2 vials and add to an infusion 
bag already containing 230 mL saline, for a total of 262 mL to be infused. 
Similarly, an 80 kg subject receiving 20 mg/kg elotuzumab [predose] will require 1600 mg of 
study drug for infusion. Withdraw 64 mL of elotuzumab (25 mg/mL) from 4 vials and add to an 
infusion bag already containing 340 mL saline, for a total of 404 mL to be infused.  
Use a new sterile needle for withdrawing solution from each vial.
The same vial must not be used to prepare elotuzumab for more than one subject. Used 
elotuzumab vials will be stored until study drug accountability has been completed by the BMS 
designee, and destruction or return is authorized. Used vials do not need to be refrigerated.
Note: Subjects must be premedicated as described in Section 4.5.4 prior to elotuzumab infusion.
Administration Instructions
The first dose of elotuzumab will be administered following premedications (described in 
Section 4.5.4) to each subject as an IV infusion, using an automated infusion pump set at an 
initial rate of 0.5 mL per minute (30 mL/hour). If the subject does not have an infusion reaction 
within 30 minutes, escalate the infusion rate by 0.5 mL per minute. If the subject still does not 
have an infusion reaction within 30 minutes, escalate the infusion rate to a maximum of 2 mL
per minute (120 mL/hour). If a subject experiences a Grade ≥2 infusion reaction, the infusion 
must be interrupted. Please refer to Section 4.5.5.1 for detailed information on the management 
of infusion reaction and re-initiation of infusion.
The second dose of elotuzumab must be initiated at an infusion rate of 3 mL per minute if no 
infusion reactions were observed with the first elotuzumab infusion. If the subject does not 
experience an infusion reaction during the first 30 minutes of the second dose of elotuzumab, 
escalate the infusion rate to 4 mL per minute.
The third dose of elotuzumab must be initiated at an infusion rate of 5 mL per minute if no 
infusion reactions were reported with the second elotuzumab infusion.
The fourth and subsequent doses of elotuzumab must be initiated at an infusion rate of 5 mL
per minute if no infusion reactions were reported. 
Revised Protocol No.: 03
Date: 08-Mar-2018
128
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Elotuzumab Infusion Rate 
The elotuzumab infusion rate will be increased gradually to a maximum of 5 mL/min as 
presented in Table 1. Table 1 represents an example for an 80 kg subject receiving 10mg/kg 
dose. The total volume varies according to the subject weigh and the elotuzumab administered 
dose.
Table 1, Appendix 3: Elotuzumab Infusion Rate Plan 
Infusion Rate
Duration of infusion
Volume delivered
Volume remaining
Cycle 1 Dose 1
Approximate Total Duration: 2hrs 50min
262 mL*
0.5 mL/min
30 min
15 mL
247 mL
1 mL/min
30 min
30 mL
217 mL
2 mL/min
110 min
217 mL
0 mL
Cycle 1 Dose 2
Approximate Total Duration: 1hrs 13min
262 mL
3 mL/min
30 min
90 mL
172 mL
4 mL/min
43 min
172 mL
0 mL
Cycle 1 Dose 3 and 4
Approximate Total Duration: 53min
262 mL
5 mL/min
53 min
262 mL
0 mL
Cycle 2 +
Approximate Total Duration: 53min
262 mL
5 mL/min
53 min
262 mL
0 mL
* Volume for 80 kg subject. Total volume varies according to the subject weight.
Please note that infusion rate increase to the next higher level only if no infusion reactions encountered.
If a subject experiences a Grade ≥2 infusion reaction, the infusion must be interrupted. 
Please refer to Section 4.5.5.1 for detailed information on the management of infusion reaction 
and re-initiation of infusion. If a subject experiences a Grade ≤3 elotuzumab infusion reaction 
that has resolved to Grade ≤1, subsequent infusion rate of elotuzumab should be escalated in a 
stepwise fashion (0.5 mL every 30 minutes as per Section 4.5.5.1).
1. Administer through a low-protein-binding 0.22 - micrometer or smaller in-line filter (placed 
as proximal to the subject as is practical). Prime the infusion line with study drug before 
starting the infusion.
2. Set the IV pump to deliver the infusion at the rate of 0.5 mL per minute (including the drug 
in the line). The total time of infusion will vary depending upon the maximum tolerated 
mL/min infusion rate as discussed above.
3. Record every time the infusion is started and stopped and the reason why the start and stop 
occurred.
4. Monitor the IV setup and the subject’s IV site frequently during infusion, checking for the 
correct infusion rate and IV site infiltration.
5. Ensure that the full volume of elotuzumab is infused.
Revised Protocol No.: 03
Date: 08-Mar-2018
129
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
After elotuzumab has been infused from the line, discontinue the infusion, disconnect the 
IV tubing, and dispose of materials appropriately according to the facility’s standard procedure.
Note: Subjects must be premedicated as described in Section 4.5.4 prior to elotuzumab infusion.
Revised Protocol No.: 03
Date: 08-Mar-2018
130
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
APPENDIX 4
DEFINITIONS OF RESPONSE AND PROGRESSION CRITERIA 
(MODIFIED FROM IMWG)
Response Subcategory
Response Criteriaa
Stringent Complete Response 
(sCR)
CR, as defined below, plus the following:
Normal FLC ratiob and absence of clonal cellsc in bone marrow by 
immunohistochemistry or immunofluorescence.
Complete Response (CR)b
Negative immunofixation of serum and urine and disappearance of any soft 
tissue plasmacytomas, and < 5% plasma cells in bone marrow.
Very Good Partial Response 
(VGPR)
Serum and urine M-protein detectable by immunofixation but not on 
electrophoresis or ≥90% reduction in serum M-protein level plus urine 
M-protein level < 100 mg per 24 hour.
Partial Response (PR)
≥50% reduction of serum M-protein and reduction in 24-hour urinary 
M-protein by ≥90% or to < 200 mg per 24 hour. If serum and urine 
M-protein are unmeasurable, a ≥50% decrease in the difference between 
involved and uninvolved FLC levels is required in place of the M-protein 
criteria. In addition to the above criteria, if present at baseline, ≥50% 
reduction in the size of soft tissue plasmacytomas is also required
Minor (Minimal) Response (MR)
25-49% reduction of serum M-protein and reduction in 24-hour urine 
M-protein by 50-89%, which still exceeds 200 mg per 24 hours. In addition, 
if present at baseline, 25-49% reduction in the size of soft tissue 
plasmacytomas is also required. No increase in the size or number of lytic 
bone lesions (development of compression fracture does not exclude 
response).
Stable Disease (SD)
Not meeting criteria for CR, VGPR, PR, MR, or progression.
Progressive disease
Any of the following: 
•
Increase of 25% from lowest response value in any one or more of 
the following:
1.
Serum M-component (absolute increase must be 
≥0.5 g/dL)d and/or
2.
Urine M-component (absolute increase must be ≥200 mg 
per 24 h) and/or
3.
Only in patients without measurable serum and urine 
M-protein levels: the difference between involved and 
uninvolved FLC levels (absolute increase must be 
> 10 mg/dL)
4.
Bone marrow plasma cell percentage (absolute % must be 
≥10%)
•
Definite development of new bone lesions or soft tissue 
plasmacytomas or definite increase in the size of existing bone 
lesions or soft tissue plasmacytomas
•
Development of hypercalcemia (corrected serum calcium 
> 11.5 mg/100 mL) that can be attributed solely to the plasma cell 
proliferative disorder
Revised Protocol No.: 03
Date: 08-Mar-2018
131
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
a All response categories require 2 consecutive assessments made at any time before the institution of any new 
therapy; all categories also require no known evidence of progressive or new bone lesions if radiographic studies 
were performed. Radiographic studies are not required to satisfy these response requirements. Bone marrow 
assessments need not be confirmed.
b Note clarification to IMWG criteria for coding CR and VGPR in patients in whom the only measurable disease is 
by serum FLC levels: CR in such patients is defined as a normal FLC ratio of 0.26-1.65 in addition to CR criteria 
listed above. VGPR in such patients is defined as a > 90% decrease in the difference between involved and 
uninvolved FLC levels.
c Presence or absence of clonal cells is based upon the κ/λ ratio. An abnormal κ/λ ratio by immunohistochemistry 
and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting 
presence of an abnormal clone is κ/λ of > 4:1 or < 1:2.
d For progressive disease, serum M-component increase of ≥1 g/dL is sufficient to define progression if starting 
M-component is ≥5 g/dL
Revised Protocol No.: 03
Date: 08-Mar-2018
132
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
APPENDIX 5
THE INTERNATIONAL STAGING SYSTEM (ISS) FOR MULTIPLE 
MYELOMA
Stage
Criteria
Median Survival 
(months)
Stage I
Serum β2-microglobulin < 3.5 mg/L
Serum albumin ≥3.5 g/dL
62
Stage II
Not stage I or III
(There are two categories for stage II)
serum β2-microglobulin < 3.5 mg/L but serum 
albumin < 3.5 g/dL OR
β2-microglobulin 3.5 to < 5.5 mg/L 
irrespective of the serum albumin level
44
Stage III
Serum β2-microglobulin ≥5.5 mg/L
29
Greipp PR, San Miguel JF, Brian GM, Durie JJ, Crowley BB, Blade J, Boccadoro J, Child A, Avet-Loiseau H, Kyle 
RA, Laheuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I,
Westin J. International Staging System for Multiple Myeloma. J Clin Oncology 2005 23:3412-3420.
Revised Protocol No.: 03
Date: 08-Mar-2018
133
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
APPENDIX 6
POMALIDOMIDE PREGNANCY RISK PREVENTION PLAN
Appendix 5 only applies to subjects receiving clinical supply of pomalidomide.
Subjects receiving commercial supply of pomalidomide will follow the Pomalyst ® REMS 
program.
1
PREGNANCY PREVENTION RISK MANAGEMENT PLANS
1.1
Pomalidomide (CC-4047) Pregnancy Prevention Risk Management Plan
1.1.1
Pomalidomide Pregnancy Risk Minimization Plan for Celgene Clinical
Trials 
The following Pregnancy Risk Minimization Plan documents are included in this Appendix: 
1) Pomalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth 
Control Methods (Section 1.1.1.1); 
2) Pomalidomide Education and Counselling Guidance Document (Section 1.1.1.2); 
3) Pomalidomide Information Sheet (Section 1.1.1.1).
1. The Pomalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable 
Birth Control Methods document (Section 1.1.1.1) provides the following information:
•
Potential risks to the fetus associated with pomalidomide exposure
•
Definition of Female of Childbearing Potential (FCBP)
•
Pregnancy testing requirements for patients receiving Pomalidomide who are females 
of childbearing potential
•
Acceptable birth control methods for both female of childbearing potential and male 
patients receiving pomalidomide in the study
•
Requirements for counselling of all study patients receiving pomalidomide about 
pregnancy precautions and the potential risks of fetal exposure to pomalidomide
2. The Pomalidomide Education and Counselling Guidance Document (Section 1.1.1.2) must 
be completed and signed by either a trained counsellor or the Investigator at the participating 
clinical center prior to each dispensing of pomalidomide study treatment.  A copy of this 
document must be maintained in the patient records.
3. The Pomalidomide Information Sheet (Section 1.1.1.1) will be given to each patient 
receiving pomalidomide study therapy. The patient must read this document prior to starting 
pomalidomide study treatment and each time they receive a new supply of study drug.
Revised Protocol No.: 03
Date: 08-Mar-2018
134
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
1.1.1.1
Pomalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines 
and Acceptable Birth Control Methods 
Risks Associated with Pregnancy
Pomalidomide was found to be teratogenic in a developmental study in rabbits.  Pomalidomide is 
an analogue of thalidomide. Thalidomide is a known human teratogen that causes severe life-
threatening human birth defects.  If Pomalidomide is taken during pregnancy, it may cause birth 
defects or death to an unborn baby.
Criteria for females of childbearing potential (FCBP)
This protocol defines a female of childbearing potential as a sexually mature woman who: 1) has 
not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally 
postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) 
for at least 24 consecutive months (ie, has had menses at any time in the preceding 
24 consecutive months).
Counselling
For a female of childbearing potential, pomalidomide is contraindicated unless all of the 
following are met (ie, all females of childbearing potential must be counselled concerning the 
following risks and requirements prior to the start of pomalidomide study therapy): 
•
She understands the potential teratogenic risk to the unborn child
•
She understands the need for effective contraception, without interruption, 28 days before 
starting study treatment, throughout the entire duration of study treatment, dose interruption 
and 28 days after the end of study treatment
•
She should be capable of complying with effective contraceptive measures
•
She is informed and understands the potential consequences of pregnancy and the need to 
notify her study doctor immediately if there is a risk of pregnancy
•
She understands the need to commence the study treatment as soon as study drug is 
dispensed following a negative pregnancy test
•
She understands the need and accepts to undergo pregnancy testing based on the frequency 
outlined in this protocol (Section 1.1.1.1)
•
She acknowledges that she understands the hazards and necessary precautions associated 
with the use of pomalidomide
The investigator must ensure that females of childbearing potential:
•
Comply with the conditions for pregnancy risk minimization, including confirmation that she 
has an adequate level of understanding
•
Acknowledge the aforementioned requirements
Revised Protocol No.: 03
Date: 08-Mar-2018
135
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
For a female NOT of childbearing potential, pomalidomide is contraindicated unless all of the 
following are met (ie, all females NOT of childbearing potential must be counselled concerning 
the following risks and requirements prior to the start of pomalidomide study therapy): 
•
She acknowledges that she understands the hazards and necessary precautions associated 
with the use of pomalidomide
The effect of pomalidomide on spermatogenesis is not known and has not been studied. 
Therefore, male patients taking pomalidomide must meet the following conditions (ie, all males 
must be counselled concerning the following risks and requirements prior to the start of 
pomalidomide study therapy):
•
Understand the potential teratogenic risk if engaged in sexual activity with a pregnant female 
or a female of childbearing potential
•
Understand the need for the use of a condom even if he has had a vasectomy, if engaged in 
sexual activity with a pregnant female or a female of childbearing potential.  
Contraception
Females of childbearing potential (FCBP) enrolled in this protocol must agree to use two reliable 
forms of contraception simultaneously or to practice complete abstinence from heterosexual 
contact during the following time periods related to this study: 1) for at least 28 days before 
starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 
28 days after study treatment discontinuation. 
The two methods of reliable contraception must include one highly effective method and one 
additional effective (barrier) method. FCBP must be referred to a qualified provider of 
contraceptive methods if needed. The following are examples of highly effective and additional 
effective methods of contraception:  
•
Highly effective methods:
Intrauterine device (IUD)
Hormonal (birth control pills, injections, implants)
Tubal ligation
Partner’s vasectomy
•
Additional effective methods:
Male condom
Diaphragm
Cervical Cap
Because of the increased risk of venous thromboembolism in patients with multiple myeloma 
taking pomalidomide and dexamethasone, combined oral contraceptive pills are not 
recommended. If a patient is currently using combined oral contraception the patient should 
Revised Protocol No.: 03
Date: 08-Mar-2018
136
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
switch to another one of the effective methods listed above. The risk of venous 
thromboembolism continues for 4−6 weeks after discontinuing combined oral contraception. The 
efficacy of contraceptive steroids may be reduced during co-treatment with dexamethasone.
Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk 
of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics 
should be considered particularly in patients with neutropenia. 
Pregnancy testing
Medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/mL must be 
performed for females of childbearing potential, including females of childbearing potential who 
commit to complete abstinence, as outlined below.
Before starting study drug
Female Patients:
FCBP must have two negative pregnancy tests (sensitivity of at least 25 mIU/mL) prior to 
starting study drug.  The first pregnancy test must be performed within 10-14 days prior to the 
start of study drug and the second pregnancy test must be performed within 24 hours prior to the 
start of study drug.  The patient may not receive study drug until the study doctor has verified 
that the results of these pregnancy tests are negative.
Male Patients:
Must practice complete abstinence or  agree to use a condom during sexual contact with a 
pregnant female or a female of childbearing potential while participating in the study, during 
dose interruptions and for at least 28 days following study drug discontinuation, even if he has 
undergone a successful vasectomy.  
During study participation and for 28 days following study drug discontinuation 
Female Patients:
FCBP with regular or no menstrual cycles must agree to have pregnancy tests weekly for the 
first 28 days of study participation and then every 28 days while on study, at study 
discontinuation, and at day 28 following study drug discontinuation. If menstrual cycles are 
irregular, the pregnancy testing must occur weekly for the first 28 days and then every 
14 days while on study, at study discontinuation, and at days 14 and 28 following study drug 
discontinuation.  
At each visit, the Investigator must confirm with the FCBP that she is continuing to use two 
reliable methods of birth control.  
Counselling about pregnancy precautions and the potential risks of fetal exposure must be 
conducted at a minimum of every 28 days. 
If pregnancy or a positive pregnancy test does occur in a study patient, study drug must be 
immediately discontinued.
Revised Protocol No.: 03
Date: 08-Mar-2018
137
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
Pregnancy testing and counselling must be performed if a patient misses her period or if her 
pregnancy test or her menstrual bleeding is abnormal. Study drug treatment must be
discontinued during this evaluation.
Females must agree to abstain from breastfeeding during study participation and for at least 
28 days after study drug discontinuation.
Male Patients:
Counseling about the requirement for complete abstinence or condom use during sexual 
contact with a pregnant female or a female of childbearing potential and the potential risks of 
fetal exposure to pomalidomide must be conducted at a minimum of every 28 days.  
If pregnancy or a positive pregnancy test does occur in the partner of a male study patient 
during study participation, the investigator must be notified immediately.
Additional precautions
Patients should be instructed never to give this medicinal product to another person and to 
return any unused capsules to the study doctor at the end of treatment.
Patients should not donate blood during therapy and for at least 28 days following 
discontinuation of study drug.
Male patients should not donate semen or sperm during therapy or for at least 28 days 
following discontinuation of study drug.
Only enough study drug for one cycle of therapy may be dispensed with each cycle of 
therapy. 
Revised Protocol No.: 03
Date: 08-Mar-2018
138
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
1.1.1.2
Pomalidomide Education and Counselling Guidance Document 
To be completed prior to each dispensing of study drug.
Protocol Number: ____________________________________________
Patient Name (Print): __________________ DOB: _____/_____/_____ (mm/dd/yyyy)
(Check the appropriate box to indicate risk category)
Female:
If female, check one:
FCBP (Female of childbearing potential): sexually mature female who: 1) has not 
undergone a hysterectomy (the surgical removal of the uterus) or bilateral 
oophorectomy (the surgical removal of both ovaries) or 2) has not been naturally 
postmenopausal (amenorrhea following cancer therapy does not rule out 
childbearing potential) for at least 24 consecutive months (ie, has had menses at 
any time during the preceding 24 consecutive months)
NOT FCBP
Male:
Do Not Dispense study drug if:
The patient is pregnant.
No pregnancy tests were conducted for a FCBP.
The patient states she did not use TWO reliable methods of birth control (unless practicing 
complete abstinence of heterosexual contact) [at least 28 days prior to therapy, during 
therapy and during dose interruption].
FCBP:
1. I verified that the required pregnancy tests performed are negative.
2. I counselled FCBP regarding the following:
−
Potential risk of fetal exposure to pomalidomide:  If pomalidomide is taken during 
pregnancy, it may cause birth defects or death to any unborn baby. Females are advised 
to avoid pregnancy while taking pomalidomide. The teratogenic potential of 
pomalidomide in humans cannot be ruled out. FCBP must agree not to become pregnant 
while taking pomalidomide. 
−
Using TWO reliable methods of birth control at the same time or complete abstinence 
from heterosexual contact [at least 28 days prior to therapy, during therapy , during dose 
interruption and 28 days after discontinuation of study drug].
−
That even if she has amenorrhea she must comply with advice on contraception  
Revised Protocol No.: 03
Date: 08-Mar-2018
139
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
−
Use of one highly effective method and one additional method of birth control AT THE 
SAME TIME. The following are examples of highly effective and additional effective 
methods of contraception:  
♦Highly effective methods:
•
Intrauterine device (IUD)
•
Hormonal (birth control pills, injections, implants)
•
Tubal ligation
•
Partner’s vasectomy
♦Additional effective methods:
•
Male condom
•
Diaphragm
•
Cervical Cap
−
Pregnancy tests before and during treatment, even if the patient agrees not to have 
reproductive heterosexual contact.  Two pregnancy tests will be performed prior to 
receiving study drug, one within 10-14 days and the second within 24 hours of the start of 
study drug.
−
Frequency of pregnancy tests to be done:
−
Every week during the first 28 days of this study and a pregnancy test every 28 days
during the patient’s participation in this study if menstrual cycles are regular or every 14 
days if cycles are irregular.
−
If the patient missed a period or has unusual menstrual bleeding.  
−
When the patient is discontinued from the study and at day 28 after study drug 
discontinuation if menstrual cycles are regular. If menstrual cycles are irregular, 
pregnancy tests will be done at discontinuation from the study and at days 14 and 28 after 
study drug discontinuation.
−
Stop taking study drug immediately in the event of becoming pregnant and to call their 
study doctor as soon as possible. 
−
NEVER share study drug with anyone else.
−
Do not donate blood while taking study drug and for 28 days after stopping study drug.
−
Do not breastfeed a baby while participating in this study and for at least 28 days after 
study drug discontinuation.
−
Do not break, chew, or open study drug capsules.
−
Return unused study drug to the study doctor.
3. Provide Pomalidomide Information Sheet to the patient.
FEMALE NOT OF CHILDBEARING POTENTIAL (NATURAL MENOPAUSE FOR AT 
LEAST 24 CONSECUTIVE MONTHS, A HYSTERECTOMY, OR BILATERAL 
OOPHORECTOMY):
Revised Protocol No.: 03
Date: 08-Mar-2018
140
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
I counselled the female NOT of childbearing potential regarding the following:
Potential risk of fetal exposure to pomalidomide (Refer to item #2 in FCBP)
NEVER share study drug with anyone else.
Do not donate blood while taking study drug and for 28 days after stopping study drug.
Do not break, chew, or open study drug capsules
Return unused study drug capsules to the study doctor.
Provide Pomalidomide Information Sheet to the patient.
MALE:
I counselled the Male patient regarding the following:
Potential study drug fetal exposure to pomalidomide (Refer to item #2 in FCBP).
To engage in complete abstinence or use a condom when engaging in sexual contact 
(including those who have had a vasectomy) with a pregnant female or a female of 
childbearing potential, while taking study drug, during dose interruptions and for 28 days 
after stopping study drug.
Males should notify their study doctor when their female partner becomes pregnant and 
female partners of males taking study drug should be advised to call their healthcare provider 
immediately if they get pregnant
NEVER share study drug with anyone else.
Do not donate blood while taking study drug and for 28 days after stopping study drug.
Do not donate semen or sperm while taking study drug and for 28 days after stopping study 
drug.
Do not break, chew, or open study drug capsules.
Return unused study drug capsules to the study doctor.
Provide Pomalidomide Information Sheet to the patient.
Investigator/Counsellor Name (Print): ____________________
(circle applicable)
Investigator/Counsellor Signature: _______________________ 
Date: _____/_____/_____
(circle applicable)
**Maintain a copy of the Education and Counselling Guidance Document in the patient records.**
Revised Protocol No.: 03
Date: 08-Mar-2018
141
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
1.1.1.3
Pomalidomide Information Sheet 
FOR PATIENTS ENROLLED IN CLINICAL RESEARCH STUDIES
Please read this Pomalidomide Information Sheet before you start taking study drug and each 
time you get a new supply. This Pomalidomide Information Sheet does not take the place of an 
informed consent to participate in clinical research or talking to your study doctor or healthcare 
provider about your medical condition or your treatment.  
What is the most important information I should know about pomalidomide?
Pomalidomide may cause birth defects (deformed babies) or death of an unborn baby. 
Pomalidomide is similar to the medicine thalidomide. It is known that thalidomide causes 
life-threatening birth defects. Pomalidomide has not been tested in pregnant women but may 
also cause birth defects. Pomalidomide was found to cause birth defects when tested in 
pregnant rabbits. If you are a female who is able to become pregnant:
Do not take study drug if you are pregnant or plan to become pregnant
You must either not have any sexual relations with a man or use two reliable, separate 
forms of effective birth control at the same time: 
for 28 days before starting study drug
while taking study drug 
during dose interruptions of study drug 
for 28 days after stopping study drug 
You must have pregnancy testing done at the following times:
within 10 – 14 days and again 24 hours prior to the first dose of study drug 
weekly for the first 28 days
every 28 days after the first month or every 14 days if you have irregular menstrual 
periods
if you miss your period or have unusual menstrual bleeding
28 days after the last dose of study drug (14 and 28 days after the last dose if 
menstrual periods are irregular)
Stop taking study drug if you become pregnant during treatment
If you suspect you are pregnant at any time during the study, you must stop study 
drug immediately and immediately inform your study doctor. The study doctor will 
report all cases of pregnancy to Celgene Corporation. 
Do not breastfeed while taking study drug
The study doctor will be able to advise you where to get additional advice on 
contraception.
If you are a female not of childbearing potential:
In order to ensure that an unborn baby is not exposed to pomalidomide, your study doctor will 
confirm that you are not able to become pregnant.
Revised Protocol No.: 03
Date: 08-Mar-2018
142
4.0
Approved
930091242
4.0
v


Clinical Protocol
CA204142
BMS-901608
elotuzumab
If you are a male:
The effect of pomalidomide on sperm development is not known and has not been studied. The 
risk to the fetus in females of child bearing potential whose male partner is receiving 
pomalidomide is unknown at this time.  
Male patients (including those who have had a vasectomy) must either not have any sexual 
relations with a pregnant female or a female who can become pregnant, or must use a 
condom during sexual contact with a pregnant female or a female that can become pregnant:
o
While you are taking study drug
o
During dose interruptions of study drug
o
For 28 days after you stop taking study drug  
Male patients should not donate sperm or semen while taking study drug and for 28 days after 
stopping study drug. 
If you suspect that your partner is pregnant any time during the study, you must 
immediately inform your study doctor. The study doctor will report all cases of 
pregnancy to Celgene Corporation. Your partner should call their healthcare provider 
immediately if they get pregnant.
Restrictions in sharing study drug and donating blood:
Do not share study drug with other people. It must be kept out of the reach of 
children and should never be given to any other person.
Do not donate blood while you take study drug and for 28 days after stopping study 
drug. 
Do not break, chew, or open study drug capsules.
You will be supplied with no more than one cycle of study drug 
Return unused study drug capsules to your study doctor.
Additional information is provided in the informed consent form and you can ask your study 
doctor for more information.
Revised Protocol No.: 03
Date: 08-Mar-2018
143
4.0
Approved
930091242
4.0
v

















SAP_001.pdf: 
Official Title of Study: 
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination with Pomalidomide and Low- 
Dose Dexamethasone (EPd), and in Combination with Nivolumab (EN), in Patients with 
Multiple Myeloma Relapsed or Refractory to Prior Treatment with Lenalidomide. 
 
NCT Number: NCT02612779 
Document Date (Date in which document was last revised): August 24, 2018 


 
 
 
 
 
STATISTICAL ANALYSIS PLAN 
 
 
 
A PHASE 2, MULTIPLE COHORT STUDY OF ELOTUZUMAB IN COMBINATION 
WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE (EPD), AND IN 
COMBINATION WITH NIVOLUMAB (EN), IN PATIENTS WITH MULTIPLE MYELOMA 
RELAPSED OR REFRACTORY TO PRIOR TREATMENT WITH LENALIDOMIDE 
 
 
 
PROTOCOL CA204-142 
 
 
 
V 2.3 
 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
2 
TABLE OF CONTENTS 
 
TABLE OF CONTENTS .................................................................................................................2 
LIST OF TABLES ...........................................................................................................................3 
LIST OF FIGURES .........................................................................................................................4 
2 
STUDY DESCRIPTION ..............................................................................................8 
2.1 
Study Design .................................................................................................................8 
2.2 
Blinding and Unblinding ..............................................................................................9 
2.3 
Blinding and Unblinding ..............................................................................................9 
2.4 
Protocol Amendments ..................................................................................................9 
2.5 
Independent Data Monitoring Committee and Other External Committees ..............10 
3 
OBJECTIVES .............................................................................................................10 
3.1 
Primary .......................................................................................................................10 
3.2 
Secondary ...................................................................................................................10 
 
 
4 
ENDPOINTS ..............................................................................................................11 
4.1 
Progression Free Survival (PFS) ................................................................................11 
4.1.1 
Definition of an Adequate Tumor Assessment ............................................................11 
4.1.2 
Date of Progression or Censoring When Different Components of a Tumor 
Assessment are Conducted at Different Times ...........................................................11 
4.1.3 
Primary Definition of Progression-Free Survival ......................................................11 
4.1.4 
Secondary Definition of Progression-Free Survival ..................................................11 
4.2 
Objective Response Rate (ORR) ................................................................................12 
4.3 
Overall Survival (OS) .................................................................................................12 
 
 
 
 
4.6 
Safety and Tolerability ...............................................................................................12 
 
 
5 
SAMPLE SIZE AND POWER ..................................................................................13 
5.1 
EPd Cohort..................................................................................................................13 
5.2 
EN Cohort ...................................................................................................................13 
6 
STUDY PERIODS, TREATMENT REGIMENS AND POPULATIONS 
FOR ANALYSES .......................................................................................................13 
6.1 
Study Periods ..............................................................................................................13 
6.2 
Treatment Regimens ...................................................................................................14 
6.3 
Populations for Analyses ............................................................................................14 
7 
STATISTICAL ANALYSES .....................................................................................14 
7.1 
General Methods .........................................................................................................14 
7.2 
Study Conduct ............................................................................................................15 
7.2.1 
Accrual ........................................................................................................................15 
7.2.2 
Relevant Protocol Deviations .....................................................................................15 
7.3 
Study Population .........................................................................................................16 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
3 
7.3.1 
Subject Disposition .....................................................................................................16 
7.3.2 
Demographic and Subject Characteristics .................................................................16 
7.3.3 
Disease Characteristics at Baseline ...........................................................................17 
7.3.4 
Prior Anti-Myeloma Therapy .....................................................................................17 
7.3.5 
General Medical History ............................................................................................17 
7.3.6 
Physical Measurements ..............................................................................................17 
7.4 
Extent of Exposure .....................................................................................................18 
7.4.1 
Study Therapy .............................................................................................................18 
7.4.2 
Premedication Other than Dexamethasone for Hypersensitivity Reactions ..............23 
7.4.3 
Concomitant Medication ............................................................................................23 
7.4.4 
Discontinuation of Study Therapy ..............................................................................24 
7.5 
Efficacy .......................................................................................................................24 
7.5.1 
Progression-Free Survival..........................................................................................24 
7.5.2 
Overall Survival ..........................................................................................................24 
7.5.3 
Objective Response .....................................................................................................25 
 
 
7.6 
Safety ..........................................................................................................................26 
7.6.1 
Adverse Events ............................................................................................................26 
7.6.2 
Serious Adverse Events and Adverse Event Leading to Discontinuation ...................27 
7.6.3 
Adverse Events of Special Interest ..............................................................................27 
7.6.4 
Deaths .........................................................................................................................28 
7.6.5 
Clinical Laboratory Evaluations ................................................................................28 
7.6.6 
Vital Signs ...................................................................................................................29 
8 
CONVENTIONS ........................................................................................................29 
8.1 
Age Definition ............................................................................................................29 
8.2 
Duration and Study Day Definition ............................................................................29 
8.3 
Day Conversion of Date Imputation ...........................................................................29 
8.4 
AE, Laboratory Results and Concomitant Medication ...............................................30 
9 
CONTENT OF REPORTS .........................................................................................30 
Topline Analyses ...........................................................................................................................30 
10 
DOCUMENT HISTORY ...........................................................................................31 
 
 
APPENDIX 1 
LIST OF ABBREVIATIONS ....................................................................33 
APPENDIX 2 
LIST OF MEDDRA TERMS TO BE INCLUDED AS INFUSION 
REACTIONS (PERI-INFUSIONAL ADVERSE EVENTS) ....................................34 
APPENDIX 3 
DEFINITIONS OF RESPONSE AND PROGRESSION 
CRITERIA (MODIFIED FROM IMWG) ..................................................................38 
 
LIST OF TABLES 
Table 2: 
Treatment Schedule ...................................................................................18 
Table 3: 
Dexamethasone Dosing, All Subjects Receiving Elotuzumab ..................22 
Table 4: 
Document History ......................................................................................31 
Table 5: 
List of Abbreviations .................................................................................33 
Table 6: 
MedDRA Terms.........................................................................................34 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
4 
Table 7: 
DEFINITIONS OF RESPONSE AND PROGRESSION 
CRITERIA (MODIFIED FROM IMWG) .................................................38 
 
LIST OF FIGURES 
Table 2: 
Treatment Schedule ...................................................................................18 
Table 3: 
Dexamethasone Dosing, All Subjects Receiving Elotuzumab ..................22 
Table 4: 
Document History ......................................................................................31 
Table 5: 
List of Abbreviations .................................................................................33 
Table 6: 
MedDRA Terms.........................................................................................34 
Table 7: 
DEFINITIONS OF RESPONSE AND PROGRESSION 
CRITERIA (MODIFIED FROM IMWG) .................................................38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 








Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
8 
 
 
 
  
 
2 
STUDY DESCRIPTION 
2.1 
Study Design 
This is a Phase 2, multi-center, open-label, multiple cohort study of elotuzumab in combination 
with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination 
with nivolumab (EN Cohort) to assess the safety and efficacy of this combination therapy for 
treatment of relapsed or refractory MM patients. 
Approximately 100 subjects will be screened in this study. A minimum of 60 subjects will be  
treated in the EPd Cohort. Approximately 25 subjects will be treated in the EN Cohort.The 
estimated duration of enrollment is 18 to 24 months, and the duration of the study is estimated at 
48 months from the date of first patient first visit. 
The study design schematic is presented in Figure 3.  
 
 
Figure 3: 
Study design Schematic 
In the EPd Cohort, subjects will receive treatment with elotuzumab in combination with 
pomalidomide and low-dose dexamethasone in a 28 day cycle. Subjects will receive 10 mg IV 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
9 
elotuzumab on Days 1, 8, 15, and 22 of Cycles 1 and 2. Starting with Cycle 3, subjects will 
receive 20 mg/kg on Day 1. As of Amendment 02, subjects who progress as defined by IMG 
criteria in the EPd cohort will be eligible to add nivolumab 240 mg every 2 weeks (Q2W) on 
Days 1 and 15 of each cycle.  
As of Amendment 02, subjects will also be enrolled in the EN cohort to receive a combination of 
elotuzumab and nivolumab in a 28-day cycle. Subjects will receive nivolumab 240 mg IV on 
Days 1 and 15 for Cycles 1-4. Starting with Cycle 5 and beyond, subjects will receive 480 mg IV 
on Day 1. Subjects will also receive elotuzumab 10 mg on Days 1, 8, 15, and 22 of Cycles 1 and 
2. Starting with Cycle 3 and beyond, subjects will receive 20 mg of elotuzumab IV on Day 1. If 
subjects do not achieve clinical benefit represented by at least minimal response (MR) after 2 
cycles of treatment, or do not achieve an objective response (PR) after 5 cycles of treatment, 
they may cross over to the EPd cohort at Day 1 of the subsequent cycles if they also meet the 
eligibility criteria for cross-over specified in protocol Section Error! Reference source not 
found.. 
2.2 
Blinding and Unblinding 
All subjects with eligibility of enrollment after the screening will be treated with IP/non-IP as 
indicated in Figure 3. 
2.3 
Blinding and Unblinding 
Not applicable. 
2.4 
Protocol Amendments 
Revised Protocol 01 (16-May-2016)  incorporates Amendment 01, Administrative Letters 01 and 
02: 
Amendment 01 16-May-2016: 
 Patients with multiple myeloma who may have received prior treatment with elotuzumab 
outside of a clinical trial are now eligible, provided the patient did not discontinue 
treatment due to intolerability to elotuzumab 
 The requirement of 6 months or less for relapse to prior treatment with lenalidomide has 
been removed as a criteria for eligibility. 
 Monthly dosing of elotuzumab will now begin at Cycle 3 rather thanat Cycle 7. 
 
Administrative Letter 02, 14-Dec-2015:  Personnel changes 
 
Administrative Letter 01, 21-Sep-2015: Alignment of the following protocol sections with 
revised washout period for study drug: 
1. Protocol Sections 3.3.1 Age and Reproductive Status 
2. Protocol Table 5.1-3 Pregnancy Test Note 
3. Protocol Table 5.3.4-1 Pregnancy Test Note 
4. Protocol Section 6.4 Pregnancy 
 
Revised Protocol 02 (15-Feb-2017)  incorporates Amendment 02. Amendment 02 15-Feb-2016: 
 Allows subjects who received elotuzumab in combination with pomalidomide and low-dose 
dexamethasone (EPd Cohort) to receive nivolumab upon progression. 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
10 
 Adds a cohort to receive elotuzumab in combination with nivolumab in a separate cohort (EN 
Cohort). 
Revised Protocol 03 draft (08-Feb-2018)   
 Exploratory objective for EPd cohort have been removed. 
 Removed the option to add nivolumab to EPd cohort, removed the option to add 
pomalidomide/lenalidomide to the EN cohort, added the option for EN patients to crossover 
to EPd if they not respond to EN treatment. 
 Increased the EN cohort size to 30 patients. 
2.5 
Independent Data Monitoring Committee and Other External 
Committees 
Not applicable. 
3 
OBJECTIVES 
3.1 
Primary 
The primary objectives of this study is to estimate the PFS in patients with MM treated by EPd 
as second or third line regimen after relapse or being refractory or intolerant to a prior 
lenalidomide-based regimen, and to estimate the ORR in EN Cohort.  
3.2 
Secondary 
The secondary objectives are: 
 To estimate the ORR and Overall Survival (OS) rate for EPd Cohort. 
 To estimate  the PFS and OS for EN Cohort.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
11 
4 
ENDPOINTS 
4.1 
Progression Free Survival (PFS) 
4.1.1 
Definition of an Adequate Tumor Assessment 
In the analysis of PFS, subjects who do not progress are censored. A non-progressing subject can 
be censored on the date of a tumor assessment only if there is sufficient information to rule out 
progression. An “adequate” tumor assessment visit for ruling out progression will require the 
following information: 
 Serum monoclonal paraprotein results, if measurable at baseline by central lab, and 
 Urine monoclonal paraprotein results, if measurable at baseline 
 Serum free light chain results, if measurable at baseline by central lab. This is only relevant 
for subjects who do not have measurable serum and urine monoclonal paraprotein results. 
4.1.2 
Date of Progression or Censoring When Different Components of a 
Tumor Assessment are Conducted at Different Times 
As different tumor measurements may be conducted on different days, for instance, the blood 
draw for serum M-protein may be on a different date than 24-hour urine, the investigators were 
instructed to report the earliest date of the measurements associated with that time point for 
progression. In contrast, if tumor measurements are done on different dates and the subject is 
being censored, instructions were to report the latest date of the measurements associated with 
that time point. 
4.1.3 
Primary Definition of Progression-Free Survival 
Progression Free Survival (PFS) is defined as the time from first dosing date to the date of the 
first documented progression per IMWG uniform criteria or death due to any cause, whichever 
occurs first. Subjects who die without a reported prior progression will be considered to have 
progressed on the date of their death. Subjects who did not progress or die will be censored on 
the date of their last adequate tumor assessment. Subjects who did not have any on study efficacy 
assessments and did not die will be censored on the first dosing date.  
Subjects who switched to subsequent therapy prior to documented progression will be censored 
on the date of the last adequate tumor assessment prior to the initiation of the new therapy.  
4.1.4 
Secondary Definition of Progression-Free Survival 
Progression Free Survival (PFS) is defined as the time from first dosing date to the date of the 
first documented tumor progression per IMWG uniform criteria or death due to any cause, 
whichever occurs first. Subjects who die without a reported prior progression will be considered 
to have progressed on the date of their death. Subjects who did not progress or die will be 
censored on the date of their last adequate tumor assessment. Subjects who did not have any on 
study efficacy assessments and did not die will be censored on the first dosing date.  


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
12 
4.2 
Objective Response Rate (ORR) 
The best overall response is determined as the best assessment based on all on-study efficacy 
data for the subject. Overall Response Rate (ORR) is defined as proportion of subjects with a 
best overall response of partial response (PR) or better. 
4.3 
Overall Survival (OS) 
Overall Survival (OS) is defined as the time from first dosing date to the date of death from any 
cause. A subject who has not died will be censored at last known date alive. 
 
 
 
  
 
 
 
 
 
 
  
4.6 
Safety and Tolerability 
Safety and tolerability endpoints consist of all deaths, AEs, drug-related AEs, AEs leading to 
treatment discontinuation, SAEs, and drug-related SAEs and specific laboratory abnormalitites 
(worst grade) collected during the treatment and up to 60 days after discontinuation of study drug 
will be tabulated using worst grade per NCI CTCAE v3.0 criteria by system organ class and 
MedDRA preferred term.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
13 
5 
SAMPLE SIZE AND POWER 
5.1 
EPd Cohort 
Seventy-two subjects will be screened with approximately 17% projected to fail screening. This 
total number is based on logistical consideration with statistical properties outlined below. 
Screening will continue until a minimum of 60 subjects are enrolled and treated. 
Under the assumptions that: 
 progression-free survival is exponentially distributed 
 median time of progression-free survival is 11 months for subjects treated with 
pomalidomide + dexamethasone and will increase to median of 15 months with the 
addition of elotuzumab to the treatment mix; 
 an increase of 4 months in median corresponds to relative risk ratio of 0.73 (0.0462 
monthly risk in the elotuzumab add-on and 0.0630 monthly historical risk in the 
pomalidomide + dexamethasone treated-subjects) 
60 subjects enrolled over a 24-month period are sufficient to detect an increase in median from 
11 to 15 months with about 70% power in a one-sided test with a 0.05 significance level.  
Assuming a monthly hazard rate of 0.0462, 48 of the 60 treated subjects are expected to have 
PFS events over a 24-month follow up period. 
Power is calculated using PASS12 using the one-sample exponential module where the median 
is mapped to mean by dividing the assumed alternative median by logarithm of 2. The calculated 
power and event counts are consistent with power and event counts based on one sample log 
rank test where the number of events is calculated assuming relative risk ratio of 0.73. 
5.2 
EN Cohort 
The planned sample size will be approximately 30 treated subjects; screening will continue until 
a minimum of 30 patients are enrolled and treated.  
For a 30% observed ORR rate and a sample size of N=30 yields an exact confidence interval of 
[0.15, 0.49].  These design parameters ensure a lower bound higher than 15%. 
6 
STUDY PERIODS, TREATMENT REGIMENS AND POPULATIONS FOR 
ANALYSES 
6.1 
Study Periods 
There are three periods in this study: screening, on-treatment and post-treatment follow-up. 
Screening: Most screening procedures must be done no more than 14 days prior to first dose of 
treatment. Some exceptions include Serum 2-microglobulin, Pregnancy Test, Myeloma Urine 
and Serum Lab tests, Bone Marrow Aspiration/Biopsy, Skeletal Imaging, CT/MRI assessment 
for extramedullary soft tissue plasmacytoma, which can be done up to 60 days prior to first dose 
of study drug. See Section 5 of the Protocol for full details of study procedures and timings. For 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
14 
analyses purposes data collected on or after information consent date and prior to first dose will 
fall into the screening/baseline period.  
Baseline:  Baseline evaluations will be those performed within 60 days prior to first dosing date. 
When an assessment is repeated multiple times within the screening period, the baseline 
evaluation will be the one closest to the first dosing date.  
All laboratory tests and procedures done on the first date of dosing will be assumed to have 
occurred prior to dosing and therefore baseline evaluation for those parameters will be those 
prior or on the first dosing date. 
On-Treatment Period: In the post baseline period, every 28 days is defined as a cycle. AEs will 
be defined as AEs with an onset date-time on or after the date-time of the first dose of study 
treatment (or with an onset date on or after the day of first dose of study treatment if time is not 
collected or is missing) and within 60 days of the last dose of study treatment. Subjects should 
have myeloma urine and serum laboratory assessments, and the tumor response assessments per 
IMWG uniform criteria will be every 4 weeks from date of first dose of study drug on Cycle 1 
Day 1 until progression or discontinuation. Study treatment ends when the subject progresses, 
experiences unacceptable toxicity, or withdraws consent. 
Follow-up Period: Subjects who are discontinued from further study treatment for reasons other 
than progression will be followed every 4 weeks for disease progression. Following disease 
progression, subjects will be followed at least annually for survival until the subject dies or the 
study ends. 
6.2 
Treatment Regimens 
The study is a Phase 2, multi-center, open-label, multiple cohort study of elotuzumab in 
combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in 
combination with nivolumab (EN Cohort) in a 28 day cycle. The estimated duration of 
enrollment is 18 to 24 months, minimum of 24 months follow-up and study duration of about 48 
months. This includes a up to 60 day screening period, a treatment period and a follow up period. 
The end of study will be defined as the date of the last visit of the last subject undergoing the 
study or death. 
6.3 
Populations for Analyses 
The following subject populations will be used for the statistical analysis: 
All Enrolled Subjects: All subjects who gave signed informed consent; 
ITT Subjects: All enrolled subjects who meet the inclusion and exclusion criteria;  
All Treated subjects: This population includes all subjects who receive at least one elotuzumab 
dose. The safety analysis set is also the all treated analysis set. 
7 
STATISTICAL ANALYSES 
7.1 
General Methods 
Continuous variables will be summarized using descriptive statistics; i.e. number of non-missing 
observations (n), mean, standard deviation (STD), median, minimum, maximum, first quartile 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
15 
and third quartile. The number of decimal places displayed in all listings will be determined by 
the number of decimal places in the raw data. Unless otherwise specified, minimum and 
maximum will be reported to the precision as the data collected, one more decimal place for the 
mean and median, and two more decimal places for the standard deviation.  The adjusted 
geometric mean, geometric mean ratio and the lower and upper limits of confidence interval will 
be displayed to three decimal places. Categorical variables will be summarized by frequencies 
and percentages. 
Safety analyses will be conducted on all treated subjects. Efficacy analyses will be conducted on 
all treated subjects, and also by subgroups based on lines of prior therapy (2L, 3L), or by age 
group (<65 years, ≥65 years), and (<75 years, ≥75 years). Descriptive statistics (n, mean, 
median, standard deviation, minimum, maximum or interquartile range) will be provided. 
Because the sample size for the study is small, summary statistics with their associated 95% 
confidence intervals and tests of hypotheses will be based, to the extent possible, using small-
sample statistics like the Clopper- Pearson for binomial data. Median time-to-event and its 95% 
confidence interval will be based on the Kaplan-Meier (KM) estimation procedure. The KM 
curves will be presented for time to event endpoints. Separate analyses will be conducted for 
each cohort EPd and EN.  
Laboratory results, adverse events, and other symptoms will be graded using the National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0, except 
where CTCAE grades are not available. Individual laboratory values will be presented in both 
the International System of Units (SI) and US unit (US). Adverse events will be categorized 
using the most current version of Medical Dictionary for Regulatory Activities (MedDRA), by 
system organ class and preferred term. Prior therapies will be summarized using the most current 
version of the World Health Organization (WHO) drug dictionary.  
Statistical analyses will be carried out in SAS (Statistical Analysis System, SAS Institute, North 
Carolina, USA), unless otherwise indicated. 
7.2 
Study Conduct 
The study shall be conducted as described in approved protocol. 
7.2.1 
Accrual 
The following will be presented on all enrolled subjects:  
 Number of subjects accrued by investigational site  
 Number of subjects accrued by month 
7.2.2 
Relevant Protocol Deviations 
Eligibility and on-study deviations as required by guidelines will be summarized and listed for 
all treated subjects. A relevant protocol deviation is defined as a deviation from the protocol 
which is programmed in the database and which could potentially affect the interpretability of 
the study results. 
 Subjects with relevant eligibility deviations:  


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
16 
o Subjects who have received 3 or more prior lines of therapy 
o Subjects have no measureable disease at screening, based on central laboratory 
results, defined as one or more of the following 
 Serum IgG, IgA, IgM M-protein 0.5 g/dL 
 Urinary M-Protein 200 mg urinary M-protein excretion in a 24 hour 
collection sample 
 Involved serum free light chain (sFLC) 10 mg/dL provided the FLC 
ratio is abnormal. 
 Subjects with on-study deviations: 
o Non-protocol specified systemic anti-myeloma therapy prior to discontinuation of 
study therapy 
o No baseline efficacy assessment. This occurs when there are no tumor 
assessments at all (laboratory assessments) on or prior to first day of dosing. 
A by subject listing of relevant protocol deviations will be provided. 
7.3 
Study Population 
The intent-to-treat analysis set consists of enrolled subjects who meet the inclusion and  
exclusion criteria. The safety analysis set consists of subjects who receive treatment at least once. 
The safety analysis set is also the all treated subjects. 
7.3.1 
Subject Disposition 
A frequency table of all enrolled subjects, broken out by whether or not they were treated, and 
giving reasons for not being treated, will be produced.  
Subject disposition during the treatment period will be summarized. The number and percentage 
of subjects treated, still on treatment, discontinued from the treatment and reasons for 
discontinuation will be presented.  
By-subject listings will also be produced to accompany the tables on enrollment and the subject 
disposition table.  
In addition, a by-subject listing indicating whether the subject was included in each of the 
analysis populations will be provided.  
7.3.2 
Demographic and Subject Characteristics 
Demographic and baseline characteristics will be summarized. The following parameters will be 
summarized; age at the time of informed consent (years), age category at time of informed 
consent (<65 years, ≥65 years), and (<75 years, ≥75 years), gender (Male, Female), race (White, 
Black/African American, American Indian/Alaska Native, Asian, Native Hawaiian/Other Pacific 
Islander, Other), ethnicity – for US subjects only (Hispanic/Latino, Not Hispanic/Latino), ECOG 
performance status (0, 1, 2, 3, 4, 5), time from disease diagnosis to first dose of study drug 
(months) and lines of prior therapy (2L vs. 3L). 
An accompanying by-subject listing of demographic and subject characteristics will be presented 
for all treated subjects.  


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
17 
7.3.3 
Disease Characteristics at Baseline  
Baseline disease characteristics will be summarized. The following parameters will be presented 
to summarize baseline disease: 
 Myeloma Serum M-protein (g/dL) 
 Myeloma Urine M-protein (mg/24 hours) 
 Skeletal Imaging: number of lytic bone lesions 
 CT/MRI assessment for extramedullary soft tissue plasmacytoma 
 Bone Marrow Aspiration/Biopsy: percentage of plasma cells 
 β2 microglobulin (mg/L) (<3.5, ≥3.5-5.5, >5.5) 
 Albumin (g/L) (<3.5, ≥3.5) 
 ISS Stage at enrollment (I, II, III) 
 Myeloma Type 
 Disease Status (Relapsed and Refractory, Relapsed, Refractory, Intolerant). Intolerant 
subjects are classified in the CRF as “Neither Relapsed or Refractory”.  All categories will be 
selected from CRF entries.  
An accompanying by-subject listing of disease characteristics at baseline will be presented for all 
treated subjects. Laboratory results will be presented in standard international (SI) units and US 
units. 
7.3.4 
Prior Anti-Myeloma Therapy 
Prior systemic anti-myeloma therapy (which will be identified from the eCRF page “Prior 
Systemic Therapy for Multiple Myeloma”) will be categorized using the WHO drug dictionary 
and will be summarized. The latest version of the drug dictionary at the time of the analysis will 
be used.  
A summary of the number and percentage of subjects receiving prior stem cell therapy and prior 
radiotherapy will be presented.  
A by-subject listing containing relevant information on prior stem cell transplant, prior 
radiotherapy and prior systemic anti-myeloma therapy will be provided for all treated subjects.  
7.3.5 
General Medical History 
The number and percentage of subjects with any relevant medical history and by body system 
will be presented.  
7.3.6 
Physical Measurements 
Physical measurements will not be summarized. 
A by subject listing of weight will be provided.  


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
18 
7.4 
Extent of Exposure 
7.4.1 
Study Therapy 
Pomalidomide, oral dexamethasone and IV dexamethasone are given at fixed doses and are not 
adjusted for body surface area or weight. The elotuzumab dose, in contrast, is adjusted for 
weight. Throughout this SAP, a subject’s elotuzumab dose level at a particular time point will 
refer to the actual dose, in mg/kg, rather than their planned dose. A subject’s actual elotuzumab 
dose level will be computed by dividing their total dose delivered, in mg, as recorded on the 
“Record of Study Medication - Elotuzumab” eCRF page, by their latest pre-dose weight, in kg, 
on Day 1 of that cycle.  
7.4.1.1 
Duration of Study Therapy 
The number of cycles of treatment received by subjects will be summarized (using n, mean, 
STD, median, min, max, q1 and q3).  
If there is no treatment interruption, The duration of each treatment (elotuzumab, dexamethasone 
[oral and IV combined] and pomalidomide), in months, will be calculated as: 
 (date of last dose of the drug - date of first dose of the drug + 1) / 30. 4375 
If there is treatment interruption, The duration of each treatment (elotuzumab, dexamethasone 
[oral and IV combined] and pomalidomide), in months, will be calculated as: 
 (date of last dose of the drug - date of first dose of the drug – days of treatment  interruption + 
1) / 30. 4375  
Duration of each of the study treatments will be summarized.  
Table 2: 
Treatment Schedule 
 
 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
19 
7.4.1.2 
Dose Modifications  
7.4.1.3 
Elotozumab 
7.4.1.4 
Dose Reduction 
Reduction of elotuzumab dosing is not permitted as per the protocol.  
7.4.1.5 
Dose Delay 
Dose delays of elotuzumab beyond the allowed dosing window are not permitted as per the 
protocol. Delays within the allowed dosing window could be for logistical or no reasons and will 
not be summarized. 
7.4.1.6 
Dose Omission 
An omission for elotuzumab will be calculated based on records from the dosing CRF page. If 
the interval between the two dosing dates for elotuzumab is > 10 days (in cycles 1, 2 or 3) or > 
35 days (from cycle 3 onwards), the dose will be considered to have been omitted. 
The number and percentage of subjects with a dose omission, and with 1, 2, 3, or  4 omissions 
will be summarized. For subjects with an omission, their reason for omission (from the dose 
modification page of the CRF) will be summarized in the groups: “hematologic toxicity”, “non-
hematologic toxicity”, “AE”, “dosing error” and “other”. For subjects without an available 
reason for omission, the category “unknown” will be used.  
A by-subject listing for dose omission will be presented for all treated subjects. This listing will 
include all reported omission per CRF, regardless of whether the subject had a computed 
omission based on the actual dosing dates. 
7.4.1.7 
Infusion Interruption 
The number and percentage of subjects with any interruption in their elotuzumab infusion, with 
1, 2, 3, or  4 interruptions, with an interruption due to “infusion reaction”, “infusion 
administration issues” and “other” will be presented. In addition, duration of interruptions (in 
minutes) will be summarized via descriptive statistics.  
A subject listing will be generated for elotuzumab IV interruptions. This listing will include 
reason for interruption, whether the interruption was resumed, and duration of the interruption. 
The number and percentage of subjects with any elotuzumab IV rate reduction, with 1, 2, 3, or  
 4 rate reductions, and with rate reductions due to “infusion reaction,” “infusion administration 
issues,” and “other” will be presented.  
A listing will be generated for elotuzumab IV rate reductions. 
7.4.1.8 
Pomalidomide 
The number and percentage of subjects with a dose reduction, omission and discontinuation 
which will be collected on the records from the dosing CRF page.  
Reduction of Pomalidomide will also be computed based on the actual dose received. In any 
study day (excluding, cycle 1, day 1), the drug will have a calculated reduction compared to the 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
20 
previous day, if the actual level of the administered dose is below the actual level of the 
administered dose in the previous instance. The information for this analysis will be derived 
programmatically, using 
the total daily dose on the “Record of Study Medication - pomalidomide” eCRF page. 
The daily dose levels are defined as follows: 
• Dose level 0 or full dose (4mg) 
• Dose level -1 (3mg) 
• Dose level -2 (2mg) 
• Dose level -3 (1mg) 
The number and percentage of subjects with a dose reduction, and the lowest dose level achieved 
per subject (-1, -2, -3), will be presented. 
The reason for dose reduction as reported by the investigator will be tabulated for all instances 
with a calculated reduction based on the dose modification for Pomalidomide page. A category 
“unknown” will be defined for all calculated reductions with no reason reported by the 
investigator. 
The number of subjects with any reported dose changes including reduction, omission and 
discontinuation, with 1, 2, 3, or  4 reported dose changes will be provided. The reason for dose 
changes (from the dose modification page of the CRF) will be summarized in the groups: 
“hematologic toxicity”, “non-hematologic toxicity”, “AE”, “dosing error” and “other”. For 
subjects without an available reason for omission, the category “unknown” will be used.  
A by-subject listing of dose reductions will be generated. This will include all reported 
reductions per investigator, regardless of whether it met the requirements for a calculated 
reduction 
7.4.1.9 
Dexamethasone (Oral) 
For PO dexamethasone the following summaries will be produced: 
 The number of subjects with any dose modification, and with a reason for the modification of 
“hematologic toxicity”, “non-hematologic toxicity”, “AE”, “dosing error” and “other”). 
 The total number of modifications of the drug experienced by a subject, both overall and by 
the reason for the modification. 
By subject listings of record of study medication for each of IV dexamethasone and PO 
dexamethasone will be provided.  
7.4.1.10 
Cumulative Dose, Dose Intensity, and Relative Dose Intensity 
A subject’s cumulative dose of elotuzumab is measured in mg/kg, and is defined as the sum of 
their elotuzumab doses (mg/kg) (actual, not planned) over all infusions. Most recent weight will 
be used for the calculation. A subject’s cumulative dose of pomalidomide is defined as the sum 
of each dose they took, as recorded in their medication diary. In order to compute the cumulative 
dose of dexamethasone however, IV dexamethasone will have to be converted to its equivalent 
oral dose. This will be done by treating each mg of IV dexamethasone as 1.32mg of oral 
dexamethasone, i.e. making use of the fact that the mean bioavailability of oral dexamethasone 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
21 
was estimated to be 0.7619). A subject’s cumulative dose of dexamethasone will be defined as the 
sum of all dexamethasone doses, oral and IV, converted to oral equivalent. The cumulative dose 
administered will be summarized for each of these drugs. 
Elotuzumab: 
Elotuzumab dose intensity (mg/kg/week) per subject will be calculated separately for Cycles 1 
and 2, and Cycle 3 and beyond, since elotuzumab dosing in Cycles 1 and 2, and Cycle 3 and 
beyond differ from each other.  
Cycle 1 and 2:  
7x[cumulative dose of Elotuzumab during the first 2 cycles/ (min(date of first dose of 
Elotuzumab in the last cycle among the first 2 cycles+28, discontinuation date, death date) - date 
of first dose of Elotuzumab in cycle 1)] 
Cycle 3 and beyond:  
7x[cumulative dose of Elotuzumab staring from Cycle 3 / (min(date of first dose of Elotuzumab 
in the last cycle+28, discontinuation date, death date) - date of first dose of Elotuzumab in cycle 
3 )] 
The relative dose intensity will be calculated as 
(Dose Intensity/Planned Dose Intensity(PDI))
Planned dose per week for elotuzumab is 10mg/kg/week for the first 2 cycles, 5mg/kg/week for 
cycles 3 and beyond. The PDI per subject for elotuzumab will be computed by averaging the 
planned doses per week over the treatment duration e.g., planned elotuzumab PDI for a subject 
whose last dose was the first dose of third cycle would have the PDI computed as 
𝐸𝑙𝑜𝑡𝑢𝑧𝑢𝑚𝑎𝑏 𝑃𝐷𝐼 ((𝑚𝑔/𝑘𝑔/𝑤𝑘) = 4 ×  10 + 4 ×  10 + 4 ×  5
12
 
Dose intensity and relative dose intensity of elotuzumab will be summarized. 
Pomalidomide: 
Dose intensity and relative dose intensity for pomalidomide (mg/week) will be calculated as the 
standard daily dose, 4 mg from Day 1 to Day 21 during each cycle. 
The pomalidomide dose intensity, per subject, will be calculated as:  
7x[cumulative dose of pomalidomide / (min(date of first dose of Pomalidomide in the last cycle 
in which Pomalidomide was administered+28, discontinuation date, death date) - date of first 
dose of Pomalidomide )] 
The relative dose intensity of pomalidomide is the dose intensity per week divided by the 
planned dose intensity per week, 21mg times 100%. 
Dexamethasone: 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
22 
The dose intensity (mg/week) of dexamethasone, per subject, will be calculated separately for 
the period encompassing Cycles 1 and 2 and for the periods from Cycles 3 and beyond.  
Cycle 1 and 2:  
7x[cumulative dose of Dexamethasone during the first 2 cycles/ (min(date of first dose of 
Dexamethasone in the last cycle among the first 2 cycles+28, discontinuation date, death date) - 
date of first dose of Dexamethasone in cycle 1)] 
Cycle 3 and beyond:  
7x[cumulative dose of Dexamethasone staring from Cycle 3 / (min(date of first dose of 
Dexamethasone in the last cycle+28, discontinuation date, death date) - date of first dose of 
Dexamethasone in cycle 3 )] 
 
Table 3: 
Dexamethasone Dosing, All Subjects Receiving Elotuzumab 
 
 
The relative dose intensity of dexamethasone is the dose intensity per week divided by the 
planned dose intensity per week times 100%. The planned dose of dexamethasone (indicated in 
table 3) on elotuzumab dosing days, 8 mg IV dexamethasone plus 28 mg oral dexamethasone, is 
equivalent to 38.56 mg of oral dexamethasone for subjects ≤ 75 years old; similarly for subjects 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
23 
> 75 years old, the planned dose on elotuzumab dosing days, 8 mg IV dexamethasone plus 8 mg 
oral dexamethasone, is equivalent to 18.56 mg of oral dexamethasone. The planned dose when 
dexamethasone is not being administered with elotuzumab is 40 mg per week for subjects ≤ 75 
years old and 20 mg per week for subjects > 75 years old.  
Nivolumab: 
The dose intensity (mg/week) of Nivolumab, per subject, will be calculated separately for the 
period encompassing Cycles 1 to 4 and for the periods from Cycles 5 and beyond.  
Cycle 1-4:  
7x[cumulative dose of Nivolumab during the first 4 cycles/ (min(date of first dose of Nivolumab 
in the last cycle among the first 4 cycles+28, discontinuation date, death date) - date of first dose 
of Nivolumab in cycle 1)] 
Cycle 5 and beyond:  
7x[cumulative dose of Nivolumab staring from Cycle 5 / (min(date of first dose of Nivolumab in 
the last cycle+28, discontinuation date, death date) - date of first dose of Nivolumab in cycle 5 )] 
The relative dose intensity of nivolumab is the dose intensity per week divided by the planned 
dose intensity per week, 120mg times 100%.  
Descriptive statistics (n, mean, STD, median, min, max, q1 and q3) will be presented for the 
cumulative dose, and dose intensity of each agent. The number and percentage of subjects whose 
relative dose intensity falls into the following categories will be presented:  90 %, 80% to < 
90%, 70% to < 80%, 60% to < 70%, < 60%.  
7.4.2 
Premedication Other than Dexamethasone for Hypersensitivity 
Reactions 
A by-subject listing of pre-medication for elotuzumab, other than dexamethasone, will be 
provided for all treated subjects. This listing will be generated from the “Pre-medication for 
elotuzumab (other than Dexamethasone)” eCRF module and pre-medications will be coded using 
the BMS WHO drug dictionary.  
7.4.3 
Concomitant Medication 
Concomitant medications are medications, other than study medication or pre-medications for 
elotuzumab recorded on the “Pre-medication for elotuzumab” eCRF page, which are taken by 
subjects any time on-study, no earlier than the first day of study drug and no later than 60 days 
after the last dose of study drug. Concomitant medications will be coded using the BMS WHO 
drug dictionary. If there is clear evidence to suggest that the medication stopped prior to the first 
dose of study medication, the medication will be assumed to be Prior only. 
The number and percentage of subjects taking any concomitant medication and each medication 
(Anatomical Therapeutic Chemical [ATC] classification system drug name) will be summarized, 
overall and by treatment group.  
A by subject listing of concomitant medication will be provided.  


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
24 
7.4.4 
Discontinuation of Study Therapy 
The number and percentage of subjects who have discontinued study treatment and reason for 
discontinuation will be summarized using the subject status eCRF page from end of treatment. 
This is done in order to give a full accounting of all subjects who are off study treatment.  
In addition, for subjects who discontinued one drug, while continuing at least one of the other 
two study drugs, their reason for treatment discontinuation will be summarized based on the dose 
modification CRF. Subjects will be counted in this summary if there is evidence from the dosing 
CRF that the subject received the combination therapy in at least one cycle, followed by 
additional cycles, where one of the drugs in the combination was discontinued.  
7.5 
Efficacy 
7.5.1 
Progression-Free Survival 
The primary analysis of this study is to estimate the two definitions of progression free survival 
(PFS) in all treated patients. The median PFS and 2-sided 95% confidence interval will be 
caculated via Kaplan-Meier (KM) estimation procedure. The PFS function will be estimated 
using the KM product limit method and will be displayed graphically. Estimates for 1-year, 2-
year, and 3-year PFS rates will be presented along with their associated 95% CIs. These 
estimates will be come from the KM curve and their standard errors (SEs), for use in 
constructing CIs, will be computed using Greenwood’s formula17 and on log-log transformation 
applied on the survivor function.  
Analyses of PFS will be conducted based on all treated population, and also by subgroups based 
on lines of prior therapy (2L/3L groups), or by age group (<65 years, ≥65 years), and (<75 years, 
≥75 years). Subgroup analysis by ECOG PS (0-1,2), by response to most recent line of therapy 
(relapsed and refractory, relapsed, refractory, intolerant) and by ISS stage (I,II,III) if albumin and 
beta 2 microglobulin data are available  will be conducted as well. PFS is also evaluated based 
on 3 levels of response (VGPR or better, PR, SD or MR). PFS will be estimated using the 
Kaplan-Meier (KM) product limit method and presented using a KM curve. 
Time from last tumor assessment to data cut-off in months will be summarized by treatment arm 
and overall for all treated subjects. Subjects who have a PFS event will be considered as current 
for this analysis. 
A by-subject listing will be presented including PFS duration on all treated population, whether 
the subject was censored, and if censored, the reason. 
All of the analyses will be repreated for primary and secondary definitions of PFS.  
7.5.2 
Overall Survival 
One of the secondary objective of this study is to estimate the overall survival (OS) in all treated  
subjects. The median OS and 2-sided 95% confidence interval will be calculated via Kaplan-
Meier (KM) estimation procedure. The survival function will be estimated using the KM product 
limit method and will be displayed graphically. Estimates for 3-year, 4-year, and 5-year OS rates 
will be presented along with their associated 95% CIs. These estimates will be come from the 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
25 
KM curve and their standard errors (SEs), for use in constructing CIs, will be computed using 
Greenwood’s formula17 and on log-log transformation applied on the survivor function. 
Analyses of OS will also be conducted based on all treated population, and also by subgroups 
based on lines of prior therapy (2L/3L groups), or by age group (<65 years, ≥65 years), and (<75 
years, ≥75 years). Subgroup analysis by ECOG PS (0-1,2), by response to most recent line of 
therapy (relapsed and refractory, relapsed, refractory, intolerant) and by ISS stage (I,II,III) if 
albumin and beta 2 microglobulin data are available  will be conducted as well. OS is also 
evaluated based on 3 levels of response (VGPR or better, PR, SD or MR). OS will be estimated 
using the Kaplan-Meier (KM) product limit method and presented using a KM curve. 
Currentness of OS data will be summarized in months, by computing the time from “last known 
alive” date to data cut-off date. Subjects who have a death event will be considered as current for 
this analysis. 
A by-subject listing will be presented including OS duration, whether the subject was censored, 
and if censored, the reason, for all enrolled subjects. 
7.5.3 
Objective Response  
The other secondary objective of this study is to estimate the Objective Response Rate (ORR). 
The number and percentage of subjects in each category of best overall response (stringent CR 
[sCR], complete response [CR], very good partial response [VGPR], partial response [PR], 
minor (minimal response) [MR], stable disease/no change [SD], progressive disease [PD], or 
unable to determine [UD]) will be presented. An estimate of the objective response rate and an 
associated exact two-sided 95% CIs (Clopper and Pearson18) will be presented. Also, the number 
and percentage of subjects in each category of best overall response according to the investigator 
tumor assessment will be presented.  
Analyses of ORR will be conducted based on the all treated analysis population, and also by 
subgroups based on lines of prior therapy (2L, 3L), or by age group (<65 years, ≥65 years), and 
(<75 years, ≥75 years). Subgroup analysis by ECOG PS (0-1,2), by response to most recent line 
of therapy (relapsed and refractory, relapsed, refractory, intolerant) and by ISS stage (I,II,III) if 
albumin and beta 2 microglobulin data are available  will be conducted as well. 
 
 
 
 
 
 
  
 
 
 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
26 
 
  
  
7.6 
Safety 
7.6.1 
Adverse Events 
AEs will be categorized using the most recent version of the MedDRA, by system organ class 
(SOC) and preferred term. The severity of AEs will be graded using the NCI CTCAE (v 3.0). 
On-study AEs are defined as non-serious and serious AEs with an onset date on or after the first 
dose until 60 days after the last dose. See Section 8.4, Imputing AE Onset Dates, for a discussion 
of imputation rules for incomplete or missing AE onset dates. If the relationship to study drug is 
missing, then the AE will be assumed to be related to study drug. 
Unless specified otherwise, AEs will be counted only once within each SOC and preferred term, 
according to their worst CTC grade. 
Tables will be sorted by SOC and preferred term, with SOCs ordered by decreasing frequency 
overall and then alphabetically. Preferred terms will be sorted within SOCs by descending 
frequency overall and then alphabetically.  
Frequency table of the worst grade of on-study AE will be presented.  The table will be with AEs 
broken out by individual grade, 1, 2, 3, 4 or 5 together with an Any Grade category. There will 
also be a table in which grades are grouped as follows “Any, Grade 3-4 and Grade 5”. This last 
summary will be repeated for on-study drug-related AEs.  
A by-subject listing all AEs will be presented for all treated subjects. 
In addition the following will be presented: 
 Exposure-adjusted AE incidence rates (including multiple occurrences of unique events) will 
be calculated for each SOC and preferred term. 
Exposure-adjusted incidence rate per 100 person-years will be used and will be calculated as: 
100 ×
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑢𝑛𝑖𝑞𝑢𝑒 𝐴𝐸𝑠
(
𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑙𝑎𝑠𝑡 𝑑𝑜𝑠𝑒 𝑜𝑓 𝑠𝑡𝑢𝑑𝑦 𝑑𝑟𝑢𝑔−
𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑓𝑖𝑟𝑠𝑡 𝑑𝑜𝑠𝑒 𝑜𝑓 𝑠𝑡𝑢𝑑𝑦 𝑑𝑟𝑢𝑔+ 60 + 1
365.25
)
 
and will be displayed along with a count of events 
AEs can be counted multiple times within each SOC and preferred term in this summary table. 
A by-subject listing of unique AEs will be provided for all treated subjects. 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
27 
7.6.2 
Serious Adverse Events and Adverse Event Leading to Discontinuation 
Summaries of worst grade of on-study SAE, both by individual grade (1, 2, 3, 4, or 5, together 
with an Any Grade category) and by grade grouped as “Any, Grade 3-4 and Grade 5” will also 
be presented. This last summary will be repeated for: 
 On-study drug-related SAEs  
 On-study AEs leading to discontinuation. 
 On-study Drug related AEs leading to discontinuation 
By-subject listings of SAEs and AEs leading to study drug discontinuation will be produced for 
all treated subjects. 
7.6.3 
Adverse Events of Special Interest 
7.6.3.1 
Infusion Reactions 
Infusion reaction is a known elotuzumab toxicity. Two different approaches will be taken when 
defining infusion reaction.   
The first way of defining infusion reaction will be based on investigator assessment. An 
investigator reported infusion reaction will be any non-serious or serious adverse event judged 
by the investigator to be infusion related start on the day or the day after the elotuzumab 
infusion.  
A second approach will be to create a composite term called “peri-infusional adverse event”, 
which will be defined as any event from a pre-defined list of MedDRA terms (regardless of 
relationship to study drug) which starts on the day or the day after the elotuzumab infusion. See 
Appendix 2 for the list of preferred terms making up the composite term “peri-infusional adverse 
event”.  The list of terms making up “peri-infusional adverse event” is broad and is expected to 
over-estimate the true incidence of clinically meaningful infusion reaction. 
Frequency tables of the worst grade of on-study investigator infusion reaction will be presented, 
both by individual grade (1,2,3,4 or 5, together with an Any Grade category) and by grade 
grouped as “Any, Grade 3-4 and Grade 5” .  
Worst grade for “peri-infusional adverse event” and “infusion reaction” will be presented, as 
Any, Grade 3-4 and Grade 5, only the preferred terms will be presented not the system organ 
class (SOC).  
Listings for infusion reactions and peri-infusional adverse events will be provided. 
7.6.3.2 
Second Primary Malignancies 
A summary table and by-subject listing of second primary malignancies will be provided. 
Information on secondary malignancies will be obtained from the on-treatment eCRF page for 
secondary malignancies and the “Survival Status” eCRF page. 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
28 
7.6.4 
Deaths 
The number and percentage of deaths and the investigator-reported cause of death will be 
presented. This will be summarized for all deaths, and for those reported on study treatment or 
within 60 days of discontinuing study treatment. 
A by-subject listing will be provided and will present date of death and reason of death.   
7.6.5 
Clinical Laboratory Evaluations 
On-treatment laboratory tests for safety are defined as those that occur after first dose of any 
study therapy until 60 days after last dose of any study therapy.  
The number and percentage of subjects with each worst severity grade for on-study hematology 
parameters (hemoglobin, WBC, ANC, ALC and platelets) will be presented. Grades will be 
categorized as Grade 1, Grade 2, Grade 3, Grade 4, Any Grade and Grade 3-4. Subjects will be 
counted only once for each parameter, according to their worst post baseline CTC grade. The 
percentage of subjects with each worst severity grade will be calculated out of the number of all 
treated subjects with on-study assessment for lab parameter. Subjects without post-baseline (on-
treatment) assessment for a lab parameter will be reported in the “NOT REPORTED” category.  
This summary will be repeated for: 
 Liver parameters (ALT, AST, alkaline phosphatase, albumin and total bilirubin) with 
available CTC grades 
 Renal/electrolyte parameters (sodium, potassium, bicarbonate, calcium, glucose and 
creatinine) with available CTC grades 
Sodium, potassium, calcium, and random glucose will be presented separately, based on their 
high and low values.  
For blood urea nitrogen (BUN), direct bilirubin and total protein the worst category on-treatment 
will be presented. Results will be categorized as; below upper normal limits, above upper normal 
limits or not reported. 
For reporting purposes, urea will be converted to BUN, using the conversion factor:  
urea (mmol/L) / 0.357 = BUN (mg/dL).” 
Subjects experiencing any potential drug induced liver injury (DILI) will be summarized by 
treatment group and overall as follows:  
 A summary of the number and percentage of subjects with (AST or ALT > 3 x upper limit of 
normal (ULN)) and (Total bilirubin > 2 x ULN and ALP < 2 x ULN) will be presented. 
If any potential cases of DILI are identified then clinical review will be conducted to ensure no 
other immediate apparent possible causes of AT elevation and hyperbilirubinemia are present, 
including but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the 
administration of other drugs known to be hepatotoxic. 
Note: The timing for total bilirubin rising to > 2 x ULN needs to be concomitant with or within 
30 days after ALT or AST rising to > 3 x ULN. ALP needs to be < 2 x ULN at the time of or 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
29 
within 2 weeks before ALT or AST rising to > 3 x ULN or TBILI > 2 x ULN. This means a 
normal ALP value ( 2 x ULN) must be present within 2 weeks of either the ALT/AST criteria 
or the TBILI criteria. 
A by subject listing of all laboratory data will be provided for all treated subjects. A separate 
listing will be provided for all subjects potentially experiencing DILI. A by subject listing of 
pregnancy test data will also be provided. 
7.6.6 
Vital Signs  
Vital Signs will not be summarized.  
8 
CONVENTIONS 
8.1 
Age Definition 
Age (years) will be calculated as: 
𝑑𝑎𝑡𝑒 𝑜𝑓 𝑖𝑛𝑓𝑜𝑟𝑚𝑒𝑑 𝑐𝑜𝑛𝑠𝑒𝑛𝑡−𝑑𝑎𝑡𝑒 𝑜𝑓 𝑏𝑖𝑟𝑡ℎ+ 1
365.25
 
8.2 
Duration and Study Day Definition 
In instances in which study period between two dates are to be calculated (for example, duration 
of response, PFS and OS), the convention to be used is as follows: later date – earlier date +  
1 day. 
Study day is calculated as assessment date – first dose date + 1 day, if the assessment is taken on 
or after the first dose day. If the assessment is taken prior to the first dose day, study day will be 
calculated as assessment date – first dose date. Date of first dose is defined as Study Day 1. 
8.3 
Day Conversion of Date Imputation 
Conversion from days to months or years: 
 1 year = 365.25 days 
 1 month = 30.4375 days 
Imputation for partial or missing progression dates: 
 If only the day is missing, the 1st of the month will be used to replace the missing day. 
 If the day and month are missing or a date is completely missing, the date of progression will 
be moved back to the last complete tumor assessment date. 
In both the cases given above, the imputed date will still be considered an event. 
Imputation for partial or missing death dates: 
 If only the day is missing, the later of the last known alive date and the 1st of the month will 
be used to replace the missing day. 
 If both the day and the month are missing, the later of the last known alive date and Jan 1st 
will be used to replace the missing information. 
In both the cases given above, the imputed date will still be considered an event. 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
30 
8.4 
AE, Laboratory Results and Concomitant Medication 
Safety data will be handled according to the BMS safety data conventions (described in 
“Analysis of Safety Data - Reference to CT SOP 109”). This document includes descriptions on 
how to analyze AE data as well as how to handle partial dates, missing dates, and unknown end 
dates when analyzing safety data. 
The following dictionaries will be used to code medical terms and to derive toxicity grades: 
 Adverse events and other symptoms will be graded according to the NCI CTC Version 3.0 
and categorized according to the latest version of MedDRA at the time of analysis. 
 Laboratory results will be classified according to the CTC Version 3.0 grading system.   
 All medications will be coded as per the latest version of the WHO Drug dictionary at the 
time of analysis. 
 Tables and listings for laboratory results will be available in SI units and US units. 
9 
CONTENT OF REPORTS 
Statistical components for the clinical study report will be based on the content of this statistical 
analysis plan (SAP). It is assumed that a full CSR will be expected for the study CA204-142 at 
the writing of the SAP. If it is not the case, the SAP won’t be updated. Details of the tables, 
listings, and figures to be prepared for the CSR will be included in a study-specific Data 
Presentation Plan (DPP). 
9.1 
Topline Analyses 
Study conduct: 
 Relevant eligibility deviations (Table and Listing) 
Subject population: 
 End of Treatment Summary 
 Demographic Characteristics Summary 
 Response to Most Recent Line of Therapy Summary 
 Time from Diagnosis to First Dose Date 
Extent of exposure: 
 Number of Cycles Summary 
Tumor response: 
 Best Overall Response  
Progression free survival: 
 Currentness of Follow-Up for PFS (Inv) Summary  
 Kaplan-Meier plot of PFS Primary)  (Figure) 
 Kaplan-Meier plot of PFS (Secondary)  (Figure) 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
31 
Overall survival : 
 Currentness of Follow-Up for Overall Survival Summary  
 Kaplan-Meier plot of overall survival (Figure) 
Safety: 
 Adverse Event Summary by CTC Grade Combined 
 Serious Adverse Event Summary by CTC Grade Combined 
 Adverse Event Leading to Discontinuation Summary by CTC Grade Combined 
 Infusion Reaction Summary by Common Terminology Criteria 
 Deaths 
 Deaths within 60 days of last study drug 
 On study Hematology Lab Results 
 On study Chemistry Lab Results 
Specific tables corresponding to these topics will be identified in a separate Data Presentation 
Plan. 
10 
DOCUMENT HISTORY 
Table 4: 
Document History 
Version 
Number 
Author(s) 
Description 
0.1 
Original version 
0.2 
Upated upon BMS comments on draft 1 
0.3 
Upated upon BMS comments on draft 2 
0.4 
Upated upon BMS comments  
0.5 
Updated upon protocol amendment 01 
0.6 
Updated upon protocol amendment 01 & BMS comments 
1.0 
Updated upon protocol amendment 01 & approved 
1.1 
 
 
1.2 
Updated upon protocol amendment 02 & BMS comments 
that include updates on draft amendment 03. There fore the 
SAP may not be consistent with the protocol whilst the 
amendment 03 is being finalized.  
2.0 
Updated upon draft of protocol amendment 03 received on 
12Feb2018. 
2.1 
Added protocol amend 03 into section 2.4.  
Changed “last evaluable assessment” to “last adequate 
tumor assessment” 
 
 
Added sample size section 5.2 for EN cohort per amend 03 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
   
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
draft.  
2.2 
 
Updated the definition of response to most recent prior 
therapy.  
Updated the relevant protocol amendment.  
Updated the calculation of Elo omission.  
2.3 
 
Added Nivolumab dose intensity, relative dose intensity.  
Added derived reduction for Pomalidomide.  


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
33 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 1 
LIST OF ABBREVIATIONS 
Table 5: 
List of Abbreviations 
AE 
Adverse Event 
ATC 
Anatomical Therapeutic Chemical  
BMS 
Bristol Myers Squibb 
CI(s) 
Confidence Interval(s) 
CR 
Complete Response 
CRF  
Case Report Form 
CTCAE 
Common Terminology Criteria for Adverse Events 
DMC 
Data Monitoring Committee 
ECOG 
Eastern Cooperative Oncology Group 
EORTC 
European Organization for Research and Treatment of Cancer 
ESRD 
End Stage Renal Disease 
HRQOL 
Health Related Quality of Life 
ITT 
Intent-to-Treat 
IV 
Intravenous 
IVRS 
Interactive Voice Response System 
Ld 
Pomalidomide, (low-dose) Dexamethasone 
E-Ld 
Elotuzumab, Pomalidomide, (low-dose) Dexamethasone,  
MedDRA 
Medical Dictionary for Regulatory Activities 
MM  
Multiple Myeloma 
MR 
Minor Response 
ORR 
Objective Response Rate 
OS 
Overall Survival 
PD 
Progression 
PFS 
Progression-Free Survival 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
34 
Table 5: 
List of Abbreviations 
PK 
Pharmacokinetic 
PO 
Oral 
PR 
Partial Response 
SAE 
Serious Adverse Event 
SAP  
Statistical Analysis Plan 
sCR 
Stringent Complete Response 
SD 
Stable Disease 
SE 
Standard Error 
SI 
International System of Units (SI) 
SOC 
System Organ Class 
STD 
Standard Deviation 
UD 
Unable to Determine 
ULN 
Upper Limit of Normal  
VGPR 
Very Good Partial Response 
WHO 
World Health Organization 
 
APPENDIX 2 
LIST OF MEDDRA TERMS TO BE INCLUDED AS INFUSION 
REACTIONS (PERI-INFUSIONAL ADVERSE EVENTS) 
Infusion reaction is a known Elotuzumab toxicity and a composite term “peri-infusional adverse 
event” will be created. This composite term is defined as any of the following, and will be 
updated at the time of the analysis, using the latest version of MedDRA. 
MedDRA terms with a start date on the day of or the day after an infusion: 
Table 6: 
MedDRA Terms 
ACUTE RESPIRATORY FAILURE 
ALLERGIC COUGH 
ALLERGIC OEDEMA 
ALLERGIC RESPIRATORY SYMPTOM 
ANAPHYLACTIC REACTION 
ANAPHYLACTIC SHOCK 
ANAPHYLACTOID REACTION 
ANAPHYLACTOID SHOCK 
ANGIOEDEMA 
APNOEA 
BLOOD PRESSURE DECREASED 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
35 
Table 6: 
MedDRA Terms 
BLOOD PRESSURE DIASTOLIC DECREASED 
BLOOD PRESSURE IMMEASURABLE 
BLOOD PRESSURE SYSTOLIC DECREASED 
BRADYCARDIA 
BRONCHIAL OEDEMA 
BRONCHOSPASM 
CARDIAC ARREST 
CARDIAC FAILURE ACUTE 
CARDIO-RESPIRATORY ARREST 
CARDIO-RESPIRATORY DISTRESS 
CARDIOVASCULAR INSUFFICIENCY 
CHEST DISCOMFORT 
CHILLS 
CHOKING SENSATION 
CIRCULATORY COLLAPSE 
CIRCUMORAL OEDEMA 
COUGH 
DIASTOLIC HYPOTENSION 
DIZZINESS 
DRUG HYPERSENSITIVITY 
DYSPHONIA 
DYSPNOEA 
ERYTHEMA 
EYE OEDEMA 
EYE SWELLING 
EYELID OEDEMA 
FACE OEDEMA 
FIRST USE SYNDROME 
FIXED ERUPTION 
FLUSHING 
GENERALISED ERYTHEMA 
HEADACHE 
HEART RATE INCREASED 
HOT FLUSH 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
36 
Table 6: 
MedDRA Terms 
HYPERHIDROSIS 
HYPERPYREXIA 
HYPERSENSITIVITY 
HYPERVENTILATION 
HYPOTENSION 
HYPOXIA 
INFLUENZA LIKE ILLNESS 
INFUSION RELATED REACTION 
KOUNIS SYNDROME 
LARYNGEAL DYSPNOEA 
LARYNGEAL OEDEMA 
LARYNGOSPASM 
LARYNGOTRACHEAL OEDEMA 
LIP OEDEMA 
LIP SWELLING 
MYOCARDIAL INFARCTION 
NAUSEA 
OEDEMA 
OEDEMA MOUTH 
OROPHARYNGEAL SPASM 
OROPHARYNGEAL SWELLING 
OXYGEN SATURATION DECREASED 
PALPITATIONS 
PERIORBITAL OEDEMA 
PHARYNGEAL OEDEMA 
PRURITUS 
PRURITUS ALLERGIC 
PRURITUS GENERALISED 
PYREXIA 
RASH 
RASH ERYTHEMATOUS 
RASH GENERALISED 
RASH MACULAR 
RASH MACULO-PAPULAR 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
37 
Table 6: 
MedDRA Terms 
RASH MACULOVESICULAR 
RASH PRURITIC 
RASH PUSTULAR 
RESPIRATORY ARREST 
RESPIRATORY DISTRESS 
RESPIRATORY FAILURE 
RESPIRATORY RATE INCREASED 
REVERSIBLE AIRWAYS OBSTRUCTION 
SENSATION OF FOREIGN BODY 
SHOCK 
SINUS TACHYCARDIA 
SKIN REACTION 
SKIN SWELLING 
SNEEZING 
STRIDOR 
SWELLING 
SWELLING FACE 
SWOLLEN TONGUE 
SYNCOPE 
TACHYCARDIA 
TACHYPNOEA 
THROAT IRRITATION 
THROAT TIGHTNESS 
TONGUE OEDEMA 
TRACHEAL OBSTRUCTION 
TRACHEAL OEDEMA 
TYPE I HYPERSENSITIVITY 
TYPE II HYPERSENSITIVITY 
TYPE IV HYPERSENSITIVITY REACTION 
UPPER AIRWAY OBSTRUCTION 
URTICARIA 
URTICARIA PAPULAR 
VASCULITIC RASH 
VASCULITIS 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
38 
Table 6: 
MedDRA Terms 
VOMITING 
WHEEZING 
 
 
APPENDIX 3 
DEFINITIONS OF RESPONSE AND PROGRESSION CRITERIA 
(MODIFIED FROM IMWG) 
Table 7: 
DEFINITIONS OF RESPONSE AND PROGRESSION CRITERIA 
(MODIFIED FROM IMWG) 
Response Subcategory 
Response Criteriaa 
Stringent Complete Response (sCR) 
CR, as defined below, plus the following: 
Normal FLC ratiob and absence of clonal cellsc in bone 
marrow by immunohistochemistry or 
immunofluorescence. 
Complete Response (CR)b 
Negative immunofixation of serum and urine and 
disappearance of any soft tissue plasmacytomas, and < 
5% plasma cells in bone marrow. 
Very Good Partial Response 
(VGPR) 
Serum and urine M-protein detectable by 
immunofixation but not on electrophoresis or ≥ 90% 
reduction in serum M-protein level plus urine M-protein 
level < 100 mg per 24 hour. 
Partial Response (PR) 
≥ 50% reduction of serum M-protein and reduction in 
24-hour urinary M-protein by ≥ 90% or to < 200 mg per 
24 hour. If serum and urine M-protein are unmeasurable, 
a ≥ 50% decrease in the difference between involved and 
uninvolved FLC levels is required in place of the M-
protein criteria. In addition to the above criteria, if 
present at baseline, ≥ 50% reduction in the size of soft 
tissue plasmacytomas is also required 
Minor (Minimal) Response (MR) 
25-49% reduction of serum M-protein and reduction in 
24-hour urine M-protein by 50-89%, which still exceeds 
200 mg per 24 hours. In addition, if present at baseline, 
25-49% reduction in the size of soft tissuev 
plasmacytomas is also required. No increase in the size 
or number of lytic bone lesions (development of 
compression fracture does not exclude response). 
Stable Disease (SD) 
Not meeting criteria for CR, VGPR, PR, MR, or 
progression. 
Progressive disease 
Any of the following: 
 
Increase of 25% from lowest response value in any 
one or more of the following: 
1. Serum M-component (absolute increase must be 


Statistical Analysis Plan 
CA204-142 
BMS-901608 
elotuzumab 
 
39 
Table 7: 
DEFINITIONS OF RESPONSE AND PROGRESSION CRITERIA 
(MODIFIED FROM IMWG) 
Response Subcategory 
Response Criteriaa 
≥ 0.5 g/dL)d and/or  
2. Urine M-component (absolute increase must be ≥ 200 
mg per 24 h) and/or 
3. Only in patients without measurable serum and urine 
M-protein levels: the difference between involved and 
uninvolved FLC levels (absolute increase must be > 10 
mg/dL) 
4. Bone marrow plasma cell percentage (absolute % 
must be ≥ 10%) 
 
Definite development of new bone lesions or soft 
tissue plasmacytomas or definite increase in the size 
of 
existing 
bone 
lesions 
or 
soft 
tissue 
plasmacytomas 
 
Development of hypercalcemia (corrected serum 
calcium > 11.5 mg/100 mL) that can be attributed 
solely to the plasma cell proliferative disorder 
a All response categories require 2 consecutive assessments made at any time before the institution of any new 
therapy; all categories also require no known evidence of progressive or new bone lesions if radiographic studies 
were performed. Radiographic studies are not required to satisfy these response requirements. Bone marrow 
assessments need not be confirmed. 
b Note clarification to IMWG criteria for coding CR and VGPR in patients in whom the only measurable disease is 
by serum FLC levels: CR in such patients is defined as a normal FLC ratio of 0.26-1.65 in addition to CR criteria 
listed above. VGPR in such patients is defined as a > 90% decrease in the difference between involved and 
uninvolved FLC levels. 
c Presence or absence of clonal cells is based upon the κ/λ ratio. An abnormal κ/λ ratio by immunohistochemistry 
and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting 
presence of an abnormal clone is κ/λ of > 4:1 or < 1:2. 
d For progressive disease, serum M-component increase of ≥ 1 g/dL is sufficient to define progression if starting M-
component is ≥ 5 g/dL